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SUMMARY   
 
Acute myocardial infarction (AMI), which is caused by occlusion of coronary 
artery, results in myocardial infarction and this may eventually contribute to the 
development of heart failure. Ironically, reperfusion therapy, which restores blood 
flow and significantly limits ischemic injury, causes reperfusion injury and 
contributes to the final infarct size. Amelioration of reperfusion injury will 
therefore improve the efficacy of reperfusion therapy.  However, there is still no 
effective treatment to limit reperfusion injury, and this is contributing to a 
growing epidemic of heart failure.  Recent developments have indicated that 
secretion of mesenchymal stem cells (MSCs) can reduce reperfusion injury. 
However, the cardioprotective factor in the secretion and underlying mechanism 
of its cardioprotection remains to be elucidated.  
To identify the active component in MSC secretion, 0.2 µM filtered culture 
medium conditioned by human embryonic stem cell-derived MSCs was filtered 
sequentially through filters with decreasing pore sizes.  Only the >1000 kDa 
fraction reduced infarct size in a mouse MI/R injury model. This physically 
limited the size of cardioprotective factor to 100-220 ηm and the candidate factor 
to exosome. Electron microscopy showed the presence of 100 ηm particles in the 
conditioned medium. Further analysis revealed the presence of co-
immunoprecipitating exosome-associated proteins and the co-sedimentation of 
these proteins with membrane lipids after ultracentrifugation.  These proteins were 
determined to have an exosome-like flotation density of 1.10-1.16 µg/ml by 





exclusion on HPLC and this purified exosome significantly reduced infarct size in 
the same mouse model.  
To assess if the secretion of cardioprotective exosome was restricted to hESC-
derived MSCs, we derived 5 MSCs cultures from various tissues of 3 first-
trimester aborted fetuses. These MSCs were highly expandable, displayed typical 
MSC surface antigen and gene expression profile, and possessed the MSC tri-
lineage differentiation potential. Like hESC-MSCs, they produced exosomes that 
were cardioprotective in mouse MI/R injury model. Therefore, production of 
cardioprotective exosomes was not restricted to hESC-MSCs but was common to 
all MSCs. 
To understand the cardioprotective mechanism of MSC exosome, the biochemical 
potential of exosome in vitro and in vivo was assessed. Proteomic profiling of 
exosome identified 866 proteins that together had the potential to drive diverse 
biological processes. Several of these processes had the potential to reduce injury 
during reperfusion including enhancing glycolysis, inhibiting the formation of 
membrane attack complex, reducing oxidative stress and activating pro-survival 
kinases. Consistent with the in vitro data, exosome treatment in mouse model 
promoted pro-survival signaling, enhanced ATP production and redox balance. 
These probably contributed to the reduced infarct size and preserved cardiac 
function and geometry that observed in the exosomes treated group.   
In summary, we identified exosome as the cardioprotective component in MSCs 
secretion.  We further demonstrated that secretion of cardioprotective exosomes 
was not restricted to hESC-MSCs and suggested potential mechanisms underlying 
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This introduction are adapted with modifications from a published review article 
“Mesenchymal stem cell exosome: a novel stem cell-based therapy for 
cardiovascular disease”1 of which I am the first author. 
 
Myocardial Ischemia/Reperfusion Injury 
Acute myocardial infarction (AMI), commonly known as heart attack occurs 
during a sudden obstruction of blood supply to part of the heart by vulnerable 
atherosclerotic plaque rupture2. AMI causes substantial irreversible cell death if 
left untreated for a substantial period of time3. Based on estimates by World 
Health Organization, 7.2 million people died from AMI in 2004, representing 12% 
of all global deaths. It is projected that by 2030, almost 10 million people will die 
from AMI, a 38% increase in 25 year4. In Singapore, AMI accounted for 19.2% of 
all deaths in 20095, which was the number two cause of death.  
Reperfusion therapy or the restoration of blood flow by percutaneous coronary 
intervention (PCI), thrombolytic therapy or bypass surgery is currently the 
mainstay of treatment for AMI and is responsible for the significant reduction in 
AMI mortality6. It was shown that the mortality rate of AMI in Germany reduced 
from 16.2% in 1994 to 9.9% in 2002 in tandem with the increasing use of 
reperfusion therapy6. The efficacy of reperfusion therapy has led to increasing 
survival of patients with severe AMI who would not otherwise survive.  Despite 
adequate reperfusion, however, most patients still suffer irreversible myocardial 
cell loss. Ironically, reperfusion itself is an important contributor to irreversible 





on studies in animal models of AMI, reperfusion injury contributed up to 50% of 
the final infarct size7. Amelioration of reperfusion injury and subsequent reduction 
of myocardial infarct size will dramatically improve patient prognosis. More 
importantly, by reducing reperfusion injury, the progression of AMI to heart 
failure that is highly dependent on infarct size8-13 might be reduced, thus relieving 
the phenomenon of the ever-growing epidemic of heart failures14-16.  
It was recognized by Jennings et al. as early as 1960 that reperfusion of severely 
ischemic tissue causes lethal injury17. They observed significant morphological 
alteration in ischemic canine myocardium after the onset of reperfusion. These 
include cardiomyocyte swelling, mitochondrial clarification, 
amorphous/flocculent densities representing calcium phosphate deposits, 
hypercontracture and loss of sarcomere organization. It was believed that several 
abrupt biochemical and metabolic changes during reperfusion causes lethal 
reperfusion injury. These include the generation of reactive oxygen species 
(ROS)18,19, intracellular Ca2+ overload20, the rapid restoration of physiologic pH21 
and inflammation22. The complex interaction of each biochemical and metabolic 
changes, together mediates cardiomyocyte death through apoptosis, necrosis, 
inflammation and hypercontracture7. But the very existence of lethal reperfusion 
injury was actively debated23. It became more widely accepted only when infarct 
size was shown to be reduced by interventions applied at the onset of reperfusion8.  
These interventions including postconditioning which involved several cycles of 
brief mechanically interrupted-reperfusion applied at the onset of reperfusion or 
pharmacological agents applied before the onset of reperfusion have demonstrated 
some protection against reperfusion injury in animals or small clinical trials in 





implication of these findings is that adjunctive therapies at the onset of reperfusion 
might salvage more myocardium at risk. Unfortunately, over the past 30 years, 
most of the agents failed to reproduce these beneficial effects in large-scale 
clinical trial and none has been translated into clinical practice24-27. This have led 
to speculations that reducing reperfusion injury may not be tractable to 
pharmaceutical interventions28.  
 
Mesenchymal Stem Cells In The Treatment Of Acute Myocardial Infarction 
With the emergence of stem cells as potential regenerative medicine, attempts to 
use stem cells to reduce infarct size and enhance cardiac function in animal 
models and patients have increased exponentially.  To date, stem cell therapy for 
the heart accounts for one third of the publications in the regenerative medicine 
field29. The rationale for the use of stem cells to repair cardiac tissues was based 
on the hypothesis that these cells could differentiate into cardiomyocytes and 
supporting cell types to replace cells lost during MI/R injury, and achieve cardiac 
repair30.  Among stem cells currently being tested in clinical trials for the heart, 
MSCs are the most widely used stem cells. Part of the reasons is their easy 
availability in accessible tissues such as bone marrow aspirate, fat tissue31 and 
their large capacity for ex vivo expansion32.  MSCs are also known to have 
immunosuppressive properties33. Therefore another attractive advantage is that 
they could be used in allogeneic transplantation which is very practical in clinic. 
Besides, they are also reported to have highly plastic differentiation potential that 
included not only adipogenesis, osteogenesis and chondrogenesis34-39, but also 
endothelial and cardiovascular differentiation40, neurogenic differentiation41-43, 





MSCs transplantation in most AMI animal models generally resulted in reduced 
infarct size, improved left ventricular ejection fraction, increased vascular density, 
and myocardial perfusion47-51. In a recent phase I randomized double blind 
placebo-controlled dose-escalation clinical trial, single infusion of allogeneic 
MSCs in patients with AMI was documented to be safe with some provisional 
indications that the MSC infusion improved outcome with regard to cardiac 
arrhythmias, pulmonary function, left ventricular function, and symptomatic 
global assessment52.   
Despite numerous studies on the transplantation of MSCs in patients and animal 
models, insight into the mechanistic issues underlying the effect of MSC 
transplantation remains vague.  An often-cited hypothesis is that transplanted 
MSCs differentiate into cardiomyocyte and supporting cell types to repair cardiac 
tissues.  However, contrary to this differentiation hypothesis, most transplanted 
MSCs are entrapped in the lungs and the capillary beds of tissues other than the 
heart53,54.  And depending on the method of infusion, 6% or less of the 
transplanted MSCs persist in the heart two weeks after transplantation55.  In 
further contradiction, transplanted MSCs were observed to differentiate 
inefficiently into cardiomyocytes56 while ventricular function was rapidly restored 
less than 72 h after transplantation57.  All these observations are physically and 
temporally incompatible with the differentiation hypothesis and have thus 
prompted an alternative hypothesis that the transplanted MSCs mediate their 







Paracrine Secretion of MSCs 
Paracrine secretion of MSCs was reported more than 15 years ago when 
Haynesworth et al. reported that MSCs synthesize and secrete a broad spectrum of 
growth factors and cytokines such as VEGF, FGF, MCP-1, HGF, IGF-I, SDF-1 
thrombopoietin59-63 that exert effects on cells in their vicinity 64. Paracrine 
secretion have been postulated to promote arteriogenesis61; support the stem cell 
crypt in the intestine65; protect against ischemic renal59,60 and limb tissue injury62; 
support and maintain hematopoiesis63; support the formation of megakaryocytes 
and proplatelets66; and promote breast cancer metastasis67. Many of these factors 
such as VEGF, HGF, bFGF were also found to exert beneficial effects on the heart, 
including neovascularization68, attenuation of ventricular wall thinning50 and 
increased angiogenesis69,70.  
In 2005, Gnecchi et al. showed that intramyocardial injection of either culture 
medium conditioned by MSCs overexpressing the Akt gene (Akt-MSCs) or the 
Akt-MSCs reduced infarct size in a rodent model of AMI to the same extent. This 
provided the first direct evidence that cellular secretion alone could be 
cardioprotective57,71.  Again, in 2008, Timmers et al. showed that culture medium 
conditioned by hESC-MSCs significantly reduced infarct size by approximately 
50% in a pig and mouse model of MI/R injury when administered intravenously in 
a single bolus just before reperfusion72. These observations represent a very 
important step forward in our understanding of the cardioprotective mechanism of 
MSC-based therapy in AMI. It clearly demonstrated that cardiac repair could be 
achieved without the actual participation of the cells themselves but by simply 
administering their secretion. These discoveries explained the fast acting effect of 





and differentiation did not affect the efficacy of the MSC transplantation. More 
importantly, these findings could potentially facilitate the translation of cell-free 
secretion as an adjunctive therapy to reperfusion therapy if the active 
cardioprotective factor of these paracrine secretions could be identified.  
 
Thesis 
The specific aims of this PhD project were to identify the active cardioprotective 
factor of the MSCs secretion and to elucidate the mechanisms of the 
cardioprotection.  The findings from this project have been either published in 
peer-reviewed papers or are in manuscripts under peer review for publication. The 
papers and manuscripts are attached in the following chapter. I am also a co-
author of 4 publications73-76 where I contributed my expertise in exosome biology.  
These publications are in areas that are not directly relevant to my thesis.  
Four papers in the following chapters described the work leading to discoveries 
that exosome is the cardioprotective factor in the MSC secretion, secretion of 
cardioprotective exosome is a property of MSCs, exosome carries a cargo that has 
diverse biochemical and cellular potential and the exosome elicits cellular 
responses that are known to be cardioprotective and are consistent with its 
biochemical cargo. 
In the first paper, “Exosome secreted by MSC reduces myocardial 
ischemia/reperfusion injury”, we addressed the question “What is the active 
cardioprotective factor of the MSCs secretion?” By filtering the secretion 
sequentially through filters with decreasing pore sizes, fractions containing 





that only >1000 kDa 0.2µM filtered fraction reduced infarct size. This finding 
limited the physical size of cardioprotective factor to 100-220 ηm, which is much 
larger than the typical paracrine mediators that usually consist of growth factors, 
cytokines and chemokines77. Under the transmission electron microscope, we 
observed ~100 ηm diameter particles in the secretion. Based on the size range and 
morphology of these particles and current research literature we postulated that 
the likely candidate was a secreted phospholipid vesicle known as exosome.  
We next investigated whether exosomes are present in the secretion.  We first did 
a proteomic analysis of MSC secretion using mass spectrometry and antibody 
array to check if the secretion contained proteins that are commonly found in 
exosomes such as CD9, CD81 and Alix78. 738 proteins were detected and these 
included most of the reported exosomes-associated protein. The presence of some 
of exosomes-associated proteins was confirmed by Western blot analysis. 
Furthermore, we observed exosome-associated proteins, CD9 and Alix, co-
immunoprecipitated with another exosome-associated proteins, CD81, suggesting 
that these proteins were in a single complex. As exosomes are routinely purified 
by ultracentrifugation, we checked if we could precipitate CD9 by 
ultracentrifuging the secretion. The result showed that CD9 could be precipitated. 
At the same time, we also observed enrichment of major plasma membrane 
component such as cholesterol, sphingomyelin and phosphotidylcholine in the 
ultracentrifugation pellet. We further checked if the flotation densities of CD9 and 
CD81 fall within the typical density range of exosome, which is 1.10-1.18 g/ml. 
The results showed that they both floated in the density range of exosome and 
pretreatment with a detergent-based cell lysis buffer decreased the apparent 





weight range. By limited trypsinization, we also showed that CD9, a membrane-
bound protein, was partially susceptible to trypsin digestion, and this partial 
susceptibility of CD9 was detergent-sensitive. This was consistent with its 
localization in a lipid membrane. In summary, these observations suggested the 
existence of exosomes in the secretion.  
To prove the existence of exosome in the secretion, we tried to purify exosomes 
from the secretion by size exclusion on a HPLC. The first 8 eluted fractions (F1 to 
F8, based on the absorbance profile at 220 nm) from HPLC were collected. Only 
F1 to F4 contained proteins as shown by silver staining. Proteins were distributed 
among F2, F3, and F4 fractions according to the principle of size-exclusion 
fractionation that larger proteins were eluted first followed by smaller proteins.  
Proteins in F2 were generally larger than those in F3 which in turn were larger 
than those in F4.   In contrast, proteins in the F1 fraction had a MW distribution 
that spanned the entire MW spectrum of F2, F3, and F4.  Dynamic light scattering 
analysis showed that F1 contained homogeneously sized particles with a 
hydrodynamic radius of 55-65 ηm. Western blot analysis showed that CD9 was 
present exclusively in the F1 and had a flotation density in the range of exosome, 
i.e. 1.10-1.18 g/ml. These features of the F1 fraction, i.e., the proteins with a wide 
spectrum of MW, exclusive presence of CD9 and homogenously sized particles 
were consistent with presence of exosome and indicated that exosomes were 
successfully purified from the secretion by HPLC fractionation.  When 0.4 μg of 
F1 proteins were administered to a mouse model of MI/R injury 5 min prior to 
reperfusion, it reduced infarct size to the same extent as 3 μg secretion proteins. In 







In the second paper, “Derivation and characterization of human fetal MSCs: an 
alternative cell source for large-scale production of cardioprotective 
microparticles”, we assessed if cardioprotective exosome was secreted by MSCs 
in general. Five MSC cultures were derived from limb, kidney and liver tissues of 
3 first-trimester aborted fetuses. These fetal tissue-derived MSCs have a stable 
karyotype and similar telomerase activities to hESC-MSCs. They are highly 
expandable, each line has the potential to generate at least 1016-19 cells or 107–10 
doses of cardioprotective secretion for a pig model of MI/R injury. They displayed 
a typical MSC surface antigen profile, but unlike previously described fetal MSCs, 
they did not express pluripotency-associated markers such as Oct4, Nanog or 
Tra1-60.  They have the potential to differentiate into adipocytes, osteocytes and 
chondrocytes in vitro. Global gene expression analysis by microarray revealed a 
typical MSC gene expression profile that was highly correlated among the five 
fetal MSC cultures and with that of hESC-MSCs. Most importantly, like hESC-
MSCs, they produced exosomes that were cardioprotective in a mouse model of 
MI/R injury. Together we demonstrated that fetal tissues-derived MSCs also 
produced cardioprotective exosome and that the secretion of protective exosomes 
was not an exclusive characteristic of hESC-MSCs but possibly a universal 
property of all MSCs. 
 
In the third paper, “Characterizing the biological potency of MSC exosome by 
cellular and biochemical validation of its proteome”, we assessed the biochemical 





cardioprotective effect of hESC-MSCs. We profiled the proteome of MSC 
exosome to identify 866 proteins. These proteins could be functionally clustered 
into 32 over-represented biological processes. Together, these suggested 
exosomes had a potential to drive a diverse spectrum of cellular and biochemical 
activities. To evaluate and verify this potential, we selected proteins for which 
assays to assess either their biochemical and/or cellular activities were available 
and that together, would demonstrate the wide spectrum of biochemical and 
cellular potential in exosomes, and provide candidate molecular mechanisms for 
the cardioprotective properties of MSC exosomes. The proteins investigated here 
include glycolytic enzymes for the breakdown of glucose to generate ATP and 
NADH, PFKB3 that increases glycolysis, CD73 that hydrolyses AMP to 
adenosine capable of activating signaling cascades through adenosine receptors, 
CD59 that inhibits the formation of membrane attack complex (MAC) and 20S 
proteasome that degrade oxidized protein.   
All five enzymes (GAPDH, PGK, PGM, ENO, PKm2) in the ATP generating 
stage of the glycolysis were present in the exosome proteome. In addition, 
PFKFB3 a powerful allosteric activator of phosphofructokinase, which catalyzes 
the commitment to glycolysis79, was shown to be present in the phosphorylated 
form. This predicted that exposure of cells to exosome could result in increased 
glycolytic flux in the cells. Consistent with the prediction, exosomes significantly 
increased ATP level in oligomycin-treated cells. Another group of proteins, 
PMSA1-7 and PMSB1-7, which form the 20S proteasome, were also detected in 
our exosome proteome. The presence of all seven α- and all seven β-subunits of 
the 20S core particle suggest that MSC exosomes contained intact 20S proteasome 





Consistent with this, MSC exosome was able to degrade short fluorogenic 
peptides and this degradation was inhibited by lactacystin, a specific proteasome 
inhibitor.  
Besides these 2 groups of proteins, CD73, an enzyme that converts AMP into 
adenosine, was also found in exosome proteome. This suggested that exosomes 
might have the potential to induce adenosine-mediated signaling. Consistent with 
this hypothesis, we demonstrated exosomes could hydrolyze AMP to adenosine 
by CD73 and subsequently induced phosphorylation of AKT and ERK1/2 in a 
serum starvation cell model. This phosphorylation of ATK and ERK1/2 could be 
abolished by theophylline, a non-selective adenosine receptor antagonist that 
antagonized A1, A2A, A2B, and A3 receptors80. In addition, we also verified the 
functional ability of another important protein detected in exosome, CD59, an 
inhibitor of the formation of membrane attack complex (MAC). We showed that 
MSC exosomes were able to inhibit complement-mediated lysis of sheep red 
blood cells. This inhibition was abolished when a CD59 blocking antibody was 
used to pre-treat the exosome, showing that CD59 of exosomes was directly 
involved in the inhibition of complement lysis. All together, in this paper, our 
interrogation and biochemical validation of the exosome proteome have 
uncovered a diverse range of biochemical and cellular activities and identified 
several candidate biological processes for the cardioprotective effect of the 
exosome.  Further validation studies in appropriate animal models will be required 
to determine if one or more of these candidate pathways contributed to the 






In the fourth paper, “Exosomes target multiple mediators to reduce cardiac injury”, 
we described both therapeutic and mechanistic actions of MSC exosomes in an 
animal model MI/R injury. First, we studied the mode of action of exosome 
cardioprotection by asking whether exosomes exert their therapeutic effect via 
blood cells or via direct interaction with myocardial cells. Exosome treatment in 
ex vivo MI/R experiments by the Langendorff setup reduced infarct size to the 
same extent as in vivo. This suggested that exosomes directly targeted myocardial 
cells to reduce MI/R injury without involving circulating cells. We further showed 
that vigorous agitation to disrupt exosome abolished its cardioprotective effect. 
This demonstration highlighted the importance of intact lipid membrane in 
mediating exosome cardioprotection. 
We then examined the cardiac performance of exosome-treated heart. Functional 
and geometry assessment of left ventricle by MRI measurement showed 
significant preservation of both end-diastolic and end-systolic volume, improved 
ejection fraction, decreased thinning of the infarct area during scar maturation and 
improved systolic thickening of the infarcted area in the exosome-treated group. 
These observations were consistent with the infarct size reduction seen after 
exosome treatment. By invasive pressure-volume loop recording, we also 
observed higher contractility and relaxation in exosome treated mice 28 days after 
infarction, which is consistent with the consequences of reduced dilation and 
improved systolic performance. Besides functional improvement, we also 
observed attenuation of inflammation including reduced neutrophil infiltration and 
reduced white blood cell count after MI/R injury in exosome treated mice. These 





Having established the functional improvement in exosomes treated heart after 
MI/R injury, we explored potential mechanisms of this therapeutic effect. We 
selectively evaluated the potential mechanisms that we previously proposed in our 
exosome biochemical study paper to confirm whether they are valid in the in vivo 
MI/R injury model. We first explored the possibility that exosome reduced infarct 
size by activating survival pathways, especially PI3K/AKT pathway. Exosome 
treatment induced AKT and GSK3 phosphorylation within 1-hour after 
reperfusion. However, ERK1/2 phosphorylation was not altered in exosome 
treated group. These suggested that exosomes specifically target AKT and GSK3 
pathway to induce pro-survival effects. At the same time, c-JNK, a known 
activator of pro-apoptotic was significantly dephosphorylated. In addition, we 
demonstrated that ADP/ATP and NAD+/NADH ratio in the area at risk of 
exosome-treated mice were significantly lower in 30 minutes after reperfusion 
compared with the saline-treated control. These observations were consistent with 
our previous in vitro biochemical and cellular validations. Together, these findings 
highlighted the fast acting effect of exosomes and suggested that activating 
survival pathway, enhancing ATP production and correcting redox balance 
through glycolysis might be the potential cardioprotective mechanisms of 
exosome. In conclusion, this study showed the therapeutic action of exosome and 
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Abstract Human ESC-derived mesenchymal stem cell (MSC)-conditioned medium (CM) was previously shown to
mediate cardioprotection during myocardial ischemia/reperfusion injury through large complexes of 50–100 nm. Here we show
that these MSCs secreted 50- to 100-nm particles. These particles could be visualized by electron microscopy and
were shown to be phospholipid vesicles consisting of cholesterol, sphingomyelin, and phosphatidylcholine. They contained
coimmunoprecipitating exosome-associated proteins, e.g., CD81, CD9, and Alix. These particles were purified as a homogeneous
population of particles with a hydrodynamic radius of 55–65 nm by size-exclusion fractionation on a HPLC. Together these
observations indicated that these particles are exosomes. These purified exosomes reduced infarct size in a mouse model of
myocardial ischemia/reperfusion injury. Therefore, MSC mediated its cardioprotective paracrine effect by secreting exosomes.
This novel role of exosomes highlights a new perspective into intercellular mediation of tissue injury
and repair, and engenders novel approaches to the development of biologics for tissue repair.
© 2009 Elsevier B.V. All rights reserved.
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Introduction
Mesenchymal stem cells (MSCs) derived from adult bone
marrow have emerged as one of the most promising stem
cell types for treating cardiovascular disease (Pittenger and
Martin, 2004). Although the therapeutic effect of MSCs has
been attributed to their differentiation into reparative or
replacement cell types (e.g., cardiomyocytes, endothelial
cells, and vascular smooth cells) (Minguell and Erices, 2006;
Zimmet and Hare, 2005), it remains to be established if the
number of differentiated cell types generated is therapeu-
tically relevant. Recent reports have suggested that some of
these reparative effects are mediated by paracrine factors
secreted by MSCs (Caplan and Dennis, 2006a; Gnecchi et al.,
2005, 2006; Schafer and Northoff, 2008). In support of this
paracrine hypothesis, many studies have observed that MSCs
secrete cytokines, chemokines, and growth factors that
could potentially repair injured cardiac tissue mainly
through cardiac and vascular tissue growth and regeneration
(Caplan and Dennis, 2006b; Liu and Hwang, 2005). This
paracrine hypothesis could potentially provide for a non-
cell-based alternative for using MSCs in treatment of
cardiovascular disease (Pittenger and Martin, 2004). Non-
cell-based therapies as opposed to cell-based therapies are
generally easier to manufacture and are safer as they are
nonviable.
We have previously performed an unbiased proteomic
analysis of a chemically defined medium conditioned by
highly expandable human ESC-derived MSC cultures (Lian et
al., 2007; Sze et al., 2007). We identified N200 proteins in
the secretion of these MSCs (Sze et al., 2007). Computational
analysis of the secretome predicted that collectively, the
secretome has the potential to repair injured tissue such as
in myocardial ischemia/reperfusion (MI/R) injury (Sze et al.,
2007). MI/R injury refers to cell death and functional
deterioration that occurs during reperfusion therapy to
restore blood flow and salvage cardiomyocytes at risk of
dying from ischemia in an acute MI (AMI) (Cannon et al.,
2000; Saraste et al., 1997). Therefore, the effectiveness of
reperfusion therapy can be greatly enhanced by preventing
reperfusion injury for which there is currently no treatment
(Knight, 2007). We tested the computational prediction of
tissue salvage during reperfusion injury in a pig and mouse
models of MI/R injury. An intravenous bolus administration of
MSC-CM just before reperfusion substantially reduced infarct
size in both pig and mouse models of MI/R injury by ~60 and
~50%, respectively (Timmers et al., 2008). There was also a
significant preservation of cardiac function and reduction of
oxidative stress as early as 4 h after reperfusion (Timmers et
al., 2008). However, the active component in the secretion
and the mechanism by which it mediates this fast-acting
effect on MI/R injury have not been elucidated.
It is obvious that the immediacy of this protective effect
precludes the relatively lengthy process of gene transcription
and tissue regeneration as part of themechanism. Also, many
of the secreted proteins are membrane and intracellular
proteins, and are not known to cross plasma membranes
readily. This suggests that if these proteins mediate the
cardioprotective effect, the mechanism underlying the
therapeutic effect of MSC secretion must involve a vehicle
that facilitates crossing of membranes, thus representing a
radical shift from our present understanding of MSC paracrine
secretion which is limited to extracellular signaling by
cytokines, chemokines, and growth factors. To better
understand the cardioprotective paracrine effects of MSCs,
we then systematically fractionated the MSC-CM using
membranes with different molecular weight cut off
(MWCO). Based on these fractionations, we demonstrated
that the cardioprotective activity was in a N1000-kDa MW
fraction (Timmers et al., 2008). This suggested that the
cardioprotective effect was mediated by large complexes
with a diameter of 50–100 nm.
Here we demonstrate that these large complexes are
exosomes. By improving our proteomic analysis, we extend-
ed our previously reported list of 201 secreted proteins to
739 proteins and observed the presence of many exosome-
associated proteins. Some of these proteins were in
detergent-sensitive complexes. These proteins can be
sedimented by ultracentrifugation together with the mem-
brane phospholipids. Size-exclusion fractionation by HPLC
and dynamic light scattering analysis revealed the presence
of a population of particles with a hydrodynamic radius (Rh)
of 55–65 nm. More importantly, this HPLC fraction reduced
infarct size in a mouse model of MI/R injury.
Results
Cardioprotective secretion contains
exosome-associated proteins that form multiprotein
complexes
To identify the active component, we had previously
fractionated the CM by ultrafiltration through membranes
with different MWCO. It was shown that CM filtered through a
membrane with MWCO of 1000 kDa was not protective in a
mouse model of MI/R injury (Timmers et al., 2008). However,
CM concentrated by 125 times against a similar membrane
was protective. We observed that after filtration through
filters with a MWCO smaller than 0.2 mm such as 100, 300,
500, or 1000 kDa, the filtered CM was not cardioprotective
(Fig. 1A). In contrast, CM concentrated against a 1000-kDa
membrane (Timmers et al., 2008) or a 100-kDa membrane to
retain particles N1000 or 100 kDa, respectively, was
cardioprotective (Fig. 1). These observations suggested
that the active fraction consisted of large complexes of
N1000 kDa or had a predicted diameter of 50–100 nm.
Consistent with this, visualization of the CM by electron
microscopy revealed the presence of spherical structures
with a diameter of 50–100 nm and the morphology of a lipid
vesicle (Fig. 1B). Based on this size range and morphology,
we postulated that the likely candidate was a secreted
phospholipid vesicle known as exosome (Fevrier and Raposo,
2004; Keller et al., 2006).
To test this, we first determined if the CM contained the
subset of proteins that are commonly found in exosomes such
as CD9, CD81, and Alix (Olver and Vidal, 2007). These
proteins were not present in our previous proteomic profiling
of the secretion (Sze et al., 2007). By making modifications
to our proteomics methodology, we extended our list of
proteins found in the MSC secretion from 201 to 739 proteins
(Supplementary Table 1). The computationally predicted
biological activities of this proteome suggested that the
secretion will have significant biological effects on cardiac
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tissue injury and repair (Fig. S1). The subsets of exosome-
associated proteins CD9, CD81, and Alix were confirmed to
be present in the secretion by Western blot analysis (lane 1,
Fig. 2A). The MW of CD9 and CD81 was the expected 25 and
22–26 kDa, respectively. Consistent with our hypothesis that
the large complexes are exosomes, we observed that CD9
and Alix coimmunoprecipitated with CD81, suggesting that
these proteins were in a single complex (Fig. 2A).
A 24-kDa CD9 sediments at 200 000 g and is retained
by membrane with 500-kDa MWCO
As exosomes are routinely purified by ultracentrifugation
(Thery et al., 2006), we next determined if CD9 was
associated with a large complex that can be precipitated
by ultracentrifugation. The CMwas first fractionated through
a membrane (MWCO=500 kDa) into a N500-kDa retentate
fraction and a b500-kDa filtrate fraction followed by
ultracentrifugation of both fractions. The 24-kDa CD9 was
found in the N500-kDa retentate fraction and could be
precipitated by ultracentrifugation (Fig. 2B). CD9 was not
detected in the b500-kDa filtrate fraction. Consistent with
our exosome hypothesis, major plasma membrane phospho-
lipids such as cholesterol, sphingomyelin, and phosphatidyl-
choline were also precipitated by ultracentrifugation at
200 000 g for 2 h as evidenced by their enrichment in the
precipitate (Fig. 2C).
Figure 1 Cardioprotective properties of CM fractions. (A)
Saline, HEK293 CM, or different preparations of hESC-MSC CM
were administered to a mouse model of MI/R injury as described
under Materials and methods. The b1000, b500, b300, and
b100 kDa represented CM filtered sequentially with membranes
that had MWCO of 1000, 500, 300, and 100 kDa, respectively.
The N100 kDa represented CM concentrated 50 times against a
TFF membrane with MWCO of 100 kDa. The infarct size (IS) was
expressed as a fraction of the area at risk (AAR) in the left
ventricle. (B) Transmission electron microscopic picture of CM;
scale bar represents 500 nm.
Figure 2 Presence of large lipid complexes in CM. (A)
Coimmunoprecipitation of CD81, CD9, and Alix. After immuno-
precipitation of hESC-MSC CM with anti-CD81 or mouse IgG, the
immunoprecipitate (IP) and supernatant (S) were analyzed by
Western blot hybridization using antibody against CD9 and Alix.
(B) Size fractionation by ultrafiltration and ultracentrifugation.
CM was concentrated 5X using a membrane with MWCO of
500 kDa. The retentate and the unfiltered CM were then
ultracentrifuged at 200 000 g for 2 h. The supernatant and the
pellet were analyzed by Western blotting for the presence of
CD9. Lanes 1–3: Different protein amount of CM. Lanes 4 and 5:
The pellet (P) and supernatant (S) after ultracentrifugation of
unfiltered CM. Lane 6: Retentate (R) after filtration of CM
through a membrane with MWCO of 500 kDa. Lanes 7 and 8: The
pellet (RP) and supernatant (RS) after ultracentrifugation of
retentate. Lane 9: Filtrate (F) after filtration of CM through a
membrane with MWCO of 500 kDa. (C) Amount of cholesterol,
spingomyelin, and phosphatidylcholine in CM and in the pellet
after 200 000 g ultracentrifugation of the CM was assayed and
quantitated as picomole per microgram protein.
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Proteins in the CM are associated with phospholipid
membrane
As exosomes are phospholipid vesicles, they are known to have
a typical density range of 1.10 to 1.18 g ml−1 that could be
resolved on sucrose gradients (Raposo et al., 1996; Thery et
al., 2006).We therefore postulated that the flotation densities
of the putative exosome-associated proteins would be
different before and after release from such vesicles by a
detergent-based buffer. Therefore, CM or CM pretreated with
a detergent-based lysis buffer was fractionated on a sucrose
density gradient by equilibrium ultracentrifugation. The
fractions were analyzed for the distribution of CD9 and
CD81. Both CD9 and CD81 which coimmunoprecipitated (Fig.
2A) had a similar flotation density that was heavier than that
expected of proteins in their MW range (Fig. 3). Pretreatment
with a detergent-based cell lysis buffer decreased the
apparent flotation densities of CD9 and CD81 to that of
proteins in a similar MW range (Fig. 3). Our observations
demonstrated that the detergent-sensitive flotation densities
of proteins were consistent with their location in lipid vesicles.
Exosomal proteins are either membrane bound or
encapsulated
As many of the secreted proteins in the CM are known
membrane or cytosolic proteins, we investigated if these
proteins in the CM were also membrane bound or localized
within the lumen of the putative exosomes by limited
trypsinization. Membrane-bound proteins would expected
to be partially resistant whereas luminal proteins are
expected to be resistant to trypsinization. Treatment with
a detergent-based lysis buffer would abrogate this resis-
tance. As expected, CD9, a membrane-bound protein was
susceptible to trypsin digestion and generated two detect-
able tryptic peptide intermediates (Fig. 4). In contrast, SOD-
1, a cytosolic protein was resistant to trypsin digestion.
Pretreatment of CM with a detergent-based cell lysis buffer
abolished the resistance of CD9 and SOD-1 to trypsin
digestion. The detergent-sensitive partial susceptibility of
CD9 and resistance of SOD-1 to trypsin digestion were
consistent with their localization in a lipid membrane and
lumen of an exosome, respectively.
Purification of a homogeneous population of
exosomes by HPLC fractionation
To demonstrate directly that the active cardioprotective
component in the secretion is an exosome, CM and
nonconditioned medium (NCM) were first fractionated by
size exclusion on a HPLC column (Fig. 5A).The eluent was
monitored by absorbance at 220 nm and then examined by
dynamic light scattering which has a hydrodynamic radius
(Rh) detection range of 1 to 1000 nm. The first four eluting
fractions in CM (F1–F4) were not present in the NCM and
therefore represented secretion from the hESC-MSCs. F1, the
fastest eluting fraction with a retention time of 12 min,
represented the fraction containing the largest particles in
the CM. The particles in F1 were sufficiently homogeneous in
size such that they could be determined by dynamic light
scattering to have a hydrodynamic radius (Rh) of 55–65 nm.
All other peaks contained particles that were too heteroge-
neous in size to be estimated by dynamic light scattering. F1
contained 4% of total protein input but contained ∼50% of
the CD9 in the input (Fig. 5B). Proteins were distributed
among F2, F3, and F4 fractions according to the principle of
size-exclusion fractionation such that larger proteins were
eluted first in F2 followed by the smaller proteins in F3 and
the smallest in F4 (Fig. 5C). In contrast, proteins in the F1
fraction had a MW distribution that spanned the entire MW
spectrum of F2, F3, and F4 (Fig. 5C). The proteins in the F1
fraction despite having a MW range of 20 to 250 kDa
Figure 3 Protein analysis of CM fractionated on a sucrose
gradient density. CM or CM pretreated with lysis buffer was
loaded on a sucrose density gradient prepared by layering 14
sucrose solutions of concentrations from 22.8 to 60% (w/v) in a
SW60Ti centrifuge tube and then ultracentrifuged for 16.5 h at
200 000 g, 4 °C, in a SW60Ti rotor. The gradients were removed
from the top and the density of each fraction was calculated by
weighing a fixed volume of each fraction. The fractions were
analyzed by Western blot analysis for CD9 and CD81 in CM (upper
panel) and pretreated CM (lower panel). The distribution of a
protein standardmolecular weightmarker set after fractionation
in a similar gradient is denoted at the bottom of the figure.
Figure 4 Trypsinization of CM. CM treated with either PBS or
lysis buffer was digested with trypsin and an aliquot was
removed at 0.5, 2, 10, and 20 min. A trypsin inhibitor, PMSF,
was then added to terminate the trypsinization reaction and the
aliquots were analyzed for the presence of CD9 and SOD-1 by
Western blot hybridization.
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sedimented at a similar flotation density of 1.11–1.16 g/ml
(Fig. 6B) that was similar to that of CD9 in the CM (Fig. 3).
These features of the F1 fraction, i.e., the presence of
proteins with a wide spectrum of MW sizes and identical
flotation density, the exclusive presence of CD9, and a
homogeneous size, indicated that a homogeneous exosome
population was purified from the CM by HPLC fractionation.
When 0.4 μg of F1 protein was administered to a mouse
model of MI/R injury 5 min prior to reperfusion, the F1
fraction reduced infarct size to the same extent as 3 μg CM
protein (Fig. 7A). All animals in this study had the same
degree of endangered myocardium, as illustrated by similar
area at risk within the left ventricle (Fig. 7B).
Paracrine effect was mediated through heart tissues
For elucidating the mechanism of this paracrine effect, an
important prerequisite is the identification of the target
tissues. Here we determine that the paracrine effect on MR/I
injury was a heart autonomous effect and was independent of
circulating cells including immune cells. Using an ex vivo
mouse Langendorff heart model of ischemia/reperfusion
injury, we observed that conditioned medium reduced
relative infarct size to the same extent as in a mouse model
(Fig. 8).
Discussion
The trophic effects of MSC transplantation on ameliorating the
deleterious consequences of myocardial ischemia have been
implicated in several studies (Caplan and Dennis, 2006a).
Transplantation of MSCs into ischemic myocardium has been
shown to induce several tissue responses such as an increased
Figure 6 Flotation densities of proteins in CM and HPLC-
purified F1 fraction were determined by fractionating CM and F1
onto a sucrose gradient density as described above. The 13
fractions for (A) CM and (B) F1 were separated on a SDS-PAGE and
then stained with silver. (C) To evaluate the distribution of
smaller proteins, the F1 was also assayed for CD9 (20 kDa) by
Western blot hybridization. Proteins in the N1.20 g/ml density
fractions were denatured proteins.
Figure 5 HPLC fractionation of CM. (A) HPLC fractionation and
dynamic light scattering of CM and NCM. CM and NCM were
fractionated on a HPLC using a BioSep S4000, 7.8 mm×30 cm
column. The components in CM or NCM were eluted with 20 mM
phosphate buffer with 150 mM NaCl at pH 7.2. The elution mode
was isocratic and the run time was 40 min. The eluent was
monitored for UV absorbance at 220 nm. Each eluting peak was
then analyzed by light scattering and signals as measured in
voltage are represented by solid triangles. The eluted fractions,
F1 to F8, were collected, their volumes were adjusted to 50% of
the input volume of CM, and an equal volume of each fraction
was analyzed for (B) the presence of CD9 by Western blot
hybridization. Lanes 1–3 were CM loaded at 2X, 1X, or 0.5X of
the volume loaded used for each of the fractions, F1 to F8 (lanes
4–11), and therefore represented the equivalent of 100, 50, and
25% input CM. (C) Equal volumes of F1–F8 were separated on a
SDS-PAGE and then stained with silver.
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production of angiogenic factors and decreased apoptosis
(Tang et al., 2005). It was postulated that these responses
were better explained by secretion of paracrine factors than
by differentiation of MSCs. In this context, MSCs were shown
to secrete many growth factors and cytokines that have
effects on cells in their vicinity. To date, many of these
studies have focused exclusively on proteins that are known to
be secreted. These proteins generally included cytokines,
chemokines, and other growth factors (Caplan and Dennis,
2006a). However, our unbiased proteomic profiling of proteins
in the secretion of MSCs revealed an abundance of membrane
and cytosolic proteins (Sze et al., 2007). This suggests that the
trophic effects of MSCs may not be mediated by soluble
growth factors and cytokines alone. This was underscored by
our observation that the cardioprotective effects of CM were
mediated by 50- to 100-nm complexes of N1000 kDa (Timmers
et al., 2008) and not small soluble proteins.
Based on the size of the complex, we postulated that the
cardioprotective complex in the CM was likely to be an
exosome. Exosomes are formed from multivesicular bodies
with a bilipid membrane (Fevrier and Raposo, 2004; Keller et
al., 2006). They have a diameter of 40–100 nm and are known
to be secreted by many cell types (Fevrier and Raposo, 2004;
Keller et al., 2006). Electron microscopy confirmed that the
CM contained lipid-like vesicles of about 50–100 nm in
diameter. The functions of exosomes are not known but they
are thought to be important in intercellular communications.
Although exosomes are known to have a cell-type-specific
protein composition, most carry a common subset of proteins
that included CD9, CD81, Alix, TSP-1, SOD-1, and pyruvate
kinase (Olver and Vidal, 2007). CD9 and CD81 are tetrapannin
membrane proteins that are also localized in the membrane
of exosomes. Consistent with the presence of exosomes, CM
contained coimmunoprecipitating complexes of CD81, CD9,
and Alix. Ultracentrifugation precipitated CD9 with phospho-
lipids and cholesterol, suggesting that the CD81, CD9, and
Alix complex was associated with a phospholipid vesicle. This
was confirmed by the detergent-sensitive flotation densities
of these proteins where we demonstrated that the flotation
densities of these proteins in the CM were that of phospho-
lipid vesicles and that detergent treatment which dissolved
phospholipid membrane altered the flotation densities of the
proteins. We further demonstrated that CD9 in the CM was a
membrane-bound protein while SOD-1 was localized within a
lipid vesicle by their respective partial and complete
resistance to trypsin degradation and the abrogation of this
resistance by detergent. Taken together, our observations
demonstrated that exosomes with a diameter of 50–100 nm
are present in the CM and are therefore the likely candidate
for the cardioprotective component in the CM. This was
confirmed when a HLPC-purified homogeneous population of
particles that had an enrichment of CD9 and a Rh of 55–
65 nm substantially reduced infarct size in a mouse model
of MI/R injury at a reduced protein dosage equivalent to
∼10% of the CM dosage. We further demonstrated using an
ex vivo mouse Langendorff heart model of MI/R injury that
this paracrine effect was a heart autonomous effect, and
was independent of circulating cells, such as immune cells or
platelets.
In summary, we have identified exosome as the cardio-
protective component in MSC paracrine secretion. This
involvement of exosomes represents a radical shift in our
current understanding of the paracrine effect of MSC
transplantation on tissue repair which hitherto has been
limited to cytokine, chemokine, or growth factor-mediated
extracellular signaling. It also highlights for the first time the
role of exosome as mediator of tissue repair. As lipid vesicles,
Figure 7 Cardioprotective exosomes. A 0.4 μg F1 protein was
administered intravenously to a mouse model of MI/R injury
5 min before reperfusion. Infarct sizes (IS) as a percentage of the
area at risk (AAR) on treatment with saline (n=10), conditioned
medium from hESC-MSCs (n=6), and HPLC fraction (n=5) were
measured. Saline treatment resulted in 34.5±3.3% infarction.
CM treatment resulted in 21.2±2.6% infarction (P=0.022
compared to saline) and F1 fraction treatment resulted in 17.0±
3.6% infarction (P=0.004 compared to saline). (B) AAR as a
percentage of the left ventricle (LV), showing the amount of
endangered myocardium after MI/R injury. All animals were
affected to the same extent by the operative procedure,
resulting in 39.1±2.2% of AAR among the groups. Each bar
represents mean±SEM.
Figure 8 Secretion reduced myocardial ischemia-reperfusion
injury ex vivo. Perfusion buffer containing 3.5 μg/ml CM was
used to perfuse mouse heart in an ex vivo mouse Langendorff
heart model of MI/R injury 5 min before reperfusion. Infarct
sizes (IS) as a percentage of the area at risk (AAR) on treatment
with PBS (n=4) and CM (n=4) were measured after 3 h
reperfusion. Langendorff_PBS treatment resulted in 49.3±5.3%
infarction. Langendorff_CM treatment resulted in 24.6±4.4%
infarction (Pb0.001 compared to Langendorff_PBS). As a
reference for comparison, the in vivo effects of saline and CM
on IS/AAR as described in Fig. 7 are also included.
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exosomes represent an ideal vehicle to effect an immediate
physiological response to repair and recover from injury
through the rapid intracellular delivery of functional
proteins. Recently, it was demonstrated that in addition to
proteins, microvesicles have the potential to mediate
intercellular transfer of genetic material (reviewed in
Quesenberry and Aliotta, 2008). Several tumor cell types
(Rosell et al., 2009; Taylor and Gercel-Taylor, 2008),
peripheral blood cells (Hunter et al., 2008; Valadi et al.,
2007), endothelial progenitor cells (Deregibus et al., 2007),
and embryonic stem cells (Ratajczak et al., 2006) have been
shown to secrete RNA-containing microvesicles. More impor-
tantly, these microvesicular RNA could be transferred to
other cells and translated in the recipient cells (Deregibus et
al., 2007; Ratajczak et al., 2006; Valadi et al., 2007). We also
recently demonstrated that the MSC-derived exosomes
described here also contained miRNAs and these miRNAs
were predominantly in the precursor form (Chen et al.,
2010). For reperfused ischemic myocardium, this feature of
rapid initiation of cellular repair through the intracellular
delivery of functional proteins and possibly RNA is particu-
larly critical as the time window for therapeutic intervention
is very narrow. We speculate that the involvement of
exosomes in cardioprotection may represent a general
function of exosomes in tissue repair. It is possible that
different cell types produce exosomes that are specific for
certain type of cells or injuries. If true, this novel tissue-
repair function of exosomes could potentially engender new
approaches to the development of biologics.
Materials and methods
Preparation of CM
The culture of HuES9.E1 cells and preparation of HuES9.E1 CM
were performed as described previously (Lian et al., 2007; Sze
et al., 2007). For the b100-, b300-, b500-, or b1000-kDa
preparations in Fig. 1, the CM was first concentrated 25X by
tangential flow filtration (TFF) using a membrane with a 10-
kDa MWCO (Sartorius, Goettingen, Germany) and then filtered
sequentially through membranes with MWCO of 1000 kDa
(Sartorius), 500 kDa (Millipore, Billerica, MA), 300 kDa
(Sartorius), and finally 100 kDa (Sartorius). All other CM and
NCM used were concentrated 25X or 50X by TFF using a
membrane with 10- or 100-kDa MWCO (Sartorius). The CM and
NCM preparations were filtered with a 0.2-μm filter before
storage or use.
Electron microscopy, antibody array assay,
protein analysis
Electron microscopy, antibody array assay, and protein
analysis were done using standard protocols; for details
please refer to Supplementary Materials and Methods.
LC MS/MS analysis
Proteins in 2ml of dialyzed CM or NCMwere analysis by LCMS/
MS using standard protocols with some modifications; for
details please refer to Supplementary Materials and Methods.
Immunoprecipitation of exosome-associated
proteins
Dynabead M-280 sheep anti-mouse IgG (Invitrogen Corpora-
tion, Carlsbad, CA) was washed using 0.1% BSA/PBS before
incubation with mouse anti-human CD81 antibody for 2 h
with gentle shaking at room temperature. The dynabeads
were washed twice and incubated with CM with gentle
shaking for 2 h at room temperature. The supernatant was
then collected, and the dynabeads were gently washed twice
before PBS was added. The supernatant and the dynabeads
were denatured, resolved on 4–12% SDS-PAGE, and analyzed
by Western blotting.
Sucrose gradient density equilibrium centrifugation
To generate the sucrose gradient density for centrifugation,
14 sucrose solutions with concentrations from 22.8 to 60%
were prepared and layered sequentially in an ultracentrifuge
tube (Beckman Coulter Inc., CA) starting with the most
concentrated solution. CM was loaded on top before
ultracentrifugation for 16.5 h at 200 000 g, 4 °C in a
SW60Ti rotor (Beckman Coulter Inc.). After centrifugation,
13 fractions were collected starting from the top of the
gradient. The densities of each were determined by weighing
a fixed volume. For pretreatment with detergent-based lysis
buffer (Cell Extraction Buffer, Biovision, Mountain View,
CA), CM was incubated with an equal volume of the lysis
buffer containing protease inhibitors (Halt Protease Inhibitor
Cocktail, Thermo Fisher Scientific Inc., Waltham, MA) for
30 min at room temperature with gentle shaking. The protein
concentration of CM was quantified using the NanoOrange
Protein Quantification kit (Invitrogen Corporation) according
to the manufacturer's instructions.
Sphingomyelin, phosphatidylcholine, and cholesterol
assay
Cholesterol, sphingomyelin, and phosphatidylcholine concen-
tration in CM and pellet from the ultracentrifugation of CM at
200 000 g for 2 h at 4 °C was determined using commercially
available assay kits. Cholesterol was measured using the
Amplex Red Cholesterol Assay kit (Invitrogen Corporation),
sphingomyelin, and phosphatidylcholine were measured using
the Sphingomyelin Assay Kit and Phosphatidylcholine Assay Kit
(Cayman Chemical Company, Ann Arbor, MI) respectively.
Limited trypsinization of CM
CM was incubated with equal volumes of either PBS or lysis
buffer (Cell Extraction Buffer, Biovision, Mountain View, CA)
for 45 min at 4 °C with gentle shaking. Then 16 μl of 10×
trypsin (Invitrogen Corporation) was added and incubated at
37 °C with gentle shaking. An aliquot was removed at 30 s,
1 min, 5 min, and 20 min, and 1 μl of a 100 mM trypsin
inhibitor, PMSF (Sigma-Aldrich, St. Louis, MO), was added. The
mixture was denatured and analyzed byWestern blot analysis.
HPLC dynamic light scattering
The instrument setup consisted of a liquid chromatography
system with a binary pump, an auto injector, a thermostated
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column oven and a UV-visible detector operated by the
Class VP software from Shimadzu Corporation (Kyoto,
Japan). The Chromatography columns used were TSK
Guard column SWXL, 6×40 mm and TSK gel G4000
SWXL, 7.8×300 mm from Tosoh Corporation (Tokyo,
Japan).The following detectors, Dawn 8 (light scattering),
Optilab (refractive index), and QELS (dynamic light
scattering), were connected in series following the UV-
visible detector. The last three detectors were from
Wyatt Technology Corporation (CA, USA) and were
operated by the ASTRA software. For details please refer
to Supplementary Materials and Methods.
MI and surgical procedure
All experiments were performed in accordance with the
Guide for the Care and Use of Laboratory Pigs prepared by
the Institute of Laboratory Animal Resources and with prior
approval by the Animal Experimentation Committee of the
Faculty of Medicine, Utrecht University, the Netherlands.
The CM and the HPLC fraction 1 (F1) were tested in a mouse
model of MI/R injury. MI was induced by 30 min left
coronary artery (LCA) occlusion and subsequent reperfu-
sion. Five minutes before reperfusion, mice were intrave-
nously infused with 200 μl saline-diluted CM containing 3 μg
protein or HPLC F1 containing 0.4 μg protein via the tail
vein. Control animals were infused with 200 μl saline. After
24 h reperfusion, infarct size (IS) as a percentage of the
area at risk (AAR) was assessed using Evans’ blue dye
injection and TTC staining as described previously (Arslan
et al., 2010).
Mouse Langendorff heart model of ischemia/
reperfusion injury
For the mouse Langendorff heart model of ischemia/
reperfusion injury, mice were given heparin 50 IE subcuta-
neously. The suture was placed in vivo without placing the
knot. Hereafter, the heart was excised and aortic root was
canulated and perfused in the Langendorff setup. After
10 min recovery, the suture was tightened to induce
ischemia for 30 min. Just 5 min prior to reperfusion, the
perfusion buffer was changed for a second buffer contain-
ing 3.5 μg/ml MSC-CM. Reperfusion was allowed for 3 h
before Evans' blue dye injection and TTC staining for infarct
size assessment, as described previously (Arslan et al.,
2009).
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Supplementary Table 1 
Alphabetical list of 739 unique gene products identified by LC-MS/MS and antibody array 
 
02-Sep BPNT1 COL5A3 FAM3C        HINT1        ITGB4BP      MYH9 PPIA RPLP2        THBS2 
07-Sep BTD          COL6A1       FAM49B       HIST1H4      K-ALPHA-1 MYL6         PPIB         RPS10        THOP1        
AARS         C14orf141    COL6A2 FAM62A       HIST1H4A     KPNB1        NAGK         PPP2R1A      RPS15A       THY1         
ACAA2        C19orf10 COL6A3       FBLN1 HIST1H4B     KRT1 NANS PPP2R4       RPS16        TIMP1 
ACAT2 C1orf58 COL7A1 FBLN5        HIST1H4C     KRT14        NARS         PPP5C        RPS19        TIMP2 
ACO1         C1orf78      COPA FBN1 HIST1H4D     KRT2         NEDD8 PPP6C        RPS2 TIMP3        
ACTB C1QBP        COPG         FBN2         HIST1H4E     KRT27        NEFM         PRDX1 RPS20        TKT 
ACTC1        C1R COPS3        FDPS         HIST1H4F     KRT4         NIT2         PRDX2        RPS23 TLN1 
ACTN1 C1S          COPS4        FGF16 HIST1H4H     KRT5         NME1 PRDX3 RPS3 TMOD2        
ACTN2        C21orf33     COPS8        FGFRL1 HIST1H4I     KRT6L        NPC2         PRDX4 RPS4X        TMOD3        
ACTN3 CALR CORO1B FH HIST1H4J     KRT7         NPEPPS PRDX5        RPS5 TNC 
ACTN4 CAND1 CORO1C       FKBP10       HIST1H4K     KRT75        NPM1         PRDX6 RPS7         TNFRSF11B    
ACTR1A       CAP1         COTL1 FKBP1A HIST1H4L     KRT77        NQO1         PRG1         RPS8         TNFRSF12A  
ACTR1B       CAP2 CRIP2        FKBP3        HIST2H2AA3   KRT9         NRP1 PRKACA       RPS9         TNFSF12  
ACTR2 CAPG CS           FLNA         HIST2H2AA4   KRTHB4       NRP2         PRKCSH RPSA TNPO1 
ACTR3        CAPN1 CSE1L        FLNB HIST2H4A     LAMA4        NT5E         PRNP         RSU1         TP53I3       
ACTR3B       CAPN2        CSRP1 FLNC         HIST2H4B     LAMB1 NUCB1        PROCR RTN4         TPI1         
ADAM9 CAPZA1 CSRP2        FLRT2        HIST4H4      LAMC1        OLFML3       PROSC        S100A11 TPM1 
ADSL         CAPZA2       CST3 FLT1 HLA-A        LANCL1       P4HA1        PRSS23 S100A16      TPM2         
ADSS         CAPZB CTGF         FN1          HLA-B        LAP3 P4HB PRSS3        SARS TPM3 
AEBP1        CARS         CTHRC1       FSCN1 HMX1         LASP1        PABPC1 PSAP         SDC4 TPM4         
AGA          CBR1 CTSB         FSTL1        HNRPA1 LDHA         PABPC4       PSAT1 SDCBP        TRAP1 
AGRN CBR3         CTSD FSTL5 HNRPA1L-2    LDHAL6B      PAFAH1B1     PSMA1        SEC22B       TRHDE        
AHCY CCBL2        CTSZ         FTL          HNRPA2B1     LDHB PAFAH1B2 PSMA2        SEC23A       TROVE2       
AK1 CCDC19       CXCL1 G6PD         HNRPC LEPRE1       PAFAH1B3     PSMA3        SEC31A       TSKU         
AK2          CCL18 CXCL12       GALNT2 HNRPCL1      LGALS1 PAICS PSMA6 SEMA3C       TUBA1A       
AKR1A1 CCL2 CXCL16 GALNT5       HNRPD        LGALS3       PAM          PSMA7        SEMA7A TUBA6        
AKR1B1       CCL7 CXCL2 GANAB        HNRPDL       LGALS3BP PAPPA PSMB1        SERPINB1     TUBA8        
ALCAM CCN4 CXCL9 GAPDH        HNRPH2       LMNA         PARK7        PSMB2        SERPINB6     TUBB 
ALDH2 CCR4 CYCS         GARS HNRPK LOC196463    PARP1 PSMB3        SERPINE1 TUBB2C       
ALDH7A1      CCR5 D4ST1        GAS6         HNRPL        LOC283523 PARVA        PSMB4        SERPINE2     TUBB3        
ALDOA CCT2 DAG1         GBA          HNRPR LOC347701    PCBP1 PSMB5        SERPINF1 TUBB4 
ALDOC        CCT3         DCI          GBE1 HNRPU        LOC646821    PCBP2        PSMD11       SERPINH1     TUBB6        
ANGPT4 CCT4 DCN          GDF1 HNT          LOC649125    PCDH18 PSMD13       SERPINI2     TUBB8        
ANP32B CCT5 DDAH2        GDF11 HSP90AB1     LOC653214    PCDHGB6      PSMD5 SFRP1 TWF1         
ANXA1        CCT6A        DDB1         GDF15        HSP90B1      LOC654188    PCK2 PSMD6        SFRP4 TXN          
ANXA2 CCT7 DDT          GDF3 HSPA1A       LOC728378    PCMT1        PSMD7        SH3BGRL3     TXNL5        
ANXA5        CCT8         DDX17        GDF5 HSPA1B       LOXL2        PCNA PSME1 SIL1         TXNRD1       
ANXA6 CD109 DES          GDF8 HSPA1L LRP1         PCOLCE PSME2        SLC1A5       UBE1         
AP1B1        CD248 DKK1 GDI1 HSPA4        LTA PDCD6IP      PTBP1 SLC3A2 UBE2L3 
AP1S1        CD44 DLD          GDI2         HSPA5        LTA4H PDGFA PTK7         SND1         UBE2N        
AP2A1 CD59 DNAJC3       GLO1         HSPA6 LTB  PDGFC        PTPRCAP      SNRPD1 UBE2V1       
AP2A2        CD81 DPP3 GLRX HSPA8        LTB4DH       PDGFRB       PTX3 SNRPE        UBE3B        
AP2B1 CD9 DPYSL2       GLT8D3       HSPB1 LTBP1        PDIA3 PURA         SOD1         UCHL1        
AP3B1        CDC37        DPYSL3 GLUD1        HSPD1        LTBP2 PDIA4        PXDN SPARC        UCHL3 
APEX1        CDC42 DSTN         GM2A         HSPE1 LUM          PDIA6 PYCR1        SPOCK UGDH         
API5 CDH11 DYNLL1       GNPDA1       HSPG2        M6PRBP1      PDLIM1       PYGB         SPTAN1 UGP2 
APOA1BP CDH13 ECHS1        GNPNAT1      HSPH1        MACF1 PDLIM5 QARS         SPTBN1       UROD         
APOE         CDH2 ECM1 GOT1 HTRA1        MADH4 PDLIM7       QPCT         SPTBN4       USP14 
36
APP CFL1 EEF1A1       GOT2         IDH1 MAP1B        PEPD QSCN6 SRP9         USP5         
APRT         CFL2         EEF1A2 GPC1 IFNG MAPK1        PFN1         RAB11B       SRPX         VARS         
ARCN1        CHID1        EEF1B2       GPC5 IGF2R MAPRE1       PFN2         RAB1A SRPX2        VASN         
ARHGAP1      CHRDL1 EEF1G        GPI          IGFBP2       MAT2A PGCP RAB6A        SSB          VAT1 
ARHGDIA CLEC11A      EEF2 GREM1 IGFBP3 MAT2B        PGD RAC1         ST13 VCL          
ARPC1A CLIC1 EFEMP2       GRHPR        IGFBP4       MCTS1        PGK1         RAN ST6GAL2      VCP 
ARPC1B       CLIC4        EIF2S3 GRN IGFBP5 MDH1 PGK2 RANBP5       STAT1 VEGFC 
ARPC2        CLSTN1 EIF3S9       GSN IGFBP7       MDH2         PGLS         RARRES2 STC1         VIL2         
ARPC3        CLTC         EIF4A1       GSR          IGKC         MFAP4        PGM1         RARS         STC2 VIM 
ARPC4 CLTCL1 EIF4A2 GSS          IL13 MGAT5 PGRMC2       RBMX         STIP1        VPS26A       
ARTS-1       CLU          EMILIN1      GSTK1        IL15 MIF          PHGDH        RHOA SULF1 VPS35 
ATIC         CMPK EML2 GSTO1 IL15RA MMP1         PHPT1 RNASE4       SVEP1        VTN          
ATP5B CNDP2 ENO1 GSTP1        IL1RAP MMP10 PICALM       RNH1         SYNCRIP      WARS         
ATP6AP1 CNN2         ENO2         GTPBP9       IL2 MMP14        PKM2         RNPEP        TAGLN        WDR1 
ATP6AP2      CNN3 ENO3 GZMA IL21R MMP2 PLAU RPL10A       TAGLN2 WNT5A        
ATP6V1B2 COL12A1 EPPK1        H2AFY IL3 MRC2         PLEC1        RPL11        TALDO1       WNT5B 
ATP6V1G2     COL18A1      EPRS         HADH         IL6 MRLC2 PLEKHC1 RPL12 TARS XPO1         
B2M          COL1A1 ESD          HARS         IL6ST MSN          PLOD1        RPL14 TCN2         YKT6         
B4GALT1 COL1A2       ETF1 HARS2        IL8 MTAP PLOD2 RPL18        TCP1         YWHAB 
BASP1 COL2A1 ETFB         hCG_1641617  ILF2 MTPN         PLOD3        RPL22        TFPI         YWHAE        
BAT1         COL3A1       ETHE1        hCG_2023776  ILF3         MVP          PLS1 RPL30        TGFB1 YWHAG 
BBS1         COL4A1 EXT1         HEXA         INHBA        MXRA5        PLS3         RPL5 TGFB2 YWHAH        
BCAT1        COL4A2       FAH          HEXB IQGAP1       MXRA8        PLSCR3       RPL7         TGFBI YWHAQ 
BGN COL5A1 FAHD1        HGF ISOC1        MYH11 POSTN RPLP0 THBS YWHAZ        
BLVRA        COL5A2       FAM129B      HIBCH        ITGA2 MYH14        PPCS         RPLP1        THBS1  
 
 Black font Identified by LC MS/MS 
Grey shade Identified by antibody array 
Underline Identified by LC MS/MS and antibody array 
 White font Identified by LC MS/MS and are present on exosomes secreted by at least 4 different cell types(Olver and Vidal, 2007) 
 
 
Table 1.  Proteomic profile of CM as determined by LC MS/MS and antibody array.  For LC MS/MS, 4 
independent samples were analyzed, proteins were considered present if detected in at least 3 of 4 samples. 
For antibody array, 3 independent samples were analyzed, the cytokines and other proteins were considered 
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Cytoskeletal regulation by Rho GTPase
Parkinson disease
Inflammation mediated by
















































































Cellular Assembly and Organization
Cellular Development
Cellular Function and Maintenance
Tissue Morphology
Embryonic Development
Cell-To-Cell Signaling and Interaction
Cell Death
Cellular Growth and Proliferation

























Skeletal and Muscular Disorders
Connective Tissue Development and Function
Skeletal and Muscular System Development and Function
Dermatological Diseases and Conditions
Hair and Skin Development and Function
Renal and Urological System Development and Function
Renal and Urological Disease
Neurological Disease
Ophthalmic Disease
Nervous System Development and Function
















































































































































































































































Starch and Sucrose Metabolism
 Inositol Metabolism






Phenylalanine, Tyrosine and Tryptophan Biosynthesis
Arginine and Proline Metabolism
Glyoxylate and Dicarboxylate Metabolism
Alanine and Aspartate Metabolism
Stilbene, Coumarine and Lignin Biosynthesis
Lysine Degradation
Glycosaminoglycan Degradation
Valine, Leucine and Isoleucine Degradation







Pantothenate and CoA Biosynthesis
Virus Entry via Endocytic Pathways
Clathrin-mediated Endocytosis
FcȖ Receptor-mediated Phagocytosis in Macrophages and
Caveolar-mediated Endocytosis
Hepatic Fibrosis / Hepatic Stellate Cell Activation
Leukocyte Extravasation Signaling
 Integrin Signaling
NRF2-mediated Oxidative Stress Response
Glucocorticoid Receptor Signaling
Dendritic Cell Maturation
Airway Pathology in Chronic Obstructive Pulmonary Disease
 IL-15 Production







Semaphorin Signaling in Neurons
PI3K/AKT Signaling
Oncostatin M Signaling
Aryl Hydrocarbon Receptor Signaling
Actin Cytoskeleton Signaling
Regulation of Actin-based Motility by Rho
Tight Junction Signaling









































































































































































































































































































































































































































































































































































































































Supplementary Materials and Methods 
Electron Microscopy 
Formvar-coated carbon grids were coated with a drop of 0.01% Poly Lysine for 1 
minute before excess fluid was drained off with a filter paper. 50concentrated 
samples of either MSC-CM or NCM were pipetted onto the labeled grids and after 
one minute, excess samples were drained off with a filter paper.  A drop of 1% pH 
6 phosphotungstic acid was then added onto each grid and after one minute, 
excess liquid was drained off with a filter paper leaving a thin monolayer that was 
allowed to dry thoroughly at room temperature. The samples grids were screened 
using a high-resolution transmission electron microscope, Philips CM120 and 
micrographs images were taken. 
 
LC MS/MS analysis 
Proteins in two ml of dialyzed CM or NCM were reduced, alkylated and tryptic 
digested as described. The samples were then desalted by passing the digested 
mixture through a conditioned Sep-Pak C-18 SPE cartridge (Waters, Milford, MA, 
USA), washed twice with a 3% acetonitrile (ACN) (JT Baker, Phillipsburg, NJ) 
and 0.1% formic acid (FA) buffer, and eluted with a 70% ACN and 0.1% FA 
buffer. The eluted samples were then dried to about 10% of their initial volumes 
by removing organic solvent in a vacuum centrifuge. To reduce the sample 
complexity, offline peptide fractionation was carried out with a HPLC system 
(Shimadzu, Japan) through a Polysulfoethyl SCX column (200 mm x 4.6 mm) 
(PolyLC, USA).  Mobile phase A (5 mM KH4PO4 + 30% acetonitrile) and mobile 
phase B (5 mM KH4PO4 + 30% acetonitrile + 350 mM KCl) at 1 ml/min. Eight 
fractions were collected and dried with a vacuum centrifuge. Fractionated samples 
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were loaded into the auto sampler of a Shimadzu micro HPLC system coupled 
online to a LTQ-FT Ultra linear ion trap mass spectrometer (Thermo Electron, 
Bremem, Germany) fitted with a nanospray source.  Injected peptides were 
trapped and desalted in a Zorvax 300SB-C18 enrichment column (5 mm x03 mm, 
Agilent Technologies, Germany) and eluted into a nano-bored C18 packed 
column (75 µm x 100 Å, Michrom Bioresources, Auburn, CA).  A 90 minute 
gradient at a constant flow rate of 20 ml/min with a splitter to an effective flow 
rate of 200 ηl/min was used to elute the peptides into the mass spectrometer. The 
LTQ was operated in a data-dependent mode by performing MS/MS scans for the 
8 of the most intense peaks from each MS scan in the FTMS.  For each 
experiment, MS/MS (dta) spectra of the eight SCX fractions were combined into a 
single mascot generic file by a home-written program. Protein identification was 
achieved by searching the combined data against the IPI human protein database 
(version 3.34; 69,164 sequences, 29,064,825 residues) via an in-house Mascot 
server (Version 2.2.04, Matrix Science, UK). The search parameters were: a 
maximum of 2 missed cleavages using trypsin; fixed modification was 
carbaminomethylation of cysteine and variable modifications was oxidation of 
methionine. The mass tolerances were set to 10 ppm and 0.8 Da for peptide 
precursor and fragment ions respectively. Protein identification was accepted as 
true positive if two different peptides were found to have scores greater than the 
homology scores. 
 
Antibody array assay 
500 µl of conditioned or non-conditioned medium from 3 independent 
preparations were assayed for the presence of cytokines and other proteins using 
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RayBio® Biotin Label-based Human Antibody Array I according to 
manufacturer’s instructions (RayBio, Norcross, GA). The cytokines and other 
proteins were considered to be present in the conditioned medium if the signal 
intensity is 2 fold higher (p<0.05) than that in non-conditioned medium. 
 
Protein analysis 
Analysis of proteins by western blot hybridization was performed using standard 
protocols.  Briefly, proteins were denatured, separated on 4-12% polyacrylamide 
gels, electroblotted onto a nitrocellulose membrane and probed with antibodies 
against human CD9, CD81, Alix and SOD-1 (Santa Cruz Biotechnology, Santa 
Cruz, CA) followed by horseradish peroxidase-coupled secondary antibodies 
against the mouse primary antibody (Santa Cruz Biotechnology, Santa Cruz, CA).  
The blot was then incubated with a chemiluminescent HRP substrate to detect 
bound primary antibody, and therefore the presence of the antigen.  
 
HPLC dynamic light scattering 
The instrument setup consisted of a liquid chromatography system with a binary 
pump, an auto injector, a thermostated column oven and a UV-visible detector 
operated by the Class VP software from Shimadzu Corporation (Kyoto, Japan). 
The Chromatography columns used were TSK Guard column SWXL, 6 x 40 mm 
and TSK gel G4000 SWXL, 7.8 x 300 mm from Tosoh Corporation (Tokyo, 
Japan). The following detectors, Dawn 8 (light scattering), Optilab (refractive 
index) and QELS (dynamic light scattering) were connected in series following 
the UV-visible detector. The last three detectors were from Wyatt Technology 
Corporation (California, USA) and were operated by the ASTRA software.  The 
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components of the sample were separated by size exclusion i.e. the larger 
molecules will elute before the smaller molecules. The eluent buffer used was 20 
mM phosphate buffer with 150 mM of NaCl at pH 7.2. This buffer was filtered 
through a pore size of 0.1 μm and degassed for 15 minutes before use. The 
chromatography system was equilibrated at a flow rate of 0.5 ml/min until the 
signal in Dawn 8 stabilized at around 0.3 detector voltage units. The UV-visible 
detector was set at 220 ηm and the column was oven equilibrated to 25ºC. The 
elution mode was isocratic and the run time was 40 minutes. The volume of 
sample injected ranged from 50 to 100 µl. The % area of the exosome peak vs. all 
other peaks was integrated from the UV-visible detector. The hydrodynamic 
radius, Rh, was computed by the QELS and Dawn 8 detectors. The highest count 
rate (Hz) at the peak apex was taken as the Rh.  Peaks of the separated components 
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The therapeutic effects of mesenchymal stem cells (MSCs) transplantation are increasingly thought to be
mediated by MSC secretion. We have previously demonstrated that human ESC-derived MSCs (hESC-MSCs)
produce cardioprotective microparticles in pig model of myocardial ischemia/reperfusion (MI/R) injury. As
the safety and availability of clinical grade human ESCs remain a concern, MSCs from fetal tissue sources
were evaluated as alternatives. Here we derived ﬁve MSC cultures from limb, kidney and liver tissues of
three ﬁrst trimester aborted fetuses and like our previously described hESC-derived MSCs; they were highly
expandable and had similar telomerase activities. Each line has the potential to generate at least 1016–19 cells
or 107–10 doses of cardioprotective secretion for a pig model of MI/R injury. Unlike previously described fetal
MSCs, they did not express pluripotency-associated markers such as Oct4, Nanog or Tra1-60. They displayed
a typical MSC surface antigen proﬁle and differentiated into adipocytes, osteocytes and chondrocytes in vitro.
Global gene expression analysis by microarray and qRT-PCR revealed a typical MSC gene expression proﬁle
that was highly correlated among the ﬁve fetal MSC cultures and with that of hESC-MSCs (r2N0.90). Like
hESC-MSCs, they produced secretion that was cardioprotective in a mouse model of MI/R injury. HPLC
analysis of the secretion revealed the presence of a population of microparticles with a hydrodynamic radius
of 50–65 nm. This puriﬁed population of microparticles was cardioprotective at ∼1/10 dosage of the crude
secretion.
© 2010 Elsevier Ltd. All rights reserved.
1. Introduction
Mesenchymal stem cells (MSCs) are multipotent stem cells that
have a limited but robust potential to differentiate into mesenchymal
cell types, e.g. adipocytes, chondrocytes and osteocytes, with
negligible risk of teratoma formation. MSC transplantation has been
used to treat musculoskeletal injuries, improve cardiac function in
cardiovascular disease and ameliorate the severity of graft-versus-
host-disease [1]. In recent years, MSC transplantations have demon-
strated therapeutic efﬁcacy in treating different diseases but the
underlying mechanism has been controversial [2–9]. Some reports
have suggested that factors secreted by MSCs [10] were responsible
for the therapeutic effect on arteriogenesis [11], stem cell crypt in the
intestine [12], ischemic injury [9,13–18], and hematopoiesis [19,20].
We have recently demonstrated that human MSCs derived from
human embryonic stem cells (hESC-MSCs) [21] secrete N200 proteins
[22] and that a single bolus administration of hESC-MSCs conditioned
medium (CM) 5 min prior to reperfusion signiﬁcantly reduced infarct
size by 60% and improved cardiac function in a pig andmousemodel of
myocardial ischemia/reperfusion (MI/R) injury [23]. In addition, this
cardioprotectionwasmediated by large complexes of about 50–100 nm
in diameter. The size of these large secreted complexes suggests that
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they are microparticles which are broadly deﬁned as secreted
membrane particles in the size range of 0.05–1 μm [24].
A requisite for translating cardioprotective MSC secretion into
clinical applications is a clinical grade MSC source but this is currently
limited by restricted access to clinical grade hESCs. Therefore,
alternative tissue or cell sources that are amenable to the generation
of highly expandable, clinical grade MSCs have to be developed. Here
we examined fetal tissues as a candidate tissue source.
Five MSC cultures, Fllb, F1ki, F2lb, F3lb and F3li were generated
from limb (lb), kidney (ki) and liver (li) tissues of three fetuses in
three independent experiments. These fetal MSCs fulﬁlled the
deﬁning criteria of a MSC. They were highly proliferative. Each line
has the potential of generating 1016–19 cells, and therefore the
capacity to produce large amount of secretion. More importantly,
these cells produce secretion that reduced infarct size in a mouse
model of MI/R injury [23]. Like the secretion of hESC-MSCs, this
cardioprotection was also mediated by large complexes. Fraction-
ation of the secretion by size exclusion on an HPLC revealed the
presence of a population of homogenously sized particles with a
hydrodynamic radius of 50–65 nm and these particles were cardio-
protective in a mouse model of MI/R injury. The size of these large
secreted complexes suggests that they are microparticles which are
broadly deﬁned as secreted membrane particles in the size range of
0.05–1 μm [24].
2. Materials and methods
2.1. Derivation of fetal tissue derived MSCs
The collection of fetal tissue was carried out under a KK Women's
and Children's Hospital (KKH) IRB approved protocol (EC200804062)
in accordance with guidelines from Singapore Bioethics Advisory
Committee [25] which stated that the decision to donate the fetal
tissue must be made independently from any decision to abort. Only
patients who have already consented to Termination of Pregnancy
(TOP) in KKH Outpatient Clinic were recruited. Recruitment was
carried out in strict adherence to KKH IRB's regulations to ensure
patient's rights and privacy, and to provide conﬁdential counseling for
patient's fully informed consent to voluntary donation. TOP for fetal
abnormalities and sexual assault cases and in minor (16 and below)
were excluded. Patients with medical problems were also excluded.
The aborted specimens were collected in special sterile plastic
bottles and sent to the hospital's Department of Laboratory Medicine
for full pathological examinations. Appropriate pieces of fetal tissues
were dissected, washed several times in sterile saline, minced, and
placed in DMEM supplemented with 10% serum replacement
medium, EGF (20 ng/ml) and FGF2 (20 ng/ml) to attach to plastic
tissue culture dishes for 24–48 h. Under this condition, MSCs whose
deﬁning characteristic is adherence to plastic migrated out of the
tissues and adherence to the plastic culture dish. The large tissue
pieces are then washed off leaving a homogenous cell culture. The
cells were maintained at 25%–80% conﬂuency or 15–50,000 cells per
cm2 and were split 1:4 at conﬂuency by trypsinization. On reaching
2×107 cells usually within 2 weeks, the culture was designated P1.
Master cell banks of early passage cells grown in culture medium
supplemented with animal replacement medium were set up for all
the lines. For all experimental work described in this study, cells at
p10 were expanded in HuES Expansion medium containing 10% ES
cell fetal bovine serum 1% L-glutamine, 1% non essential amino acids,
and 88% DMEM (high glucose, no sodium pyruvate). All medium
components were obtained from Invitrogen Corporation, Carlsbad,
CA. Differentiation of the fetal MSCs to adipocytes, chondrocytes and
osteocytes was performed using adipogenic, chondrogenic and
osteogenic hMSC Differentiation BulletKits, respectively (Lonza,
Walkersville, MD) as per manufacturer' instructions. Karyotyping by
G-banding was performed at the Cytogenetics Laboratory, KKH.
2.2. Telomerase activity
Relative telomerase activity was measured by SYBR® Green real
time quantitative telomeric repeat ampliﬁcation protocol assay using
a modiﬁed method as described by Wege et al. [26]. Brieﬂy, 3 million
cells were harvested and cell lysate was prepared using a commer-
cially available mammalian cell extraction kit (BioVision, Singapore).
The composition of the reagents for the PCR ampliﬁcation was 1 μg of
protein cell lysate, 10 μl of 2× SYBR Green Super Mix (BioRad,
Singapore) with 0.1 μg of TS primer (5′-AATCCGTCGAGCAGACTT-3′),
0.1 μg of ACX primer (5′-GCGCGG[CTTACC]3CTAACC-3′) and 10 mM
EGTA in a total volume of 25 μl. The reactionwasﬁrst incubated at 25 °C
for 20 min to allow the telomerase in the cell lysate to elongate the TS
primers followed by 2min incubation at 95 °C to inactivate telomerase
activity and denature the primers. The telomerase product was
ampliﬁed by PCR for 40 cycles of 95 °C for 30 s and 60 °C for 90 s. The
relative telomerase activitywas assessed against that of HEK cells using
the threshold cycle number (or Ct value) for 1 μg protein cell lysate.
2.3. Surface antigen analysis
Expression of cell surface antigens on fetal MSCs was analyzed
using ﬂow cytometry. The cells were trypsinized for 5 min,
centrifuged, resuspended in culture media and incubated in a
bacterial culture dish for 1 h in a 37 °C, 5% CO2 incubator. The cells
were then collected, centrifuged, and washed in 2% FBS. A total of
2.5×105 cells were then incubated with each of the following
conjugated monoclonal antibodies: CD29-PE, CD44-FITC, CD49a-PE,
CD49e-PE, CD105-FITC, CD166-PE, CD73-FITC, CD34-FITC, and CD45-
FITC (PharMingen, San Diego, CA) for 60 min on ice. After incubation,
cells were washed and resuspended in 2% FBS. Nonspeciﬁc ﬂuores-
cence was determined by incubation of similar cell aliquots with
isotype-matched mouse monoclonal antibodies (PharMingen, San
Diego, CA). Data were analyzed by collecting 20,000 events on a BD
FACSCalibur™ Flow Cytometer (BD Biosciences, San Jose, CA)
instrument using CELLQuest software.
2.4. Quantitative RT-PCR
Total RNA was extracted from cells using TRIzol® LS Reagent
(Invitrogen Corporation, Carlsbad, CA) according to manufacturer's
instruction. Total RNA was converted to cDNA using the High
Capacity cDNA Reverse Transcription Kit (Applied Biosystems Inc.,
Foster City, CA) that was based on oligo-dT primed reverse
transcription. Real time PCR was performed on a StepOne™ Plus
Real-Time PCR System (Applied Biosystems Inc, Foster City, CA) using
2× Fast SYBR® Green Master Mix (Applied Biosystems Inc, Foster
City, CA) according to manufacturer's instruction. The primers for
OCT4 were 5′-AGTGAACAGGGAATGGGTGAA-3′ and 5′-AAG CGG CAG
ATG GTC GT-3′, and for SOX2 were 5′-TGAGAGAAAGAAGAGGA-
GAGA-3′ and 5′-TGGGGGAAAAAAAGAGAGAGG-3′.
2.5. Illumina gene chip analysis
Total RNA was prepared in technical triplicates from different
passages of F1lb (p10, p12, p14), F1ki (p12, p14, p16), F2lb (p10, p12,
p14), F3lb (p10, p12, p14) and F3li (p10, p16), and from two technical
replicates of the previously described hESC-MSCs line, Hues9.E1
(p19). Five hundred nanograms of RNA was converted to biotinylated
cRNA using the Illumina RNA Ampliﬁcation Kit (Ambion, Inc., Austin,
TX) according to the manufacturer's directions. Seven hundred ﬁfty
nanograms of the biotinylated cRNA was hybridized to the Sentrix
HumanRef-8 Expression BeadChip Version 3 (Illumina, Inc., San Diego,
CA), and washing and scanning were performed according to the
Illumina BeadStation 500× manual. The data were analyzed using
Genespring GX 10. Quantile normalization was performed by a shift to
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75th percentile, and the normalized data were baseline transformed
to the median of all samples.
2.6. SDS–PAGE analysis and western blot hybridization
For SDS–PAGE analysis, total proteins in CM were separated on
4–12% SDS–polyacrylamide gels and stained with silver. For western
blot hybridization, the proteins were electroblotted onto a nitro-
cellulose membrane after ﬁrst separating on an SDS–PAGE. The
membrane was blocked and incubated with the primary anti-human
antibodies that included 1:60 dilution of mouse anti-CD9, 1:60
dilution of mouse anti-CD81, 1:56 dilution of mouse anti-Alix, 1:200
dilution of mouse anti-pyruvate kinase (PK), 1:60 dilution of mouse
anti-SOD-1 or 1:60 dilution of goat anti-TSP-1. The blot was then
incubated with a horseradish peroxidase-coupled secondary anti-
body. The secondary antibodies used were 1:1250 or 1:1364 dilution
of goat anti-mouse IgG or 1:1364 dilution of donkey anti-goat IgG.
All antibodies were obtained from Santa Cruz Biotechnology, Santa
Cruz, CA except mouse anti-PK which is from Abcam Inc., Cambridge,
MA. The blot was then incubated with HRP-enhanced chemilumi-
nescent substrate (Thermo Fisher Scientiﬁc Inc., Waltham, MA) and
then exposed to an X-ray ﬁlm.
Fig. 1. Characterization of fetal MSC cultures. (A) Cellular morphology under phase contrast. Representative images of the ﬁve different MSCs, F1lb (p8) and F1ki (p8) derived from
the limb and kidney tissues of the same fetus; F2lb (p8) derived from the limb of a second fetus; and F3lb (p8) and F3li (p8) derived from the limb and liver tissues of the same third
fetus. (B) Karyotype analysis by G-banding was performed each of the fetal MSC cultures, F1lb (p10) F2lb (p10), F3lb (p10), F1ki (p12), and F1li (p12).
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2.7. HPLC puriﬁcation of microparticles
The instrument setup consisted of a liquid chromatography system
with a binary pump, an auto injector, a thermostated column oven
and a UV–visible detector operated by the Class VP software from
Shimadzu Corporation (Kyoto, Japan). The Chromatography columns
used were TSK Guard column SWXL, 6×40 mm and TSK gel G4000
SWXL, 7.8×300 mm from Tosoh Corporation (Tokyo, Japan). The
detectors Dawn 8 (light scattering), Optilab (refractive index) and
QELS (dynamic light scattering) were connected in a series following
the UV–visible detector. The last three detectors were from Wyatt
Technology Corporation (California, USA) and were operated by the
ASTRA software. The components of the sample were separated by
size exclusion, that is, the larger molecules will elute before the
smaller molecules. The eluent buffer used was 20 mM phosphate
buffer with 150mM of NaCl at pH 7.2. This buffer was ﬁltered through
a pore size of 0.1 μm and degassed for 15 min before use. The
chromatography system was equilibrated at a ﬂow rate of 0.5 ml/min
until the signal in Dawn 8 stabilized at around 0.3 detector voltage
units. The UV–visible detector was set at 220 nm and the column was
oven equilibrated to 25°C. The elution mode was isocratic and the run
time was 40 min. The volume of sample injected ranged from 50 to
100 μl. The hydrodynamic radius, Rh was computed by the QELS and
Dawn 8 detectors. The highest count rate (Hz) at the peak apex was
taken as the Rh. Peaks of the separated components visualized at 220
nm were collected as fractions for further characterization studies.
2.8. Testing secretion for cardioprotection
The secretion was prepared by growing the fetal MSCs in a
chemically deﬁned serum-free culture medium for 3 days as
previously described [22]. Brieﬂy, cells at p12 were ﬁrst expanded
in serum-containing culture medium as described above. At p15, 80%
conﬂuent cell cultures were washed three times with PBS and then
incubated in a chemically deﬁned medium consisting of DMEM
without phenol red (Invitrogen Corporation, Carlsbad, CA) and
supplemented with insulin, transferrin, and selenoprotein (ITS)
(Invitrogen Corporation, Carlsbad, CA), 5 ng/ml FGF2 (Invitrogen
Corporation, Carlsbad, CA), 5 ng/ml PDGF AB (Peprotech, Rocky Hill,
NJ), glutamine–penicillin–streptomycin, and β-mercaptoethanol
overnight. The cell culture was then washed with PBS and replaced
with fresh chemically deﬁned medium for another 3 days to produce
the conditioned medium. This CM was collected and clariﬁed by
centrifugation at 500× g. The clariﬁed CM concentrated 50 times by
reducing its volume by a factor of 50 using a tangential ﬂow ﬁltration
system with membrane MW cutoff of 100 kDa (Satorius, Goettingen,
Germany). The use of a membrane MW cutoff of 100 kDa allows
molecules with MW of less than 100 kDa to pass through the ﬁlter
resulting a preferential loss of molecules less than 100 kDa. The
concentrated CM was then sterilized by ﬁltration through a 220 nm
ﬁlter.
The CM was tested in a mouse model of MI/R injury. MI was
induced by 30 min left coronary artery (LCA) occlusion and
subsequent reperfusion. Five minutes before reperfusion, mice were
intravenously infused with 200 μl saline diluted CM containing 3 μg
protein for Hues9.E1 (hESC-MSCs) CM or 150 μg protein for fetal MSC
CM or 10 μg protein for HPLC F1 via the tail vein. Control animals were
infused with 200 μl saline. After 24 h of reperfusion, infarct size (IS) as
a percentage of the area at risk (AAR) was assessed using Evans' blue
dye injection and TTC staining as described previously [23].
2.9. Statistical analysis
Two-way ANOVA with post-hoc Dunnett was used to test the
difference in infarct size between groups. Correlation coefﬁcient of
each pairs of array was assessed using Pearson correlation test.
3. Results
3.1. Generating MSC cultures from human fetal tissues
We generated ﬁve MSC cultures from fetal limb (F1lb, F2lb, F3lb),
kidney (F1ki) and liver (F3li) tissues of three fetuses in three
independent experiments using feeder- and serum-free culture
condition as previously described [21]. A homogenous culture of
putative ﬁbroblast-like MSCs migrated out of the tissues and adhered
to the plastic culture dish, 2 days after fetal tissues were plated on
gelatinized tissue culture plates. This observation was consistent with
the deﬁning characteristic of MSCs i.e. adherence to plastic. The large
tissue pieces were then washed off leaving a homogenous cell culture.
This procedure was performed on ﬁve different fetal tissues
originating from 3 fetuses in 3 independent experiments. Each time,
a homogenous culture of putative MSCs was obtained that form a
typical ﬁngerprint whorl at conﬂuency (Fig. 1A). The cultures were
designated P1 when 2×107 cells were generated. The average
population doubling time of all ﬁve cultures was between 48 and
72 h and was most optimal at between 25% and 80% conﬂuency or
15–50,000 cells per cm2. The cells could be maintained in continuous
culture for at least 20 passages at a 1:4 split with minimal changes in
population doubling time. The karyotype of all ﬁve cultures at p10–12
was normal i.e. 46 XX or 46XY as determined byG-banding (Fig. 1B). At
passages 14, 16 and 18, telomerase activity in all ﬁveMSC cultures was
determined and the average cellular telomerase activity over three
passages in each of the ﬁve cultures was equivalent to that of the
previously describedHues9.E1 hESC-MSCs [21] (Fig. 2). Allﬁve cultures
could be expanded to at least passage 20 without obvious changes in
the population doubling time. At a 1:4 split ratio and starting with 107
cells, each line would generate 1016 cells at passage 15 or 1019 cells at
passage 20.
3.2. Assessment of fetal cultures as MSCs
The ﬁve putative MSC cultures derived from fetal tissues were
assessed according to the ISCT minimal criteria for the deﬁnition of
human MSCs [27]. All ﬁve presumptive MSC cultures derived from
three different fetuses were grown on plastic culture dishes as a
monolayer of adherent spindle-shaped cells (Fig. 1A). They were all
CD29+, CD44+, CD49a+ CD49e+, CD105+, CD166+, MHC I+, CD34−
Fig. 2. Telomerase activity in hESC-MSCs and fetalMSCs. Relative telomerase activitywas
measured by real time quantitative telomeric repeat ampliﬁcation protocol. This qPCR-
based assay quantiﬁes product generated in vitro by telomerase activity present in the
samples. The relative telomerase activity which is directly proportional to the amount of
telomerase products was assessed by the threshold cycle number (or Ct value) for 1 μg
protein cell lysate. Hues9.E1 referred to a previously described hESC-MSCs line and HEK
is a human embryonic kidney cell line. The Ct value for each fetal MSCswas themean for
three passages, P16, P18, and P20, and that for Hues9.E1 was themean for two passages,
P20 and P22. The assay was performed in triplicate for each passage.
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and CD45− as represented by F1lb MSCs (Fig. 3A). We observed
that F1lb MSCs were HLA-DRlo but the remaining four cultures were
HLA-DR−. In contrast to previous reports [28–37], these fetal MSCs-
like hESC-MSCs did not express pluripotency-associated proteins
Oct4, SSEA-4, and Tra1-60 as exempliﬁed by F1lb MSCs (Fig. 3B).
However, transcripts of OCT4 and SOX2 were readily detected by
real time PCR but their levels were at least ten times lower than
those in hES3 human ESCs (Fig. 3C). All ﬁve presumptive fetal MSC
cultures could be induced to differentiate to osteoblasts, adipocytes
and chondroblasts in vitro (Fig. 4).
3.3. Gene expression proﬁle
Genome-wide gene expression proﬁling of the fetal MSCs and
hESC-MSCs was performed using microarray hybridization to assess
1) the relatedness among the ﬁve fetal MSC cultures derived from
three different tissues and 2) the relatedness between the fetal MSC
cultures and hESC-MSCs. Microarray hybridization was performed in
duplicate on Sentrix Human Ref-8 Expression BeadChip version 3
(Illumina, Inc., San Diego, CA) using RNA from two or three different
passages of the MSC cultures. The gene expression proﬁle between
Fig. 3. Marker proﬁling. (A, B) F1lb MSCs at p11 or p12 were stained with a speciﬁc antibody conjugated to a ﬂuorescent dye and analyzed by FACS. Nonspeciﬁc ﬂuorescence was
determined by incubation of similar cell aliquots with isotype-matched mouse monoclonal antibodies. (C) Relative transcription level of OCT4 and SOX2 was measured using
quantitative RT-PCR. hES3, a human embryonic stem cells line was set as the baseline for comparison.
Fig. 4. Differentiation of fetal MSCs. Fetal MSCs were induced to undergo osteogenesis, adipogenesis and chondrogenesis. After a) osteogenesis, b) adipogenesis and c)
chondrogenesis, the differentiated cells were stained with von Kossa stain, Oil Red and Alcian blue, respectively. Images of differentiated fetal MSCs as represented by differentiated
F3lb MSCs at 100×magniﬁcation.
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different passages of each culture, between the ﬁve cultures or
between each fetal MSC culture and hESC-MSCs was highly similar
with a correlation value of N0.9 (Fig. 5).
3.4. Cardioprotective activity of secretion
Secretion by two of the fetal MSC cultures, F1lb and F1ki were
tested for cardioprotective activity in a mouse model of myocardial
ischemia and reperfusion injury as previously described [23].
Brieﬂy, the cultures were grown in a chemically deﬁned medium
and the secretion harvested as we have previously described [22]. A
typical culture of 109 cells yielded 100 mg protein. The gross protein
composition of secretion from both F1lb and F1ki as determined by
silver staining of proteins resolved on a one-D SDS–PAGE appeared
similar to each other, to that of Hues9.E1 hESC-MSCs and also to that
from F3lb derived from fetal limb tissues of a different sex (Fig. 6A).
However, the relative abundance of speciﬁc proteins such as TSP-1,
SOD-1, CD81 and CD9 was different among all the secretions (Fig.
6B). Nevertheless, the secretion from either F1lb or F1ki when
administered to a mouse model of MI/R injury signiﬁcantly reduced
infarct size to the same extent as mice treated with hESC-MSC CM
(Fig. 6C–G). Conditioned medium from F1lb, F1ki and hESC-MSCs
reduced the relative infarct size (IS) by 50%, 42% and 39%
respectively (pb0.05; Fig. 6G). The area at risk (AAR) as a
percentage of the left ventricular (LV) wall was similar in all the
mice tested (Fig. 6G).
3.5. Microparticles mediated the cardioprotection effects of the secretion
We had previously shown that the cardioprotection effects of
secretion from hESC-MSCs were mediated by large complexes of
∼1000 kDa [23]. To determine if there were such complexes in the
secretion of the fetal MSCs, the CM was fractionated by size exclusion
on an HPLC column. We observed ﬁve fractions that were present in
the CM but not in the non-conditionedmedium (NCM) (Fig. 7A). NCM
was essentially culturemedium that had not been exposed to cells but
was processed, concentrated and ﬁltered in the samemanner as CM. It
was previously shown to have no cardioprotective effect and was
equivalent to saline in this respect [23]. These ﬁve fractions, F1–F5
therefore represented secretion from the MSCs. In a size exclusion
fractionation where larger molecules are eluted faster than smaller
ones, we observed that only proteins in fraction F2 to F5 followed this
principle of fractionation. Proteins in the fastest eluting F1 fraction
contained proteins that spanned in entire MW spectrum of F2 to F5.
This suggested that the proteins in F1 were in large aggregates
(Fig. 7B). To conﬁrm this, sizes of molecules in the ﬁve fractions were
determined by dynamic light scattering analysis which has a detection
range of 1 to 500 nm according to the manufacturer speciﬁcation
(Wyatt Technology Corporation, www.wyatt.com). The sizes of
molecules in fractions F2 to F5 were too heterogeneous to be
determined by dynamic light scattering analysis. In spite of the wide
MWspectrumof proteins in F1, the size ofmolecules in F1 fractionwas
sufﬁciently homogenous to be determined as having a hydrodynamic
radius of 50–65 nm by dynamic light scattering analysis. When
administered to the mouse model of MI/R injury as described above,
these HPLC-puriﬁed microparticles reduced infarct size at b1/10
dosage of the secretion (Fig. 7C–F).
4. Discussion
The trophic effects of MSCs transplantation on ameliorating the
deleterious consequences of myocardial ischemia have been impli-
cated in several studies [10]. Transplantation of MSCs into ischemic
myocardium has been shown to induce several tissue responses such
as an increased production of angiogenic factors and decreased
apoptosis [38] that were better explained by secretion of paracrine
factors than by differentiation of MSCs, the so-called paracrine
hypothesis.
Fig. 5. Gene expression analysis. Total RNA was prepared in technical replicates from different passages of F1lb (p10, p12, p14), F1ki (p10, p14, p16), F2lb (p10, p12, p14), F3lb (p10,
p12, p14) and F3li (p10, p16), and from two technical replicates of the previously described hESC-MSCs line, Hues9.E1 (p19). Seven hundred ﬁfty nanograms of biotinylated cRNA
from each sample was used for microarray analysis on the Sentrix HumanRef-8 Expression BeadChip Version 3 (Illumina, Inc., San Diego, CA). The gene expression proﬁle of all
samples was normalized by a shift to the 75th percentile, baseline transformed to median of all samples, and a heat map of correlation between pairs of array plotted.
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We have recently demonstrated that hESC-MSC secretion reduces
infarct size in mouse and pig MI/R injury model [23]. To translate this
ﬁnding into a clinical application, an important requisite would be a
safe, relatively accessible and highly proliferative source of MSCs that
has the potential to generate large number of cells to minimize batch
to batch variation. Although hESC-MSCs are highly proliferative and
have the capacity to generate large number of cells, the number of
clinical grade hESC lines and their accessibility is limited. To
circumvent this limitation, we derived human MSCs directly from
fetal human tissues. The traditionally used bone marrow for deriving
MSCs was not an attractive alternative as a single bone marrow
aspirate usually generates only ∼109 cells. We rationalized that fetal
tissues being developmentally less mature may generate MSCs with
expansion potential equivalent to that of hESC-MSCs.
The fetal MSCs-like hESC-MSCs, fulﬁlled the basic criteria for MSCs
as deﬁned by The International Society for Cellular Therapy [27]. They
adhered to plastic, have a typical MSCs-like surface antigen proﬁle as
deﬁned by the presence of surface antigens such as CD29, CD44,
CD49a, CD49e, CD105, CD166, and MHC I and the absence of surface
antigens such as HLA-DR, CD34 and CD45 [39–41], and a typical MSCs
differentiation potential that includes adipogenesis, chondrogenesis
and osteogenesis. Irrespective of their tissue of origin, the ﬁve fetal
Fig. 6. Cardioprotective secretion. (A) Proteins in culture medium conditioned by hESC-MSCs (Hues9.E1), F1lb, F1ki or F3lb were separated on a 4%–12% SDS–PAGE gradient gel and
stained with silver. Two micrograms of proteins was loaded in each lane. (B) Western blot analysis. CM from hESC-MSCs (Hues9.E1), F1lb, F1ki and F3lb at 4, 8, 16 and 16 μg,
respectively, were resolved on an SDS–PAGE, electroblotted onto nitrocellulose membrane and probed with antibodies against TSP-1, SOD-1, CD81 and CD9. (C–F) Representative
pictures of Evan blue (blue) and TTC (pink) staining on hearts of mice treated with (C) saline, (D) HuES9.E1, (E) F1lb, or (F) F1ki. (G) AAR as a percentage of the left ventricle (LV),
showing the amount of endangered myocardium after MI/R injury. All animals were affected to the same extent by the operative procedure, resulting in 39.4±2.0% of AAR among
the groups. Infarct size (IS) as a percentage of the area at risk (AAR) upon treatment with saline (n=10), CM from hESC-MSCs (n=10), F1lb-MSCs (n=6) and F1ki-MSCs (n=6).
Saline treatment resulted in 34.5±3.3% infarction, whereas conditioned medium from hESC-MSCs, F1lb-MSCs and F1ki-MSCs resulted in 21.2±3.3%, 17.4±3.7% and 19.9±2.6%,
respectively. Each bar represents mean±SEM.
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MSC cultures derived from different tissues of three individual fetuses
have a nearly identical genome-wide gene expression proﬁle. Their
gene expression proﬁles were also similar to that of the previously
described hESC-MSCs, Hues9.E1. They were as equally proliferative as
Hues9.E1 and had high levels of telomerase activity. Although the
secretion by MSCs derived from different tissues, that is, limb and
kidney tissues were grossly similar to that from hESC-MSCs, Hues9.E1,
closer examination of speciﬁc proteins by western blot hybridization
(Fig. 6B) demonstrated that there were quantitative differences in the
protein composition. Consistent with this observation, secretion from
the fetal MSCs signiﬁcantly reduced infarct size in a mouse model of
MI/R injury but at a higher dosage of 150 μg instead of 3 μg per mouse.
We postulate that this difference in effective dosage was due
primarily to the quantitative differences in the protein composition
and candidate proteins will have to be identiﬁed through systematic
evaluation and validation of quantitative high throughput proteomic
Fig. 7. Cardioprotective HPLC-isolated microparticles. (A) HPLC fractionation and dynamic light scattering of F1lb CM and NCM. F1lb CM and NCM were fractionated on an HPLC
using BioSep S4000, 7.8 mm×30 cm column. The components in F1lb CM or NCM were eluted with 150 mM of NaCl in 20 mM phosphate buffer, pH 7.2. The elution mode was
isocratic and the run time was 40 min. The eluent was monitored with a UV–visible detector set at 220 nm and light scattering signal was collected. The solid rhombus represented
light scattering signal as measured in voltage; (B) The eluted fractions, F1 to F12 were collected, their volumes were adjusted to 10% of the input volume of CM and equal volume
of F1–F12 was separated by gel electrophoresis and stained with silver. (C–E) Representative pictures of Evan blue (blue) and TTC (pink) staining on hearts of mice treated with
(C) saline, (D) F1lb, or (E) HPLC F1. (F) Infarct size (IS) as a percentage of the area at risk (AAR) upon treatment with saline (n=10), F1lb CM (n=6) and HPLC F1 (n=6). Saline-
treated mice had a 34.5±3.3% relative infarct size while F1lb CM- and HPLC F1-treated mice had a 17.4±3.7% and 18.1±2.0% relative infarct size, respectively. AAR as a
percentage of the left ventricle (LV), showing the amount of endangered myocardium after MI/R injury. All animals were affected to the same extent by the operative procedure,
resulting in 39.4±2.0% of AAR among the groups. Each bar represents mean±SEM.
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analysis. We further demonstrate that consistent with our previous
observations [23], the cardioprotective effect of secretion from fetal
MSCs was mediated by large complexes in the range of 100 to 200 nm
or possibly, microparticles.
Microparticle is a minimally deﬁned term that encompasses a
broad spectrum of secreted particles in the size range of 0.05–1 μm.
Microparticles are known to be produced by numerous cell types
[42–48]. Although the function of microparticles remains poorly
understood, there is irrefutable evidence that microparticles have
important functions. As summarized by many recent reviews [46–57],
microparticles are deﬁnitively associated with many diseases such as
cancer, atherosclerosis and cerebral ischemia. However, the speciﬁc
role ofmicroparticles in disease process and/or progress remains to be
determined. As some microparticles carried biologically active
materials includingproteins andRNAs that can be transferredbetween
cells, it is likely that microparticles would have an impact either
positively or negatively on a disease process and/or progress. This has
led to suggestions that microparticles could be exploited as potential
therapeutic vectors [58]. However, the broad deﬁnition of micro-
particles which encompasses all secreted membrane vesicles to
include the more deﬁned exosomes (50–100 nm), microvesicles
(100–1000 nm), ectosomes (50–200 nm), membrane particles
(50–80 nm), exosome-like vesicles (20–50 nm) and apoptotic vesicles
(50–500 nm) [24] has impeded our understanding of microparticles.
Other than exosomes which are the most stringently deﬁned
microparticles to date, the major distinguishing parameter for these
different classes of microparticles is their size.
In this report where we not only demonstrated directly for the ﬁrst
time that puriﬁed microparticles in MSC secretion were cardiopro-
tective, we also puriﬁed these microparticles by size exclusion on an
HPLC which is currently one of the most precise methods for size
fractionation of molecules or particles. The puriﬁed microparticles
were determined by dynamic light scattering analysis to be a
population of homogenously sized particles with a hydrodynamic
radius of 50–65 nm. This particle size which translated into an
approximate diameter of 100–130 nm was consistent with our
previous observation that ﬁltration through a membrane with an
MW cutoff of 1000 kDa caused the ﬁltrate to lose its cardioprotective
function while that part of secretion retained by the same ﬁlter or the
retentate was cardioprotective [23]. A membrane with an MW cutoff
of 1000 kDa has a 100-nm nominal pore size according to the
manufacturer (Pall Corp. http://www.pall.com/). This essentially
meant that the ﬁltrate contained particles with diameter of less than
50–100 nm and these b50–100 nm particles were not cardioprotec-
tive. On the other hand, the retentate containing particles N50–100 nm
was cardioprotective. Together, this study and our previous study [23]
demonstrated that cardioprotection by the secretion of hESC-MSCs
and fetal MSCs was similarly mediated by microparticles with
diameters of N50–100 nm. Our previous study also suggested that
secretion devoid of themicroparticles but containing all other secreted
proteins as represented by the CM ﬁltrate through a membrane with
an MW cutoff of 1000 kDa was not cardioprotective [23]. This
observation of no cardioprotective activity could therefore be
extrapolated to HPLC fraction 2 to 4 where there were no micro-
particles and the secreted proteins were eluted according to the size
exclusion principle, and were therefore soluble.
The involvement of microparticles in mediating the paracrine
effect of MSC transplantation on tissue repair represents a radical shift
in our current understanding of the paracrine effect of MSC which
hitherto has been limited to cytokine, chemokine or growth factor-
mediated extracellular signaling [10].
Together our report demonstrated that MSCs derived from fetal
tissues are a viable alternative to human ESCs as a tissue source of
highly proliferative MSCs that produces cardioprotective secretion. A
single fetal tissue could potentially generate 1016 to 1019 MSCs. A 109
cell culture secretes 100 mg protein. We have previously shown that
the effective cardioprotective dose for a pig model of MI/R injury was
10 mg protein per 60–70 kg pig [23]. Therefore, a single fetal tissue
could potentially generate sufﬁcient MSCs to produce 108–11 doses.
Together with the relatively simple puriﬁcation of these micro-
particles to a population of homogenously sized microparticles, the
use of secretion from fetal MSCs represents a viable strategy to
address an urgent unmet therapeutic need for treating MI/R injury
[59].
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Exosomes secreted by human ESC derived mesenchymal stem cells (hESC-MSCs) 
were recently found to reduce infarct size in a mouse model of myocardial 
ischemia reperfusion injury.  A requisite for elucidating the underlying 
mechanism is an understanding of the biological potency in these exosomes.  Here 
we profiled the proteome of MSC exosome to identify 857 proteins that together 
suggest a potential to drive a diverse spectrum of cellular and biochemical 
activities. As an illustration and validation of this diverse potential, hESC-MSC 
exosomes were determined to contain glycolytic enzymes capable of generating 
ATP and NADH or increasing glycolysis in vitro and in vivo, 20S proteasome that 
hydrolyzed small peptides, CD73 that activated adenosine-mediated signaling 
pathway to phosphorylate ERK and AKT in cells, and CD59 that inhibited 
complement-mediated cell lysis.  The presence of this diverse array of biological 
activities known to be critical in ameliorating tissue injury and facilitating tissue 
repair provides candidate mechanisms for cardioprotective effect of exosome from 
hESC-MSC. 
 
Keywords:  Mesenchymal Stem Cells, exosome, proteome, glycolysis, 




Exosomes were once thought to be “trash bags” for cells to discard unwanted 
proteins1.  However, exosomes are increasingly viewed as having important 
physiological function particularly in cellular communication.  Exosomes are bi-
lipid membrane vesicles of 50-100 ηm that are secreted by many cell types2.  They 
belong to a class of secreted cellular products known as microparticles which 
broadly encompasses all secreted membrane vesicles.  Other than exosomes, 
microparticles include microvesicles (100-1000 ηm), ectosomes (50-200 ηm), 
membrane particles (50-80 ηm), exosome-like vesicles (20-50 ηm) and apoptotic 
vesicles (50-500 ηm).  The major distinguishing parameter for these different 
classes of microparticles is their size and the best defined class is the exosomes.  
Exosomes have a density in sucrose of 1.10 to 1.19 g/ml, sedimented at 100,000 g, 
has a cholesterol-rich lipid membrane containing sphingomyelin, ceramide, lipid 
rafts and exposed phosphatidylserine.  The process of exosome biogenesis is 
complex and involves complex intracellular membrane trafficking and cargo 
sorting through the biosynthetic and endocytotic pathways.  As evidence of this 
complex biogenesis, the hallmark features of exosomes are markers of the 
endoplasmic reticulum and the endosomes such as Alix, Tsg101, Rab proteins, etc.  
Exosomes are stored in multivesicular bodies prior to release via fusion of the 
multivesicular bodies (MVBs) with the plasma membrane.  
Exosomes have been shown to mediate intercellular communication particularly 
in immune or tumor cells3-8. Recently we extended this function to include tissue 
repair when we reported that exosomes secreted by human ESC-derived MSCs 
reduced infarct size by about 50% in a mouse model of myocardial ischemia 
reperfusion (MI/R) injury9, 10. These exosomes were purified as a population of 
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homogenously sized microparticles of about 50-100 ηm in diameter by size 
exclusion on HPLC and they carry both protein and RNA load9, 11, 12.  However, 
the mechanism/s underlying this cardioprotective effect by MSC exosomes has yet 
to be elucidated.  Part of the reason could be attributed to a deficiency in our 
understanding of the biological potency of exosomes in general.  Despite 
extensive proteomic and RNA profiling of exosomes from various cell types and 
biological fluids, the biological potency of the proteins and RNAs in exosomes 
remains largely uninvestigated.  Most studies to date on the biological potency are 
limited to  the immune responses that are elicited by exosomes from immune cells, 
particularly the dendritic cells2 but the molecular or biochemical basis of these 
biological responses have yet to be elucidated. 
To address this deficiency, we performed a comprehensive proteomic profiling of 
HPLC-purified exosome to first identify proteins present in these exosomes and 
then using these proteins to predict the types of biological activity or potential in 
the exosomes.  This was then validated by either biochemical or cellular assays. A 
total of 857 unique gene products were detected and they could be functionally 
clustered into 32 over-represented biological processes indicating that exosomes 
have the potential to exert a wide spectrum of biochemical or cellular effects.  To 
evaluate and verify this potential, we selected proteins for which assays to assess 
either their biochemical and/or cellular activities are available and that together, 
would demonstrate the wide spectrum of biochemical and cellular potential in 
exosomes, and provide candidate molecular mechanisms for the cardioprotective 
properties of MSC exosomes. The proteins investigated here include glycolytic 
enzymes for the breakdown of glucose to generate ATP and NADH, PFKB3 that 
increases glycolysis, CD73 that hydrolyses AMP to adenosine capable of 
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activating signaling cascades through adenosine receptors, CD59 that inhibits the 




Materials and Methods 
 
Preparation of exosomes 
Exosomes were purified from huES9.E1 derived MSCs conditioned media (CM) 
using HPLC as described earlier. In brief, CM collected from MSCs culture was 
concentrated 50x by tangential flow filtration (TFF) using a membrane with a 100 
kDa MWCO (Sartorius, Goettingen, Germany). After that, CM was passed 
through chromatography columns (TSK Guard column SWXL, 6x40 mm and 
TSK gel G4000 SWXL, 7.8x300 mm, Tosoh Corp., Tokyo, Japan). Exosomes 
were collected from the first peak of the elution, concentrated using 100 kDa 
MWCO filter (Sartorius). Exosomes were filtered with a 0.22 µm filter before 
storage or use. 
 
LC MS/MS 
Proteins in two ml of dialyzed exosomes were reduced, alkylated and tryptic 
digested as described13. The samples were then desalted by passing the digested 
mixture through a conditioned Sep-Pak C-18 SPE cartridge (Waters, Milford, MA, 
USA), washed twice with a 3% acetonitrile (ACN) (JT Baker, Phillipsburg, NJ) 
and 0.1% formic acid (FA) buffer, and eluted with a 70% ACN and 0.1% FA 
buffer. The eluted samples were then dried to about 10% of their initial volumes 
by removing organic solvent in a vacuum centrifuge. To reduce sample 
complexity, offline peptide fractionation was carried out with a HPLC system 
63
(Shimadzu, Japan) through a Polysulfoethyl SCX column (200 mm x 4.6 mm) 
(PolyLC, USA).  Mobile phase A (5 mM KH4PO4 + 30% acetonitrile) and mobile 
phase B (5 mM KH4PO4 + 30% acetonitrile + 350 mM KCl) at 1 ml/min. Eight 
fractions were collected and dried with a vacuum centrifuge. Fractionated samples 
were loaded into the auto sampler of a Shimadzu micro HPLC system coupled 
online to a LTQ-FT Ultra linear ion trap mass spectrometer (Thermo Electron, 
Bremem, Germany) fitted with a nanospray source.  Injected peptides were 
trapped and desalted in a Zorvax 300SB-C18 enrichment column (5 mm x03 mm, 
Agilent Technologies, Germany) and eluted into a nano-bored C18 packed 
column (75 µm x 100 Å, Michrom Bioresources, Auburn, CA).  A 90 minute 
gradient at a constant flow rate of 20 ml/min with a splitter to an effective flow 
rate of 200 ηl/min was used to elute the peptides into the mass spectrometer. The 
LTQ was operated in a data-dependent mode by performing MS/MS scans for the 
8 of the most intense peaks from each MS scan in the FTMS.  For each 
experiment, MS/MS (dta) spectra of the eight SCX fractions were combined into a 
single mascot generic file by a home-written program. Protein identification was 
achieved by searching the combined data against the IPI human protein database 
(version 3.34; 69,164 sequences, 29,064,825 residues) via an in-house Mascot 
server (Version 2.2.04, Matrix Science, UK). The search parameters were: a 
maximum of 2 missed cleavages using trypsin; fixed modification was 
carbaminomethylation of cysteine and variable modification was oxidation of 
methionine. The mass tolerances were set to 10 ppm and 0.8 Da for peptide 
precursor and fragment ions respectively. Protein identification was accepted as 
true positive if two different peptides were found to have scores greater than the 
homology scores. 
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 Antibody array 
500 µl of non-conditioned media and exosomes were assayed for the presence of 
cytokines and other proteins using RayBio® Biotin Label-based Human Antibody 
Array I according to manufacturer’s instructions (RayBio, Norcross, GA). The 
cytokines and other proteins were considered to be present in the exosomes if the 
signal intensity is 2 fold higher (p<0.05) than that in non-conditioned medium. 
 
Western blot hybridization 
12 µg exosomes were separated on 4-12% SDS-polyacrylamide gels and 
electroblotted onto a nitrocellulose membrane. The membrane was transferred to 
the membrane holder of SNAP i.d. system (Millipore, Billerica, MA), blocked and 
incubated with primary anti-human antibodies, which included mouse anti-
GAPDH (1:100 dilution), mouse anti-PGK (1:60), mouse anti-PGD (1:60), rabbit 
anti-PFKFB3 (1:60), mouse anti-pyruvate kinase (PK, 1:200), mouse anti- 20S 
proteasome α1-7 (1:200), mouse anti-CD73 (1:60) and mouse anti-CD59 (1:200) . 
The blot was then incubated with a horseradish peroxidase-coupled secondary 
antibody. The secondary antibody used was goat anti-mouse IgG (1:1250) or 
donkey anti-rabbit IgG (1:1250). All antibodies were obtained from Santa Cruz 
Biotechnology, Santa Cruz, CA except mouse anti-PK which was from Abcam 
Inc., Cambridge, MA. The blot was then incubated with HRP-enhanced 
Chemiluminescent substrate (Thermo Fisher Scientific Inc., Waltham, MA) and 




Pyruvate Kinase assay:  
5 μg of exosome (in 12 μl) was lysed using a cell extraction kit (Biovision, 
Mountain view, CA). The  lysed exosome extract was incubated with 50 μl of 
reaction mix from a commercially available  PK assay kit (Biovision). In this 
assay, pyruvate produced by PK was oxidized by pyruvate oxidase to produce 
fluorescences (Ex/Em= 535/587 nm). The increase in fluorescence intensity is 
therefore proportional to the amount of pyruvate produced.  
GAPDH and PGK assay:  
GAPDH and PGK activity were measured based on their downstream product, 
ATP in the glycolysis reaction using 2 commercially available kits, KDalert 
GAPDH assay kit (Ambion Inc., Austin, TX) and ApoSENSOR ADP/ATP ratio 
assay kit (Biovision). Briefly, exosomes were lysed using a cell extraction kit 
(Biovision). To measure GAPDH activity, 10 μg of lysed exosomes was added to 
KDalert reaction buffer containing D-glyceraldehyde-3-phosphate, NAD+ and Pi 
to form 1, 3-bisphosphoglycerate + NADH+ H+. 250 U/ml of PGK and 60 µM 
ADP were then added to convert 1, 3-bisphosphoglycerate and ADP to 3-
phosphoglycerate and ATP. The amount of ATP produced which was proportional 
to GAPDH activity, was then measured using ATP luciferase assay. To measure 
PGK activity, 10 μg of lysed exosomes was added to the 1, 3-bisphosphoglycerate 
produced from the above assay. ADP was added to allow the formation of ATP. 
ATP amount which is proportional to PGK activity was then quantified using ATP 
luciferase assay. 
20S proteasome assay: 
The proteasome activity was measured using a 20S proteasome activity assay kit 
(Millipore) based on detection of the fluorophore 7-Amino-4 methylcoumarin 
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(AMC) after cleavage from the labeled substrate LLVY-AMC by 20S proteasome 
in the presence or absence of lactacystin, a specific 20S proteasome inhibitor. 
Briefly, 4 μg of exosome was incubated with a reaction buffer containing LLVY-
AMC in the presence or absence of 25µM actacystin. The samples and AMC 
standards were incubated at 37 ºC and fluorescense intensity at Ex/Em= 380/460 
nm was monitored for 2 hours.  
CD73 assay: 
CD73 (NT5E) enzymatic activity in exosome was determined by incubating 2.5 
µg of exosome in 100 µl Tris buffer pH 7.4 containing 50 µM AMP (Sigma-
Aldrich, St Louis, MO).  The amount of phosphate ions released from the 
hydrolysis of AMP was then determined by Colorlock Gold kit (Innova 
Biosciences, Cambridge, UK) as per manufacturer’s instruction. 
Cell assays 
Glycolysis  
H9C2 cardiomyocytes were plated onto a 96 well plate (poly-lysine coated) at 
30,000 cells per well. After 5 hours, the cells were washed twice with Tyrode’s 
buffer before incubating in Tyrode’s buffer containing 20 µmol oligomycin 
(Sigma-Aldrich), 6 mmol glucose, and with or without 0.1 µg/ml exosomes for 15, 
30 and 60 minutes. Cellular ATP concentration was measured using ATPlite 1step 
luminescence ATP detection assay system (PerkinElmer, Zaventem, Belgium). 
Adenosine-mediated signaling 
H9C2 cardiomyocytes were plated onto a 6 well plate at 200,000 cells per well 
and serum starved overnight. The cells were then incubated with fresh serum-free 
medium with or without 1mM theophylline for another hour.  In the meantime, 
two series of serum-free media were prepared.  One series contained no 
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supplement, 50 μM AMP alone, 0.1μg/ml exosomes alone or a combination of 50 
μM AMP and 0.1μg/ml exosomes.  The second series was similar to the first 
except that the media contained 1mM theophylline.  Both series were incubated at 
37°C for 30 minutes.  The first series was used to replace medium of the cells that 
were being cultured in serum-free medium alone and the second series to those 
cells that were being cultured in theophylline-containing medium. After five 
minutes, the cells were harvested and lysed using a commercially available 
mammalian cell extraction kit (BioVision) in the presence of a protease and 
phosphatase inhibitor cocktail 1 (Sigma Aldrich). Protein concentration was 
determined by standard Bradford assay. 10 μg of the total proteins were analysed 
by western blot hybridization using 1:2000 dilution of rabbit anti-pERK 1/2 (Cell 
Signaling, 9101S), 1:2000 dilution of rabbit anti-AKT (Cell Signaling, 9271S), 
1:500 dilution of rabbit anti-ERK1 (Santa Cruz,sc-94) and 1:500 dilution of rabbit 
anti-AKT (Cell Signaling, 9272S). 
Complement-mediated cell lysis  
Briefly, sheep red blood cells (SRBCs) were purchased (Innovative Research, 
Southfield, MI) and washed three times with phosphate buffered saline (PBS) 
before resuspending at 1×108 cell/ml PBS. Purified complement components, 
C5b6, C8 and C9 were purchased from Calbiochem (San Diego, CA), and C7 
from Sigma-Aldrich (St Louis, MO).  Assembly of intact C5b-9 on SRBCs was 
initiated by a 15 min incubation (37 °C) with 1ml each of C5b6 (0.1µg/ml) and C7 
(0.4µg/ml) in the presence or absence of exosomes at a final concentration of 0.1 
µg/ml. The SRBCs were then washed and incubated with 1ml each of C8 
(0.4µg/ml,) plus C9 (0.4µg/ml) with or without a blocking CD59 antibody at a 
final concentration of 0.05 µg/ml for an additional 30 min. After that the SRBCs 
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were centrifuged and the amount of hemoglobin released by the lysed SRBCs in 
the supernatant was measured by absorbance at 415 nm. Total (100%) hemolysis 




Proteomic profiling of exosome 
Exosomes were purified from culture medium conditioned by HuES9.E1, a human 
ESC-derived mesenchymal stem cells14 by HPLC as previously described9, 10. 
Proteomic profiling using mass spectrometry and antibody approaches were 
performed as previously described9-11on 3 independently prepared batches of 
HPLC-purified exosomes. A total of 857 proteins were detected and these proteins 
were denoted by their gene symbol to facilitate analysis (Table 1).  Of these, 320 
gene products were found in the 739 proteins previously identified in the 
unfractionated conditioned medium9, 10 (Figure. 1).  
Based on data analysis of 15 proteomic analyses carried out on exosomes purified 
from cultured cells and from biological fluids, Thery et al. had observed that a set 
of about 17 proteins, namely glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH), pyruvate kinase (PK), eukaryotic translation elongation factor 1A1 
(EEF1A1), milk fat globule EGF factor 8 protein (MFGE8), tetraspanins, 14-3-3 
proteins, Gα proteins, clathrin, Alix (PDCD6IP), MHC class1, annexins (ANX), 
Rab proteins, ezrin(VIL2), radixin(RDX) and moesin (MSN)(ERM), actin, tubulin, 
HSP70 and HSP90 were found to be present in at least 50% of the exosomes that 
were characterized2.  Not unexpectedly, most of these proteins were also found in 
the proteome of the HPLC-purified MSC exosomes (Table 1). Also consistent 
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with the endosomal origin of exosomes, we detected the presence of endosome-
associated proteins such as Alix (PDCD6IP) and Rab (Table 1). 
 
Computational analysis of exosome proteome 
To better understand the biological significance of the proteins in the exosomes, 
functional clustering of the 857 proteins into biological processes was performed 
using PANTHER (Protein ANalysis THrough Evolutionary Relationships) 
analytical software15, 16.  The observed frequency of genes from the exosome 
proteome in each biological process was compared with the reference frequency 
of genes in the NCBI database for that biological process.  The 857 gene products 
could be clustered into 32 biological processes that were over-represented 
(p<0.001) and 3 that were under-represented (p<0.001) (Figure. 2). 
These biological processes could be further classified into several activities 
associated with exosome biology e.g. communication, cellular motility, 
inflammation and exosome biogenesis.  As exosomes are generally postulated to 
function as vehicles of intercellular communication and morphogen signaling4, 17 
and mediators of immune activity2, the involvement of exosome proteins in signal 
transduction pathways, cell structure, cell motility and immune responses was not 
unexpected.  A fourth class of processes that we tentatively termed as “exosome 
biogenesis” essentially reflected the biogenesis and release of exosomes through 
the involvement of endosomes, ESCRT-mediated sorting and the formation of 
multivesicular bodies, and fusion with the plasma membrane.  Therefore, proteins 
such as those involved in trans-golgi network, intracellular protein traffic, general 
vesicle transport, endocytosis, receptor-mediated endocytosis, other protein 
targeting and localization and exocytosis are not unexpectedly enriched in 
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exosomes. Other biological processes that we classified as tissue repair and 
regeneration include those that are involved in the development and differentiation 
of mesodermal and ectodermal tissues including skeletal development and 
angiogenesis.  These biological processes are consistent with the differentiation 
potential of mesenchymal stem cells18 and reflected the cellular origin of the 
exosomes.  In our classification of metabolism, we included processes involved in 
catabolic or anabolic metabolisms that produce energy and building blocks for 
growth and regeneration.  Blood clotting was also a significantly over-represented 
biological process that we postulated may be important in ameliorating tissue 
injury. All three under-represented biological processes were not unexpectedly 
involved in regulating gene expression at the transcriptional level. Most proteins 
involved in these processes tend to be transported efficiently into the nucleus, 
making them less likely to be associated with exosomes. We also observed that 
419 proteins found in the conditioned medium (CM) were not present in the 
exosome (Figure. 1) and these proteins could be functionally clustered into eleven 
over-represented and two under-represented biological processes.  Of the over-
represented processes, six were also found in the clustering of the 857 proteins 
found in exosomes while the remaining five, namely amino acid activation, 
protein folding, chromatic packaging and remodeling, protein complex assembly 
and mRNA splicing were not.  The two under-represented biological processes 
were also found to be under-represented for the exosome proteins.  The diverse 
array of proteins in MSC exosomes indicated that they have the potential to 
participate in a wide spectrum of biochemical and cellular activities.  To test this 
hypothesis, we selected those proteins for which assays to test their biochemical 
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and cellular activities are available, and that together would provide an indication 
for the wide diversity in activities of exosomes 
 
Exosome enhanced cellular ATP production through glycolysis 
One prominent feature of the exosome proteome was the presence of all five 
enzymes in the ATP generating stage of the glycolysis (Figure. 3A): 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH), phosphoglycerate kinase 
(PGK), phosphoglucomutase (PGM), enolase (ENO) and pyruvate kinase m2 
isoform (PKm2).  Of these, GAPDH, PGK, and PKm2 that generate either ATP or 
NADH were further confirmed to be present by immunoblotting (Figure. 3B).  
Their enzymatic activities were determined to be 1.1 µU, 3.59 µU and 5.5 µU per 
µg protein respectively (Figure. 3C) where 1 unit (U) of enzyme activity is 
defined as the activity required for the production of 1 µmole of product per 
minute. 
In addition, exosome contains PFKFB3 which converts fructose 6-phosphate to 
fructose 2, 6-bisphosphate.  PFKFB3 is one of four PFKFB isoforms encoded by 
four different genes, PFKFKB1, 2, 3 and 4. PFKFBs are responsible for 
maintaining the cellular level of fructose-2,6-bisphosphate, a powerful allosteric 
activator of phosphofructokinase19 which catalyses the commitment to glycolysis.  
They are thought to be responsible for the high glycolytic rate or “Warburg effect” 
in cancer cells20. The kinase activity of PFKFB3 is upregulated by 
phosphorylation by protein kinases such as cAMP-dependent protein kinase and 
protein kinase C.  Mass spectrometry analysis revealed the presence of PFKFB3 
in the exosome and immunoblotting further demonstrated that this enzyme was 
phosphorylated (Figure. 3A).  
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The presence of ATP-generating glycolytic enzymes and phosphorylated PFKFB3 
in exosomes predicted that exposure of cells to exosome could increase glycolytic 
flux and increase ATP production. To test this, we determined if these exosomes 
could increase ATP synthesis in oligomycin-treated H9C2 cells.  Since 
oligomycin inhibits mitochondrial ATPase21, oligomycin-treated cells would have 
to utilize glycolysis as their major source of cellular ATP. Consistent with the 
presence of glycolytic enzymes and PFKFB3, and our previous demonstration that 
H9C2 cells could internalize MSC exosomes12, exosomes increased ATP level in 
oligomycin-treated cells by 75.5 + 28.8% or 55.8 + 16.5% in 15 to 30 minutes of 
exposure to exosomes respectively, possibly through increased glycolysis.  
 
20S proteasome in exosome is enzymatically active  
Mass spectrometry analysis of MSC exosomes not only detected the presence of 
all seven α- (PMSA1-7) and all seven β-subunits (PMSB1-7) of the 20S core 
particle, but also the three beta subunits of “immunoproteasome”, PMSB8 (β5i or 
LMP7), PMSB9 (β1i or LMP2), PMSB10 (β2i or LMP10) gene product 22. The 
presence of some of the 20S proteasome peptides was further confirmed by 
western blot hybridization (Figure. 4A).  The presence of all seven α- and all 
seven β-subunits of the 20S core particle suggest that MSC exosomes contain 
intact 20S proteasome complexes and therefore potentially possess 20S 
proteasome enzymatic activity. 
Consistent with this, MSC exosome was able to degrade short fluorogenic 
peptides with an enzymatic activity of 5.00 µU/µg protein and this degradation 
was inhibited by lactacystin, a specific proteasome inhibitor (Figure. 4B).  We 
also observed that unlike the glycolytic enzyme assays described above, 20S 
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proteasome activity in the exosomes could be detected without lysing the 
exosomes.  This suggested that the 20S proteasome may be present on the surface 
and not in the lumen of exosomes   It was previously observed that 20S 
proteasome preferentially assembles in an “end-on” configuration on 
phosphatidylinositol lipid monolayer, ER and Golgi lipid films23 such that 
entrance to 20S proteasome is perpendicular to membrane.  Therefore, this 
together with our observations suggests that 20S proteasomes in the exosomes 
were attached to external membrane surface and their entrances were 
perpendicular to the exosome membrane.  
 
Exosome phosphorylated ERK and AKT via CD73 (ecto-5’-ectonucleotidase, 
NT5E) 
Ecto-5'-nucleotidase (NT5E or CD73) together with ecto-apyrase (CD39) 
enzymatically convert precursor nucleotides into adenosine.  During cellular 
injury, cells release ATP and ADP24. CD39 hydrolyzes extracellular ATP and 
ADP to AMP which is then degraded to adenosine by ecto-5'-nucleotidase. 
Adenosine has a half-life of less than ten seconds in human blood.  It is a powerful 
vasodilator but is not used clinically as a vasodilator as it is very short acting.  It is 
used for the rapid treatment of supraventricular tachycardias.  Adenosine is an 
endogenous purine nucleoside that modulates many physiological processes 
through four known adenosine receptor subtypes (A1, A2A, A2B, and A3)25.  
CD73 was found to be present in the MSC exosomes by mass spectrometry 
analysis and confirmed by immunoblotting (Figure. 5A). The enzyme activity was 
determined to be 22.04 µU/µg protein. To determine if exosomes could activate 
adenosine signaling in cells via CD73-mediated hydrolysis of AMP, H9C2 
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cardiomyocytes were serum starved overnight and then exposed to exosomes and 
AMP.  Cell lysates were then analyzed for phosphorylation of ERK1/2 and AKT 
(Figure. 5B, C).  After overnight serum starvation, exposure to exosomes and 
AMP induced phosphorylation of ERK1/2 and AKT.  The phosphorylation of 
ERK1/2 and AKT was abolished in the presence of theophylline, a non-selective 
adenosine receptor antagonist that antagonized A1, A2A, A2B, and A3 receptors26. 
 
Exosome inhibited the formation of membrane attack complex  
The complement system is a part of the innate immune system which 
complements the function of antibodies.  Upon activation, a biochemical cascade 
is initiated to generate several key products: C3b which binds to the surface of 
pathogens and enhance phagocytosis of these pathogens; C5a which helps to 
recruit inflammatory cells by chemotaxis; and C5b which initiates formation of 
the MAC consisting of C5b, C6, C7, C8, and polymeric C9.  MAC deposited on 
the target cell forms a transmembrane channel which causes subsequent cell lysis.  
Aberrant activation of the complement pathway is thought to play a deleterious 
role in ischemia reperfusion injury27.  
MSC exosome was found to contain CD59 by mass spectrometry analysis and this 
was confirmed by immunoblotting (Figure. 6A). Since CD59 inhibits formation of 
MAC28, this suggested that exosomes may inhibit complement activation and 
subsequent complement-mediated cell lysis.  Consistent with this hypothesis, 
exosome inhibited complement-mediated lysis of sheep red blood cells (SRBCs) 
(Figure. 6B). This inhibition was abolished when a CD59 blocking antibody was 
used to pre-treat the exosomes, showing that CD59 of exosomes is directly 
involved in the inhibition of complement lysis.
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Discussion 
In this report, we profiled the proteome of 3 independently prepared, HPLC-
purified ESC-derived MSC exosome using mass spectrometry and cytokine array 
and identified 857 proteins.  These proteins included many proteins commonly 
found in other exosomes.  Clustering of these proteins according to their functions 
suggested that the exosome has the potential to drive many biological processes.  
To evaluate this hypothetical biological potential, we examined a set of proteins 
selected on the basis that assays for their biochemical and cellular activities are 
available, and that as a group, they would illustrate the wide ranging diversity in 
activities.  More importantly, the biochemical and cellular activities of these 
selected proteins could potentially ameliorate tissue injury in acute myocardial 
ischemia/reperfusion injury. 
The proteome of MSC exosomes contained a diverse array of proteins.  A 
significant fraction are proteins that are involved in the highly regulated and 
complex intracellular membrane trafficking and sorting through the biosynthetic 
and endocytotic pathways29 and the presence of these proteins is probably a 
reflection of the biogenesis of exosomes.  It was previously observed that 
exosomes from different cell sources carry a common set of proteins, many of 
which are reflective of their biogenesis30. The complexity in the biogenesis of 
exosome and selective loading of the protein and RNA cargo load suggest a heavy 
investment of cellular resources and such commitment must be underpinned by 
important physiological functions.   
Although exosomes have been discovered for more than 30 years, the biological 
significance of exosome is just starting to be uncovered. It has been implicated in 
an increasing number of important physiological and pathological processes such 
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as disposal of unwanted protein1, antigen presentation31, genetic exchange32, 
immune responses33, 34 and tumor metastasis33-38.  Together, these observations 
suggest that as a group or individually, exosomes may modulate many biological 
processes.  The latter possibility is supported by the wide array of proteins and 
RNAs that has been found in exosomes12, 39.  In addition to the functions of 
exosomes listed above, we have recently observed that exosomes secreted by 
MSCs could reduce infarct size in a mouse model of acute myocardial 
ischemia/reperfusion injury9. To investigate and elucidate the underlying 
molecular mechanism, we undertook a systematic proteomic interrogation of the 
MSC exosomes to reveal the cellular and biochemical potential of these exosomes 
and to identify candidate biological activities that could ameliorate tissue injury in 
acute myocardial ischemia/reperfusion injury9. 
We first determined that the glycolytic enzymes that are responsible for 
generating ATP and NADH19, were not only present in the exosomes but were 
also biochemically active.  In addition, the exosomes also contained the active 
phosphorylated form of PFKB3 that catalyzed the formation of fructose-2,6-
bisphosphate, a powerful allosteric activator of phosphofructokinase These 
observations indicated that MSC exosomes have the potential to restore cellular 
ATP and NADH through glycolysis, independent of mitochondrial function.  
Besides being the major site of ATP production, mitochondria is also the major 
organelle in regulating cell death40.  Loss of mitochondrial function and 
subsequent depletion of ATP generally represent the early steps in the cascade 
leading to cell death during pathological conditions such as acute myocardial 
ischemia/reperfusion injury.  ATP deficiency, a major index of cell viability, is the 
key consequence of mitochondrial dysfunction.  Since MSC exosomes could be 
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internalized by cells12, exosome has the potential to restore cellular ATP level by 
increasing cellular content of glycolytic enzymes or phosphorylated PFKB3 in 
cells with mitochondrial damage.  Indeed, when mitochondrial ATPase in H9C2 
cells was inhibited by oligomycin, exosomes could increase ATP production in 
these cells.  
The presence of all seven α and β subunits that together constitute the 20S 
proteasome and the subsequent validation of 20S proteasome enzymatic activity in 
the exosomes suggested that the therapeutic activity of MSC exosomes could be 
partly attributed to the presence of 20S proteasome.  20S proteasome is 
responsible for the degradation of about 90% of all intracellular oxidatively 
damaged proteins41 and reduced proteasomal activity has been postulated to be a 
contributing factor in the pathogenesis of aging-related neurodegenerative 
diseases such as Alzheimer’s disease and Parkinson’s disease42, 43 or 
cardiovascular disease44-46.   
The biochemical potential of MSC exosomes to hydrolyze AMP to adenosine by 
CD73 and to subsequently induce phosphorylation of AKT and ERK1/2 through 
the adenosine receptor illustrated the capacity of MSC exosomes to hydrolyze 
AMP released by distressed cells and stimulated survival signaling pathways.  A 
recent position paper from the European Society of Cardiology highlighted the 
activation of adenosine receptor and phosphorylation of the pro-survival kinases 
such as PI3 kinase-AKT and ERK1/2 as possibly having a role in the limiting 
reperfusion injury47.  Therefore, the activation of adenosine receptor which has 
been shown to be cardioprotective47, 48may also be a molecular mechanism 
mediating the amelioration of reperfusion injury by exosomes.  
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The inhibition of complement-mediated lysis of red blood cells by CD59 on 
exosomes represents yet another candidate mechanism for the cardioprotective 
effect of the exosome. Complement activation is a known mediator of 
ischemia/reperfusion injury in tissues such as intestines, heart and kidney, and its 
attenuation or inhibition has been shown to ameliorate tissue injury49-51.   
In summary, our interrogation and biochemical validation of the exosome 
proteome have uncovered a diverse range biochemical and cellular activities, and 
identified several candidate pathways for the cardioprotective effect of the 
exosome.  Further validation studies in appropriate animal models will be required 
to determine if one or more of these candidate pathways contributed to the 
efficacy of MSC exosome in reducing reperfusion injury in the treatment of acute 
myocardial injury.  The multitude of biochemical potentials in MSC exosomes 
provides for the possibility of simultaneously targeting more than one mediator of 
tissue injury and potentially inducing a therapeutic synergy similar to that 
observed in combination drug therapy.  This possibility of being able to target 
multiple mediators of injury is further enhanced by the use of enzymes to drive 
these targeting activities.  Since enzyme activities are dictated by their 
microenvironment e.g. substrate concentration or pH, the enzyme-based 
therapeutic activities of exosomes could be activated or attenuated in proportion to 
the severity of disease-precipitating microenvironment.  Consequently, the 
efficacy of exosome-based therapeutics could be highly responsive to and yet 
limited by the disease precipitating micro-environment.  Together, these features 
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Figure 1: Intersection of the 739 proteins previously identified in MSC 













Figure 2. Proteomic analysis of exosome proteins. The 857 gene products in 
exosomes were functionally clustered into 32 over-represented and three under-
represented biological processes (p<0.001). The 419 proteins found in the 
conditioned medium (CM) but not in the exosome were functionally clustered into 
11 over-represented and 2 under-represented biological processes.  Black bars 
represent processes for gene products in the exosomes and white bars represent 
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Figure 3: Exosome regulates glycolysis. (A) Schematic diagram of glycolysis. (B) 
Western blot analysis of conditioned medium (CM) and exosome (Exo) for 
geraldehyde phosphate dehydrogenase (GAPDH), phosphoclycerate kinase (PGK), 
pyruvate kinase m2 isoform (PKm2) and pPFKFB3. (C) Enzymatic activities of 
GAPDH, PGK and PKm2 in MSC exosome were determined by the production of 
ATP or pyruvate using commercially available assay kit. One unit (U) enzyme 
activity is defined as the activity to generate 1 µmole product per minute at 37°C. 
(D) Effect of exosome on ATP production in oligomycin-treated cells.  H9C2 
cardiomyocytes were washed twice with Tyrode’s buffer and then incubated in 
Tyrode’s buffer containing 20 µmol of a mitochondrial inhibitor, oligomycin,  6 
mmol glucose, and with or without 0.1 µg/ml exosomes for 15, 30 and 60 minutes. 
Cellular ATP concentration was measured using ATPlite 1step luminescence ATP 
detection assay system and normalized to that of sample without exosomes at 15 
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Figure 4: 20S proteasome in exosome. (A) Western blot analysis of MSC 
conditioned medium (CM) and exosome (Exo) using an antibody specific for 
PMSA 1-7 peptides. (B) Proteasome activity in MSC exosome was determined 
using a commercially available proteasome activity assay kit (Millipore).  
Proteasome activity was measured by the rate of degradation of a fluorogenic 
peptide in the absence or presence of lactacystin, a proteasome inhibitor. One unit 
(U) enzyme activity is defined as the activity to generate 1 µmole product per 



















































Figure 5: Exosome phosphorylated ERK and AKT via NT5E (ecto-5’-
ectonucleotidase CD73). (A) Western blot analysis of MSC CM and exosome for 
CD73 using a specific antibody. (B) CD73 activity in conditioned medium (CM) 
and exosomes (Exo) was measured by the production of phosphate ion from the 
hydrolysis of AMP.  (C) H9C2 cells were serum starved overnight and then 
incubated with medium with or without 1mM theophylline for one hour.  The cells 
were then exposed for 5 min to medium that had been pre-incubated for 30 
minutes with 50 μM AMP, 0.1μg/mL exosome or AMP and exosome.  The cells 
were then harvested and lysed. 10 μg total proteins were immunoblotted using 
1:2000 dilution of rabbit anti-pERK 1/2, 1:2000 dilution of rabbit anti ERK1/2, 





















































































Figure 6: Exosome inhibited the formation of membrane attack complex (MAC). 
(A) Western blot analysis of MSC conditioned medium (CM) and exosome (Exo) 
using a CD59-specific antibody. (B) SRBCs were washed and then re-suspended 
in PBS with C5b6 and C7 in the presence or absence of exosome. The mixture 
was incubated at 37°C for 15 min before C8 and C9 were added with or without a 
blocking CD59 antibody for additional 30 min incubation. The cells were 
centrifuged and the amount of hemoglobin released by the lysed SRBC in the 
supernatant was measured by absorbance at 415 nm. The positive control (total 
hemolysis) was supernatant from cells completely lysed with Triton X-100.  The 
negative control is the sample without addition of complement components.  The 


























































A2M C11orf59 COPS4 FBXW8 HNRNPA1 KRT16 MMP3 PRR4 RPS3 TGFB2
ABI3BP C1orf78 COPS8 FEN1 HP KRT17 MOS PRSS23 RPS4X TGFBI
ACAA2 C1R CPS1 FER1L3 HPX KRT18 MPO PSMA1 RPS5 TGM2
ACAT2 C1S CREG1 FGA HRSP12 KRT19 MPZL1 PSMA2 RPSA TGOLN2
ACLY C20orf114 CRIPT FGB HSP90AA1 KRT2 MRC2 PSMA3 RRAS2 THBS1
ACSL1 C3 CRTAP FGF16 HSP90AB1 KRT27 MSN PSMA4 RTN4 THBS2
ACTA1 C5orf24 CSF1 FGF18 HSP90B1 KRT28 MXRA5 PSMA5 RUVBL1 THY1
ACTA2 C9orf19 CSF2 FGF19 HSPA1A KRT3 MYADM PSMA6 S100A11 TIMP1
ACTB C9orf91 CSF3 FGFRL1 HSPA1L KRT4 MYCBPAP PSMA7 S100A13 TIMP2
ACTG2 CACNA2D1 CSPG4 FGG HSPA5 KRT5 MYH14 PSMB1 S100A8 TIMP3
ACTN1 CACNA2D4 CST4 FLG2 HSPA6 KRT6A MYH9 PSMB10 S100P TKT
ACTN2 CALR CTA-221G9.4 FLJ13197 HSPA8 KRT6B MYL6B PSMB2 SAA4 TLN1
ACTN3 CAND1 CTBP2 FLJ22184 HSPB1 KRT6C MYO1C PSMB3 SASS6 TMBIM1
ACTN4 CAP1 CTNNA1 FLJ32784 HSPD1 KRT7 NBL1 PSMB4 SCAMP3 TMED10
ACTR1A CAPNS1 CTNNA2 FLNA HSPG2 KRT72 NEFH PSMB5 SCGB2A1 TMED9
ACTR2 CAPZA1 CTNNB1 FLNB HTRA1 KRT73 NEK10 PSMB6 SCYE1 TMEM16B
ACTR3 CASP14 CTNND1 FLNC HYI KRT74 NID1 PSMB7 SDC1 TMEM2
ADAM10 CAT CTSG FLOT1 ICAM1 KRT76 NLRP8 PSMB8 SDC2 TMEM47
ADAM9 CAV1 CXCL16 FLOT2 ICAM5 KRT77 NME1 PSMB9 SDC4 TMEM51
ADAMTS12 CCDC129 CXCL2 FLT1 IDH3B KRT78 NOMO1 PSMC5 SDCBP TNC
AEBP1 CCDC64B CXorf39 FN1 IFITM2 KRT79 NRAS PSMD11 SEC14L4 TNFRSF11B
AFM CCL2 CYBRD1 FREM3 IFNG KRT8 NRG2 PSMD14 SEMA5A TNFRSF12A
AGRN CCL20 DBF4B FST IFRD1 KRT80 NRLN1 PSMD6 SEPT2 TNFRSF1A
AHCY CCL28 DCD FTL IFT140 KRT84 NRP1 PSMD7 SEPT7 TNFSF18
AHNAK2 CCL7 DCHS2 FUCA2 IGF2R KRT9 NT5E PTGFRN SERINC5 TNFSF5
AHSG CCR4 DCLK2 GALNT5 IGFBP3 LACRT NTF5 PTK7 SERPINA1 TPBG
AKR1B1 CCR5 DCN GANAB IGFBP4 LAMA4 NUSAP1 PTPRK SERPINB3 TPI1
AKR7A2 CCT5 DCTN1 GAPDH IGFBP6 LAMB1 OBFC1 PTRF SERPINE1 TRAP1
ALB CCT6A DECR1 GAPDHS IGFBP7 LAMC1 ODZ3 PTTG1IP SERPINE2 TREM1
ALCAM CD109 DEFA1 GARS IGHA1 LAMP1 OFD1 PTX3 SERPINF1 TREML2P
ALDH2 CD151 DIP2B GAS6 IGHA2 LAMP2 OPRM1 PXDN SFN TRIM40
ALDH3A2 CD248 DIRAS2 GDF1 IGHG1 LAP3 OSM PZP SFRP1 TRIM41
ALDH6A1 CD276 DKFZp686D0972 GDF11 IGHG2 LCN1 OTC QPCTL SFRP4 TSN
ALDH7A1 CD44 DKK1 GDF3 IGHG4 LCN2 OXNAD1 QSOX1 SHANK3 TSNAX
ALDH9A1 CD47 DKK3 GDF5 IGHM LDHA OXTR RAB10 SLAIN1 TSPAN14
ALDOA CD59 DMBT1 GDF8 IGJ LDHAL6B P4HB RAB11B SLC16A1 TSPAN4
ALDOB CD63 DNASE1L1 GDF9 IGKC LDHB PAICS RAB14 SLC16A3 TSPAN6
ALDOC CD81 DNPEP GDI1 IGKV1-5 LEPRE1 PAN3 RAB15 SLC1A4 TSPAN9
ALOX12P2 CD82 DPYS GDI2 IGL@ LGALS1 PAPPA RAB1A SLC1A5 TSTA3
ANG CD9 DPYSL2 GFRA3 IGLV4-3 LGALS3 PARP10 RAB1B SLC22A2 TTLL3
ANGPTL2 CDC2L5 DSP GLDC IGSF8 LGALS3BP PARP16 RAB2A SLC25A10 TTN
ANPEP CDC42 DULLARD GLUD1 IL10 LGALS8 PARVG RAB33B SLC25A13 TTYH3
ANXA1 CDH13 ECM1 GNA13 IL11 LGR6 PC RAB35 SLC2A1 TUBA1A
ANXA11 CDIPT ED1 GNAI2 IL13 LIF PCOLCE RAB39B SLC2A3 TUBA1B
ANXA2 CDK5R2 EDG2 GNAL IL15RA LMNA PDCD6 RAB5A SLC38A2 TUBA1C
ANXA2P1 CEACAM8 EDIL3 GNAS IL17B LOC124220 PDCD6IP RAB5B SLC38A3 TUBB
ANXA3 CFB EEA1 GNAT3 IL17R LOC283523 PDGFA RAB5C SLC39A14 TUBB2A
ANXA4 CFI EEF1A1 GNB1 IL19 LOC284297 PDGFC RAB6A SLC3A2 TUBB2C
ANXA5 CFL1 EEF1G GNB2 IL1F9 LOC388344 PDGFRB RAB7A SLC44A1 TUBB3
ANXA6 CFL2 EEF2 GNB4 IL1RAP LOC389827 PDIA3 RAB8A SLC44A2 TUBB6
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ANXA7 CFTR EFEMP2 GNG12 IL1RAPL1 LOC442497 PEBP1 RAB8B SLC7A10 UBA52
AP1S1 CHMP2A EHD1 GNPDA1 IL1RL2 LOC653269 PFAS RAC1 SLC7A5 UBB
APEH CHST12 EHD2 GOT2 IL22RA1 LOC727942 PFKFB3 RAC2 SMARCA4 UBE1
APOA1 CITED1 EHD4 GPC1 IL23A LOC728320 PFN1 RAD21 SMC1A UBE2N
APOE CLASP2 EIF4A1 GPC5 IL3 LOC728378 PFN2 RALA SORT1 UGP2
APP CLDN1 EMILIN1 GPI IL5 LOC730013 PGAM2 RAN SPACA1 UNC13B
ARF1 CLEC11A ENG GPR112 IL6ST LRP1 PGD RAP1A SPARC UNC45A
ARF4 CLIC1 ENO1 GREM1 IL7 LRP6 PGK1 RAP1B SPOCK1 VAMP3
ARF5 CLIC6 ENO2 GRM2 IL8 LRRFIP2 PGLYRP2 RAP1B SPRY4 VANGL1
ARHGAP18 CLPX ENO3 GRM3 INHBA LTBP1 PIGR RAP2C SPTAN1 VASN
ARHGAP23 CLSTN1 ENTPD4 GRM7 INHBB LTBP2 PIP RARRES1 SPTBN1 VAT1
ARHGDIA CLTA ENTPD4;LOXL2 GSN INSR LTF PKM2 RASA1 SPTBN4 VCAN
ARHGEF1 CLTC EPB41L3 GSTM1 IQGAP1 LYAR PLAB RASA4 SRGN VCL
ARL6IP5 CLTCL1 EPHA2 GSTM2 ITGA11 LYZ PLAU RB1CC1 SRI VCP
ARMS2 CLU EPO GSTM5 ITGA2 MADH4 PLEC1 RCOR2 SRPX2 VEGFC
ARPC3 CMIP ESM1 GSTO1 ITGA3 MAMDC2 PLEKHG3 RDH5 ST6GALNAC6 VIL1
ARPC4 CNGB1 ETFB GSTP1 ITGA4 MAP1A PLOD1 RFTN1 STAT1 VIL2
ARPC5 COL12A1 F2R GTPBP2 ITGA5 MAP2K6 PLOD2 RGN STC1 VIM
ASH1L COL14A1 F3 GYLTL1B ITGAL MAP3K1 PLOD3 RHOC STC2 VTI1A
ASL COL18A1 F8 GZMA ITGAV MARCKS PLP2 RMND5A STOM VTN
ATP1A1 COL1A1 FADD H2AFV ITGB1 MARCKSL1 PLSCR3 RNF123 STOML3 WDR49
ATP1B3 COL1A2 FAH H2AFX ITGB5 MAT1A PLTP RNF40 STX12 WDR52
ATP2B1 COL2A1 FAM108A1 HBB ITIH2 MBD3 PLUNC RPL10A STX2 WNT5A
ATP2B4 COL3A1 FAM129B HBE1 ITIH4 MCC PNO1 RPL12 SURF4 YBX1
ATP5A1 COL4A1 FAM29A HDAC5 ITPR2 MCM10 PODN RPL15 SVEP1 YWHAB
ATP5B COL4A2 FAM3B HERC5 JUP MDH1 POLN RPL18 SYT1 YWHAE
ATP8B3 COL4A3 FAM64A HGF KIAA0146 MDH2 POSTN RPL23 SYT9 YWHAG
ATRN COL5A1 FAM71F1 HGFR KIAA0256 ME1 POTE2 RPL29 TAAR2 YWHAQ
ATXN1 COL5A2 FAP HISPPD2A KIAA0467 MECP2 PPIA RPL35A TAGLN YWHAZ
AXL COL6A1 FASN HIST1H2AE KIAA1881 MFAP4 PPIB RPLP0 TALDO1 ZBTB4
BASP1 COL6A2 FAT HIST1H2BA KPNB1 MFGE8 PPME1 RPS10 TAS2R60 ZNF134
BDNF COL6A3 FAT2 HIST1H2BL KRT1 MFSD2 PPP1CC RPS16 TCN1 ZNF503
BGN COL7A1 FAT4 HIST1H4H KRT10 MIF PRDM16 RPS18 TF ZNF614
BHMT2 COMP FBLN1 HIST2H2BE KRT13 MMP1 PRDX1 RPS2 TFG
BRMS1 COPB1 FBN1 HLAA KRT14 MMP10 PRDX6 RPS24 TFRC
BSG COPS3 FBN2 HMGCS2 KRT15 MMP2 PRNP RPS27A TGFB1
Identified by LC MS/MS
Identified by antibody arrays
Identified by both LC MS/MS and antibody arrays
Identified by LC MS/MS and was found to be present in at least 50% of exosomes characterized[2]
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Paracrine factors secreted by stem cells are believed to mediate therapeutic actions of current 
cell therapy for myocardial infarction. The usage of stem cell secretion represents an 
attractive ‘off-the-shelf’ therapeutic alternative for cell therapy. Here we describe both 
therapeutic and mechanistic actions of mesenchymal stem cell (MSC)-derived exosomes in 
myocardial ischemia/reperfusion (I/R) injury. 
Methods and Results 
Mice underwent 30 minutes ischemia, followed by reperfusion. Compounds were 
administered 5 minutes before reperfusion. Cardiac function and geometry were assessed 
using 9.4T mouse-MRI and invasive PV-loop recordings. Purified exosomes reduced infarct 
size to the same extent as MSC-conditioned medium when compared to saline treatment 
(38.5±1.8% vs. 21.3±2.2%, p<.001). Ex vivo I/R experiments showed similar infarct size 
reduction compared to the in vivo situation, suggesting that exosomes directly improve 
myocardial survival. Post-infarct heart tissue analysis revealed that exosomes enhanced 
survival via Akt and GSK-3β phosphorylation. Apoptosis was also reduced as shown by 
reduced phosphorylated c-JNK levels and reduced TUNEL-positive staining. Exosomes 
prevented energy depletion (ADP/ATP) and improved redox state (NAD+/NADH) in the 
myocardium after I/R. Furthermore, exosome treatment reduced infarct-induced inflammation 
after ischemia/reperfusion. Compared to saline treatment, exosomes prevented left ventricular 
dilatation (end-diastolic volume: 81±7 vs. 58±4 μL, p=.021) and preserved systolic and 
contractile performance 28 days after I/R. 
Conclusions 
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Systemic administration of MSC-derived exosomes 5 minutes prior to reperfusion reduces 
infarct size and preserves cardiac function and geometry. Exosome treatment promotes pro-
survival signaling, enhances energy balance and reduces secondary inflammation. Hence, 
MSC-derived exosomes are a potential candidate as an adjunctive for reperfusion therapy in 
patients with myocardial infarction. 
Keywords: myocardial infarction, reperfusion, paracrine hypothesis, exosomes, mesenchymal 
stem cells 
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The socio-economic burden of myocardial infarction (MI) and related complications (e.g. 
heart failure) is increasing in Western societies. Recent advances in (interventional) 
cardiology have resulted in timely and optimized coronary flow through the culprit artery. 
Subsequently, more patients survive the initial infarction, but have worsened cardiac 
performance and increased infarct related morbidity.1 The increase in morbidity after MI 
triggered the search for adjunctive therapeutics to further limit excessive tissue loss and 
enhance cardiac performance. Stem cell therapy has been shown to have great potential in the 
treatment of patients with MI.2 More interestingly, it is widely accepted that the observed 
therapeutic effects are mediated by stem cell secretion. This so called ‘paracrine hypothesis’ 
has gained much attention and is supported by recent experimental data3. It has been shown 
that MSC-CM enhance cardiomyocyte and/or progenitors survival after hypoxia-induced 
injury.4-8 Furthermore, MSC-CM induce angiogenesis in the infarcted myocardium.5, 6, 9 We 
have shown in both murine and porcine models of myocardial I/R that MSC-CM reduces 
infarct size.10 Interestingly, we found that the therapeutic action was irrespective of the cell 
source for the MSCs; human embryonic stem cell-derived MSCs were not superior to those 
derived from distinct fetal cell sources (e.g. limb, kidney). High performance liquid 
chromatography (HPLC) and dynamic light scatter (DLS) analyses revealed that both MSC 
sources secreted similar cardioprotective microparticles with a size ranging from 50-65 ηm.11 
Purification of these microparticles resulted in the identification of exosomes as the 
cardioprotective factor in MSC-CM12.  
Exosomes are bi-lipid membrane vesicles with a diameter of 50-100 ηm. They are secreted by 
various cell types and are involved in immune responses, intercellular communication and 
antigen presentation.13  Multivesicular bodies store the exosomes within the cell and release 
them upon fusion with the plasma membrane. The identification of exosomes as the 
cardioprotective factor in MSC secretion make it an potential therapeutic tool in treating 
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myocardial reperfusion injury. In contrast to cell-based therapy, MSC-derived exosomes 
provide an ‘off-the-shelf’ therapeutic. Furthermore, exosomes are potentially safer compared 
to cell therapy since they are non-viable. In addition, the biologic-based approach of 
exosomes may reduce the manufacturing costs. Although we previously described that 
exosomes reduce infarct size in mice,12 the functional consequence and the mechanism for its 
cardioprotective actions remain unknown.  
In the present study, we describe the functional improvement after exosomes treatment in 
myocardial I/R. In addition, we identified for the first time several pathways involved in 
myocardial I/R injury that are targeted simultaneously by MSC-derived exosomes to exert 
cardioprotective actions.  
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Methods 
Animals and Experimental Design 
Male C57Bl6/J mice (10-12 wks old, 25-30 g) received standard diet and water ad libitum. 
Saline or exosomes were administered intravenously via the tail vein, 5 minutes before 
reperfusion. Myocardial infarction was induced by temporary left coronary artery ligation, 
just below the left atrial appendage as described previously.14  Where possible, 
recommendations from the National Heart Lung and Blood Institute (NHLBI) Working 
Group on the Translation of Therapies for Protecting the Heart from Ischemia15 were applied; 
Digital photos of infarcts were encrypted before being analyzed by the researcher. Heart 
function and geometry assessment was done by a technician blinded to treatment. All animal 
experiments are performed in accordance with the national guidelines on animal care and with 
prior approval by the Animal Experimentation Committee of Utrecht University.  
 
Myocardial I/R Injury In Vivo 
Mice were anesthetized with a mixture of Fentanyl (Jansen-Cilag) 0.05 mg/kg, Dormicum 
(Roche) 5 mg/kg and medetomidine 0.5 mg/kg through an intraperitoneal injection. Core 
body temperature was maintained around 37°C during surgery by continuous monitoring with 
a rectal thermometer and automatic heating blanket. Mice were intubated and ventilated 
(Harvard Apparatus Inc.) with 100% oxygen. The left coronary artery (LCA) was ligated for 
30 minutes with an 8-0 Ethilon (Ethicon) with a section of polyethylene-10 tubing placed over 
the LCA. Ischemia was confirmed by bleaching of the myocardium and ventricular 
tachyarrhythmia. In sham operated animals the suture was placed beneath the LCA without 
ligating. Reperfusion was initiated by releasing the ligature and removing the polyethylene-10 
tubing. Reperfusion of the endangered myocardium was characterized by typical hyperemia in 
the first few minutes. In a subgroup of mice, a piece of the loosened suture was left in place to 
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determine the area-at-risk (AAR) during termination. The chest wall was closed and the 
animals received subcutaneously Antisedan (Pfizer) 2.5 mg/kg, Anexate (Roche) 0.5 mg/kg 
and Temgesic (Schering-Plough) 0.1 mg/kg. 
 
Data Supplement 
The online Data Supplement contains detailed information on exosome purification, 
Langendorff I/R injury, infarct size calculation, MRI measurements, invasive LV pressure 
measurements, immunohistochemistry, flow cytometry (cytokine and survival kinases) and 
ELISA for ADP/ATP and NAD+/NADH.  
 
Statistical Analysis 
Data are represented as Mean±SEM. One-way ANOVA with post-hoc 2-sided Dunnett t-test 
adjustment (saline was set as control) was used for infarct size comparison between the 
groups. Non-parametric t-test was used for 2 group comparisons. All statistical analyses were 
performed using SPSS 15.1.1. and p < 0.05 was considered significant. The authors had full 
access to and take full responsibility for the integrity of the data. All authors have read and 
agree to the manuscript as written.
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Results 
Intact Exosomes Reduce Myocardial I/R Injury In Vivo and Ex Vivo 
Thirty minutes ischemia followed by 24 hours reperfusion in saline treated animals resulted in 
39±1.8% infarction within the AAR (IS/AAR; Figure 1A). A single i.v. bolus of exosomes 5 
minutes prior to reperfusion reduced infarct size to 45% (21±2.2% IS/AAR; p<0.001). We 
performed ex vivo I/R experiments in the Langendorff setup, to study whether exosomes exert 
their therapeutic effect via blood cells or via direct survival enhancement of myocardial cells. 
Three hours reperfusion with normal buffer after 30 minutes ischemia resulted in 49±5.3% 
IS/AAR. Surprisingly, ex vivo exosome treatment reduced infarct size to the same extent as in 
the in vivo situation (23±1.5% IS/AAR; p=0.002). This suggests that exosomes directly target 
myocardial cells to reduce I/R injury. It is postulated that exosomes fuse with target cells in 
order to release their content.13 To test this  hypothesis, we disrupted the exosomes by 
vigorous agitation (2x30 sec) in a homogenizer (Precellys®24, Bertin Technologies, France). 
As a result, disrupted exosomes failed to reduce infarct size in vivo (37±3.0% IS/AAR; 
p=.994). In our experiments, the extent of endangered myocardium was similar in all groups 
(mean AAR/LV = 40±1.3%; Figure 1B). 
 
Exosome Treatment Prevents Left Ventricular Dilatation and Improves Cardiac 
Performance 
We performed serial cardiac MRI measurements to assess both left ventricular (LV) function 
and geometry after I/R injury. There were no differences in LV function and dimensions at 
baseline. The infarct size reduction in exosome treated animals translated into significant 
preservation of both end-diastolic and –systolic volume (EDV, ESV) during follow-up. In 
addition, ejection fraction was significantly improved after exosomes treatment at all time 
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points (Figure 2A-C). Wall thickness (WT) of the infarcted area (free wall) was equally 
increased in saline and exosomes treated animals 1 day after reperfusion (Figure 2D), 
presumably caused by tissue edema. However, exosome treatment resulted in decreased 
thinning of the infarct area during scar maturation. This finding is in line with the infarct size 
reduction seen after exosome treatment. There were no differences in WT in the remote 
myocardium between the groups (Figure 2E). The higher extent of viable tissue after exosome 
treatment also significantly improved systolic thickening of the infarcted area at all time 
points (Figure 2F), and in the remote myocardium 28 days after infarction (Figure 2G).  
We performed invasive pressure-volume (PV) loop recording to determine the hemodynamic 
consequences of reduced dilatation and improved systolic performance after exosome 
treatment. In support of increased viability of the endangered myocardium, we observed 
higher contractility and relaxation in exosome treated mice 28 days after infarction. In 
addition, preserved LV geometry was associated with reduced end-diastolic pressure (EDP) in 
exosome treated animals (Table 1). 
 
Exosome Treatment Reduces Inflammation After I/R 
Myocardial I/R is characterized by accentuated tissue and systemic inflammation.16 In line 
with reduced cardiac damage upon exosome treatment, we observed reduced neutrophil 
infiltration, but not a significant macrophage influx, in exosome treated hearts compared to 
saline treatment (Figure 3A and B). In patients after MI , high peripheral white blood cell 
(WBC) count is associated with larger infarct size, worse cardiac performance and poor 
clinical outcome.17-21 In concordance with clinical studies, our experiments revealed that 
infarct size reduction and improved cardiac performance in exosome treated animals is 
associated with reduced WBC count after I/R injury (Figure 3C). The reduction of neutrophil 
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infiltration and peripheral WBC count also suggest that exosomes are probably non-
immunogenic. 
 
Exosome Treatment Phosphorylates Akt/GSK3 Pathway, Inhibits c-JNK Signaling and 
Reduces Apoptosis After I/R 
Paracrine actions of MSC secretion is shown to be mediated via enhanced phosphorylation of 
survival pathways, especially of PI3K/Akt pathway.3-7 In our study, exosome treatment 
induced Akt and GSK3 phosphorylation, it was already significant at 1 hour reperfusion 
(Figure 4A and B). ERK1/2 phosphorylation has been shown to be protective as well in 
myocardial I/R injury.22 In our experiments, however, ERK1/2 phosphorylation was not 
altered after exosome treatment (Figure 4C). These findings suggest that MSC-derived 
exosomes specifically target Akt and GSK3 pathways to induce pro-survival effects. 
Phosphorylation of c-JNK is a known activator of pro-apoptotic signaling in myocardial I/R 
injury. As shown in Figure 4D, exosome treatment also reduced deleterious phosphorylation 
of c-JNK at 1 hour reperfusion. To support the reduction of apoptotic signaling, we performed 
a TUNEL staining on heart sections 1 day after reperfusion. Indeed, apoptosis was reduced 
after exosome treatment compared to saline treated mice (Figure 4E). 
 
Exosome Treatment Restores Energy Depletion and Redox State 
Myocardial I/R injury results in rapid depletion of ATP and increased oxidation of NADH 
into NAD+.22 We studied these processes at very early time points to demonstrate the fast 
mode of action of exosome treatment after I/R injury. Figure 5A and B demonstrate that 
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exosome treatment just prior to reperfusion restores both ADP/ATP and NAD+/NADH levels 
30 minutes after reperfusion.   
109
Discussion 
Previous studies have shown that MSC transplantation is successful in improving cardiac 
function after infarction. Nevertheless, a biologic-based approach may be preferable for it to 
overcome the limitations of cell-based therapy. MSC-derived-exosomes are a) non-viable, b) 
relatively easy to scale up and manufacture, c) non-immunogenic thus facilitating d) an ‘off-
the-shelf’ therapeutic option in acute MI. So far, the vast majority of research examining the 
paracrine actions of MSCs has focused on single mediators within the secretion. However, the 
pathophysiological changes after myocardial I/R are complex and multifactorial involving 
many cell types (resident and migrating cells) and many intracellular signaling cascades. For 
this reason, it is likely that MSC secretion targets multiple mediators of injury to exert 
therapeutic effects. We have shown that exosomes are robust and reproducible candidates for 
adjunctive therapy in MI.11, 12 Exosomes have shown to be promising as vaccination vehicles 
and have great potential for cancer treatment.13, 23-25 For this reason, we believe that exosomes 
also serve as a drug delivery platform for the cardioprotective factors in MSC secretion.  
In the present study, we have demonstrated that intravenous MSC-derived exosome 
administration just 5 minutes prior to reperfusion reduces infarct size with approximately 
45%. Our clinically relevant model shows that MSC-derived exosomes have the potential to 
be successful in acute MI. Patients suffering from an acute myocardial infarction may benefit 
from MSC-derived exosomes when administered intravenously in the ambulance or in the 
emergency room before undergoing reperfusion therapy.  
Our results showed that, as a consequence of reduced infarct size, MSC-derived exosome 
treatment resulted in a significant preservation of LV geometry and both systolic and diastolic 
performance during long-term follow-up. Although infarct size was reduced, exosome 
treatment did not reduce reperfusion-induced edema as shown by equal increase of thickness 
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of the free wall (infarct area) 1 day after reperfusion. The similar extent of tissue edema at day 
1 in the MRI studies suggests that the amount of endangered myocardium did not differ 
between the groups. Ex vivo I/R experiments revealed that exosomes directly target 
myocardial cells to enhance viability. In addition, it appeared that the therapeutic action 
required intact exosomes. The latter is supported by previous experiments in which we 
showed that exosomes have shown to fuse with cardiomyocytes.26 Disruption of the bi-lipid 
membrane of the exosome could prevent fusion and thereby release of cardioprotective 
content to the target cell. 
Having established the functional improvements of MSC-derived exosomes after myocardial 
I/R, we explored potential mechanisms for the therapeutic effect. First, we observed 
decreased tissue and systemic inflammation in exosome treated animals. It is likely that the 
reduced inflammation is secondary to the reduced cardiac injury after exosome treatment, 
since leukocyte influx did not differ between the groups at 1 hour reperfusion. 
Cardioprotective interventions targeting primarily inflammation have usually profound anti-
inflammatory effects at very early time points after reperfusion.14, 16 
Secondly, MSC-derived exosomes appear to activate specific pro-survival pathways. 
Compared to saline treatment, exosomes significantly enhanced Akt and GSK3 
phosphorylation whereas phosphorylation of ERK1/2 was not altered. It is difficult to address 
whether exosomes phosphorylate Akt and GSK3 independent from each other. It is known 
that phosphorylated Akt in turn phosphorylates GSK3, thereby inactivating detrimental 
actions of GSK3 on cardiomyocyte mitochondria.27 Nevertheless, in our study the net effect 
of phosphorylated Akt and (subsequent) GSK3 is enhanced survival of myocardial cells after 
I/R injury. These findings corroborate earlier reports in which the paracrine mechanisms of 
MSC transplantation in experimental MI are mediated by Akt phosphorylation3-7. Hereafter, 
we assessed the level of apoptotic signaling and subsequent apoptosis. Phosphorylation of c-
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JNK is a known mediator of apoptosis in myocardial I/R injury.22 MSC-derived exosomes 
reduced c-JNK activation, thereby, together with enhanced survival kinase phosphorylation, 
reducing apoptosis of myocardial cells.  
Finally, we studied whether MSC-derived exosomes were also able to prevent fast occurring 
detrimental events in I/R injury. It is known that reperfusion-induced apoptosis is an active 
process causing ATP depletion within the first few minutes after reperfusion. In addition, 
reperfusion allows restoration of aerobic glycolysis in which energy is transferred to NADH. 
Subsequently, NADH is oxidized into NAD+ during oxidative phosphorylation in order to 
generate ATP in the mitochondria. We have shown that exosome treatment results in reduced 
ATP depletion and increased NADH availability compared to saline treatment. This effect 
was significantly present as early as 30 minutes after reperfusion. Whether exosomes increase 
ATP and NADH availability directly, via decreased injury to mitochondria (phosphorylated 
Akt/GSK3 pathway results in reduced mitochondrial damage) or promoted glycolysis remains 
to be addressed.  
In conclusion, we have shown that MSC-derived exosomes reduce infarct size and prevent 
heart function deterioration after myocardial I/R injury. The main mode of action of MSC-
derived exosomes is enhancing viability, preventing apoptosis of myocardial cells and 
restoring energy balance. More importantly, our study demonstrates that MSC-derived 
exosomes are effective when administered in the late ischemic period, just prior to 
reperfusion. For this reason, MSC-derived exosomes are a potential candidate for adjunctive 
therapy for patients suffering from acute myocardial infarction. 
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 Table 1. Invasive left ventricular pressure measurements 28 days after infarction 
 Saline Exosomes p 
BPM 480±7 476±3 .60 
ESP 110±2 137±10 .12 
EDP 15±1 7±1 .009 
dP/dTmax 7496±152 8951±246 .009 
dP/dTmin -6680±75 -8241±396 .009 
Data are represented as Mean±SEM, n=5/group. BPM=beats per minute, ESP=end-systolic 
pressure, EDP=end-diastolic pressure. 
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Figure 1. MSC-derived exosomes reduce myocardial I/R injury in vivo and ex vivo. A, 
Infarct size (IS) as a percentage of the area-at-risk (AAR) 1 day after I/R injury; *p<0.001 and 
†p=0.002 compared to saline. B, AAR as a percentage of the left ventricle (LV). Each bar 
represents Mean±SEM, n=6/group for in vivo and n=4/group for ex vivo experiments.  
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Figure 2. MSC-derived exosomes prevent LV dilation and improve systolic function 
after myocardial I/R injury. A, End-diastolic volume (EDV, µL); *p=0.029 and †p=0.006 
compared to saline. B, End-systolic volume (ESV); *p=0.04, †p=0.017 and ‡p=0.002 
compared to saline. C, Ejection fraction (EF, %); *p=0.035, †p=0.015 and ‡p=0.002 
compared to saline. D, Wall thickness of the infarct area (WT, mm); *p<0.001 compared to 
baseline and †p=0.04 compared to saline. E, WT of the remote myocardium. F, systolic wall 
thickening (SWT, %); *p=0.011, †p=0.042 and ‡p=0.040 compared to saline. G, SWT of the 
remote myocardium; *p=0.012 compared to saline. Representative MRI images are shown. 
Note the increased LV dimensions at systole and diastole in saline treated animals; Each bar 
represents Mean±SEM, n=10/group for ischemic/reperfused animals n=6/group for sham 





Figure 3. MSC-derived exosomes reduce secondary inflammation after myocardial I/R 
injury. A, Neutrophil influx (Ly6-Gpos cells); *p=0.016 compared to saline. B, Macrophage 
influx (MAC3pos cells). Representative staining are shown. C, Peripheral white blood cell 
counts after myocardial I/R injury; *p=0.045 and †p=0.009 compared to saline. Each bar 





Figure 4. MSC-derived exosomes reduce apotosis via induced phosphorylation of Akt 
and GSK3, and reduced c-JNK phosphorylation after myocardial I/R injury. Tissue 
levels of A, phospho-Akt (pg/ml); *p=0.025 and †p=0.025 compared to saline. B, phospho-
GSK3α/ß; *p=0.025 and †p=0.016 compared to saline. C, phospho-ERK1/2. D, phospho-c-
JNK; *p=0.045 compared to saline. E, TUNELpos nuclei in hearts 1 day after I/R injury. 
Representative images are shown above the bars; *p=0.009 compared to saline. Each bar 




Figure 5. MSC-derived exosomes restore ADP/ATP and NAD+/NADH levels and inhibit 
MAC formation. Tissue levels of A, ADP/ATP; *p=0.047 compared to saline. B, 
NAD+/NADH; *p=0.027 compared to saline. C, MACs; *p=0.045 compared to saline. Each 








Exosomes were purified from huES9.E1 derived MSCs conditioned media (CM) 
using HPLC as described earlier.1 In brief, CM collected from MSCs culture was 
concentrated 50x by tangential flow filtration (TFF) using a membrane with a 100 
kDa MWCO (Sartorius, Goettingen, Germany). After that, CM was passed 
through chromatography columns (TSK Guard column SWXL, 6x40 mm and 
TSK gel G4000 SWXL, 7.8x300 mm, Tosoh Corp., Tokyo, Japan). Exosomes 
were collected from the first peak of the elution, concentrated using 100 kDa 
MWCO filter (Sartorius). Exosomes were filtered with a 0.22 µm filter before 
storage or use. 
 
Infarct Size 
Infarct size (IS) as a percentage of the left ventricle (LV) was determined using 
Evans’ blue dye injection and TTC staining, 1 day after reperfusion (n=6/group). 
The LCA was ligated once again at the level marked by the suture left in place. 
Evans’ blue dye (4%) was injected via the thoracic aorta in a retrograde fashion. 
By doing so, one can demarcate the area-at-risk (AAR), the extent of myocardial 
tissue that underwent ischemia (i.e. endangered myocardium). Hearts were rapidly 
explanted, rinsed in 0.9% saline and put in -20ºC freezer for 1 hour. Hereafter, 
hearts were mechanically sliced into four 1-mm cross sections. Heart sections 
were incubated in 1% triphenyltetrazolium-chloride (Sigma-Aldrich) at 37ºC for 
15 minutes before placing them in formaldehyde for another 15 minutes. Viable 
tissue stains red and infarcted tissue appears white. Heart sections were digitally 
photographed (Canon EOS 400D) under a microscope (Carl Zeiss®). IS, AAR 
128
and total LV area were measured using ImageJ software (version 1.34). Infarct 
size was corrected for the weight of the corresponding heart slice. 
 
Myocardial I/R Injury Ex Vivo 
Mice (n=4/group) were given heparin 50 IE subcutaneously. The suture was 
placed beneath the LCA in vivo without ligating. Hereafter, the heart was excised 
and aortic root was canulated and perfused in the Langendorff setup. After 10 min 
recovery, the suture was tightened to induce ischemia for 30 min. Just 5 min prior 
to reperfusion, the perfusion buffer was changed for a second buffer containing 
0.4 μg/ml MSC-derived exosomes or control. Reperfusion was initiated by 
releasing the suture. Following 3 hours of reperfusion, Evans' blue dye was 
injected after re-ligating the suture to demarcate the AAR. Subsequently, TTC 
staining was performed for infarct size assessment. 
 
Cardiac Magnetic Resonance Imaging 
Twenty-six mice (n=10/group in ischemic and n=6/group in sham operated mice) 
underwent serial assessment of cardiac dimensions and function by high 
resolution magnetic resonance imaging (MRI, 9.4 T, Bruker, Rheinstetten, 
Germany) under isoflurane anesthesia before, 1, 7 and 28 days after MI. Long axis 
and short axis images with 1.0 mm interval between the slices were obtained and 
used to compute end-diastolic volume (EDV, largest volume) and end-systolic 
volume (ESV, smallest volume). The ejection fraction (EF) was calculated as 
100*(EDV-ESV)/EDV. Wall thickness (WT) and systolic wall thickening (SWT) 
were assessed from both the septum (remote myocardium) and free wall (infarct 
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area). All MRI data are analyzed using Qmass digital imaging software (Medis, 
Leiden, The Netherlands). 
 
Pressure-Volume Loop Recordings 
In a subset of mice, invasive assessment of cardiac performance and LV pressure 
development was performed 28 days after infarction. A Millar 1.4F pressure 
catheter (model SPR-839) was inserted in a retrograde fashion via the right 
common carotid artery. Systolic function was assessed by LV end-systolic 




Upon termination, hearts were excised and fixated in 4% formaldehyde and 
embedded in paraffin. Paraffin sections were stained for Ly-6G (for neutrophils; 
rat anti-mouse Ly-6G 1:100, Abcam, Cambridge, United Kingdom), MAC-3 (for 
macrophages; rat anti-mouse MAC-3 1:30, BD Pharmingen, Breda, the 
Netherlands) and Terminal deoxynucleotidyl transferase dUTP Nick End labeling 
(TUNEL) staining. 
 
Sections were stained by overnight incubation with the first antibody at 4°C for 
MAC-3 or by 1 hour incubation at RT for Ly-6G. Before staining, sections were 
deparaffinized and endogenous peroxidase was blocked by 30 minutes incubation 
in methanol containing 1.5% H2O2. Antigen retrieval was performed by 20 
minutes boiling in citrate buffer (MAC-3 and Ly-6G). 
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For MAC-3, sections were pre-incubated with normal goat serum and incubated 
with the primary antibody (1:30 overnight at 4°C). Sections were then incubated 
for 1 hour at RT with a biotin labeled secondary antibody, followed by 1 hour 
incubation with streptavidin-horseradish peroxidase at RT and developed with 
AEC. 
For Ly-6G, sections were incubated with the primary antibody (1:100 for 1 hour at 
RT). Sections were then incubated for 30 minutes with a secondary antibody 
followed by 30 minutes incubation with Powervision poly-HRP anti-rabbit IgG 
(ImmunoVision Technologies, Daily City, USA). The staining was immediately 
visualized with Vector NovaREDTM substrate kit following the manufacturer's 
instructions (Vector Laboratories Inc., Burlingame, USA).  
 
Protein Isolation 
Total protein was isolated from snap frozen infarcted heart sections using 1 ml 
TripureTM Isolation Reagent (Roche) according to the manufacturers' protocol. 
 
Flow Cytometry 
Phosphorylated target protein for Akt (Ser473), glucogen synthase kinase-3α/β 
(GSK-3α/β; Ser21/Ser9), extracellular signal-regulated kinases-1/2 (ERK1/2; 
Thr202/Tyr204), c-Jun N-terminal kinase (c-JNK; Thr183/Tyr185) were measured 
using the Bio-Plex Multiplex Assay (Bio-Rad Laboratories) according to the 
instructions of the manufacturer, after 1:5 dilution in assay buffer. 
 
ADP/ATP and NAD+/NADH measurementADP/ATP and NAD+/NADH ratio 
in area at risk of mouse model MI/R injury were measured. MI was induced by 30 
131
min left coronary artery (LCA) occlusion and subsequent reperfusion. Five 
minutes before reperfusion, mice were intravenously infused with 200 µl saline 
diluted exosomes containing 0.4 µg protein via the tail vein. Control animals were 
infused with 200 µl saline. After 0 min, 5 min and 30 min of reperfusion, area at 
risk (AAR) was excised and frozen immediately using liquid nitrogen. Frozen 
tissue samples were then homogenized with 1 ml of NAD+/NADH extraction 
buffer (Biovision, Mountain view, CA) and supernatant was collected after spinning 
at 14,000 xg for 5 minutes. After that, the supernatant was filtering through 10 
kDa MWCO filter (Biovision) before performing the ADP/ATP and 
NAD+/NADH ratio assays according to the assay manual (Biovision). For 




1. Lai RC, Arslan F, Lee MM, Sze NS, Choo A, Chen TS, Salto-Tellez M, 
Timmers L, Lee CN, El Oakley RM, Pasterkamp G, de Kleijn DP, Lim 
SK. Exosome secreted by MSC reduces myocardial ischemia/reperfusion 








This conclusion are adapted with modifications from a published review article 
“Mesenchymal stem cell exosome: a novel stem cell-based therapy for 
cardiovascular disease”1 of which I am the first author. 
 
Exosomes As The Cardioprotective Component 
The discovery that MSC secretion reduced myocardial infarct size after 
ischemia/reperfusion71,72 sparks the possibility of identifying a secreted 
cardioprotective factor to reduce the infarct size of AMI patients undergoing 
reperfusion therapy.  A secreted factor would be potentially much simpler to 
produce or manufacture, to administer to patient and to understand. 
This thesis accomplished this by identifying exosome, a bi-lipid membrane vesicle 
containing proteins and RNAs, as the cardioprotective factor in MSC secretion.  
By reducing the complexity of MSC secretion to a single entity, amelioration of 
reperfusion injury during reperfusion therapy of myocardial ischemia could be 
achieved through exosomes instead of MSC transplantation. This would 
circumvent the safety concerns and limitations associated with cell transplantation. 
These include the proarrhythmic effects when the donor cells fail to couple with 
the host tissue81-83; the risk that the biological potency of the transplanted cells 
may persist even if treatment is terminated as a result of adverse outcomes; the 
long-term safety concerns of the ossification and/or calcification in tissues due to 
the potential of MSCs to differentiate into osteocytes and chondrocytes84; the risk 





due to the relatively large size of MSCs85 and other limitations that are generally 
universal in cell-based therapy such as the immediate availability of large quantity 
of cells and the costly storage and administration of viable cells.  
Besides mitigating the risks associated with cell transplantation, exosomes can 
also circumvent some of the challenges associated with the use of small soluble 
biological factors such as growth factors, chemokines, cytokines, transcription 
factors, genes and RNAs77. The delivery of soluble factors to the right cell type 
and in the case of those factors that work intracellularly, delivery into the right 
cellular compartments while maintaining the stability, integrity and biological 
potency of these factors during manufacture, storage and subsequent 
administration remain challenging77. As a bi-lipid membrane vesicle, exosomes 
not only have the capacity to carry a large cargo load, but also protect the contents 
from degradative enzymes or chemicals. For example, protein and RNA in MSC 
exosomes were protected from degradation by trypsin and RNase as long as the 
lipid membrane was not compromised86,87. We also found that storage without 
potentially toxic cryopreservatives at -20°C for 6 months did not compromise the 
cardioprotective effects of MSC exosomes or their biochemical activities (Lai RC, 
Lim SK, unpublished data). The bi-lipid membrane, also allows exosomes to 
circumvent many of the challenges associated with small soluble biological 
factors including the maintenance of stability, integrity and biological potency 






Exosomes As The Therapeutic Agent 
In our profiling of the exosome proteome, we identified more than 800 proteins 
and uncovered a diverse range of biochemical and cellular potential of MSC 
exosomes. These observations suggested that despite being smaller than a cell, 
exosomes are relatively complex biological entities making them ideal therapeutic 
candidates to treat complex injuries such as MI/R injury7 that occurs during 
treatment to restore oxygen to ischemic heart tissues of AMI patients. During 
reperfusion, the restoration of blood and oxygen to ischemic myocardium 
paradoxically exacerbates the ischemia-induced cellular insults7. This is because 
the biochemical cascades required for cell survival that are initiated by cells 
during no-flow ischemia88 are not compatible with the rapid restoration of flow 
and oxygen supply, and at the same time, the ischemic cells cannot alter their 
biochemical activities expeditiously enough to adapt to this restoration. This latter 
phenomenon was best evidenced by the reduction of MI/R injury through 
postconditioning where cells were exposed to repeated short nonlethal cycles of 
reperfusion/ischemia to facilitate biochemical adaptation to reperfusion89-100. 
We postulate that with their complex cargo, exosomes would have adequate 
potential to participate in a wide spectrum of biochemical and cellular activities, 
and mitigate some of the MI/R injuries such as ATP deficit due to mitochondrial 
damage101, activation of complements102,103, oxidative stress7 and cell death. We 
demonstrated that exosomes could enhance glycolysis and thereby circumvent 
mitochondrial damages to increase ATP production.  Exosomes could also 
ameliorate complement activation by inhibiting the formation of membrane attack 
complex through CD59 on their membranes. The presence of intact functional 20S 





proteins. Exosomes could enhance cell survival by activating adenosine-mediated 
signaling pathway to phosphorylate ERK1/2 and AKT through adenosine 
produced by CD73 on their membrane. Furthermore, exosome treatment in a 
mouse model MI/R injury activated pro-survival kinases by phosphorylating 
AKT104, GSK3105, inhibited mediator of apoptosis by dephosphorylating c-JNK106, 
and at the same time increased ATP production, enhanced redox balance possibly 
through glycolysis within the 1st hour of reperfusion. These observations 
demonstrated the biochemical potential of exosomes and suggested possible 
mechanisms for the reduction of MI/R injury. Furthermore, the results that 
exosomes reduced infarct size in the Langendorff setup of the I/R experiment 
suggested exosomes might promote these cardioprotective mechanisms directly in 
myocardial cells.   
In addition to its potential to target many processes simultaneously, a hallmark 
feature of exosome is the exertion of its effects through enzymes. Since enzyme 
activities are catalytic rather than stoichiometric, and are dictated by their 
microenvironment (e.g., substrate concentration or pH), the enzyme-based 
therapeutic activities of exosomes could be activated or attenuated according to 
the release of injury-associated substrates, which in turn, is proportional to the 
severity of disease-precipitating microenvironment. Resolution of the disease-
precipitating microenvironment would reduce the release of injury-associated 
substrates and also the activity of exosome enzymes. Consequently, the efficacy 
of exosome-based therapeutics could be highly responsive to, but also limited by, 
the disease-precipitating microenvironment. 
Exosomes are known to bear numerous membrane proteins that have binding 





transferrin receptor, tumor necrosis factor, lactadherin, integrins and tetraspanin 
proteins (e.g., CD9, CD63 and CD81)107. These membrane bound molecules 
provide a potential mechanism for the homing of exosomes to a specific tissue or 
microenvironment. For example, integrins on exosomes could home exosomes to 
cardiomyocytes that express ICAM1, a ligand of integrins after MI/R injury108, or 
to VCAM-1 on endothelial cells109. Besides, tetraspanin proteins, which function 
primarily to mediate cellular penetration, invasion and fusion events110, could 
facilitate cellular uptake of exosomes by specific cell types.  
Together, the features discussed here render exosome a highly efficacious 
therapeutic candidate in neutralizing the complexity of MI/R and a potential 
adjuvant to complement current reperfusion therapy. Furthermore, during 28 days 
follow up in the MI/R injury mouse model, we observed that exosome treatment 
which significantly reduced infarct size after reperfusion also significantly 
preserved both cardiac function and geometry. This is consistent with the findings 
that a smaller infarct size prevents heart function deterioration and retards the 
progress to heart failure 8-13.  
More importantly, the animal models used in the demonstration of MSC exosome-
mediated cardioprotection had two important features that highlighted the clinical 
relevance and practicality of an exosome-based adjuvant to reperfusion therapy.  
Both animal models used in our study had experimentally induced lethal ischemia 
that causes similar level of pathological substrate as that in the average patient 
with AMI72.  Exosome was administered to these animals just before reperfusion, 
which is a clinically feasible time point.  These two features facilitate the 
translation of MSC exosome into an adjunctive therapy to reduce reperfusion 






Exosome As MSCs’ Vehicle of Choice for Intercellular Communication 
Besides the involvement of exosomes in MI/R injury, this thesis also showed that 
production of cardioprotective exosomes was not restricted to hESC-MSCs as 
different fetal tissue-MSCs were also found to produce cardioprotective exosomes. 
This suggested that producing protective exosomes might be a universal property 
of all MSCs. This property may be a reflection of the stromal support role of 
MSCs in maintaining a microenvironmental niche for other cells such as 
hematopoietic stem cells111,112. The secretion of exosomes may also be a dominant 
function of MSCs. We recently observed that when GFP-labeled exosome-
associated protein CD81, a tetraspanin membrane protein usually found localized 
to the plasma membrane, is expressed in hESC-MSCs, they exhibit a punctate 
cytosolic distribution and these labeled proteins were secreted (see Figure 2 of 
review attached in appendix)1. The difference in cellular distribution and secretion 
of CD81 in hESC-MSCs and HEK293 cells suggest that MSCs are prolific 
producers of exosomes. This leads to the speculation that exosome might be the 
MSCs’ vehicle of choice for intercellular communication. 
 
Future Challenge 
The future challenge of this study is to translate this finding into a clinically useful 
therapeutic agent. The first major challenge would be to manufacture Good 
Manufacturing Practice (GMP) grade exosomes from non-autologous cell sources. 
Although exosomes have already been tested in clinic as a form of cancer 





vivo culture of autologous dendritic cells. For this reason, manufacturing of these 
exosomes cannot provide sufficient guidance for the MSC exosomes GMP 
production. This manufacturing process faces many unique challenges, which 
involve ethical, legal, technical, monetary and regulatory/safety issues.  
The other major challenge will be the cell source for derivation of MSCs since the 
use of hESCs for the derivation of MSCs presents both ethical and legal 
challenges. While ethical objections to the derivation and use of hESCs have 
initially hindered hESC research, they have abated. Instead, the use and 
applications of hESCs is now being hindered by complex and widespread 
patenting in some countries116 and the ban on stem cell-related patents in other 
countries117. To encourage the development of hESC-based therapeutic 
applications, the need for freedom to use and share hESC resources and 
knowledge must be balanced with a need to incentivize commercial development 
of stem cells by protecting the intellectual property generated from research and 
development efforts. Unfortunately, this balance has not yet been reached.  
Another technical challenge is the finite expansion capacity of hESC-MSC. This 
resulted in the need for constant re-derivation of MSCs and re-validation of each 
of the derived cell batch, which are both time consuming and costly. Therefore, a 
robust scalable and highly renewable cell source will be central to the 
development of a commercially viable manufacturing process for the production 
of MSC exosomes in sufficient quantity and quality to support clinical testing or 
applications. To address this issue, we demonstrated that immortalization of the 
hESC-MSCs by Myc did not compromise the quality or yield of exosomes118. 
Therefore, this provides a potentially inexhaustible cell source for MSC exosome 





complicated by the relative novelty of exosomes with few precedents in the 
regulatory and safety space of biopharmaceuticals. This will require the 
formulation of new standards for manufacture, safety and quality control. 
 
With the demonstration of the involvement of exosomes in cardioprotection and 
the proteomic prediction of its therapeutic potential, we speculate that these 
exosomes will have similar positive effect in other reperfusion injuries such as 
those involved in stroke and renal ischemia disease. On the other hand, it is also 
possible that different cell types produce exosomes that are specific for certain 
type of cells or injuries.  If true, this novel tissue-repair function of exosomes 
could potentially engender new approaches to the development of biologics that 
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Mesenchymal stem cell exosome: a novel stem  
cell-based therapy for cardiovascular disease
Stem cells in the treatment of acute 
myocardial infarction
Acute myocardial infarction (AMI) is the primary 
cause of disease-related death in the world [1–3]. It 
is characterized by the disruption of blood sup-
ply to the heart muscle cells, which lead to myo-
cardial infarction or death of cardiomyocytes. 
Reperfusion therapy or the restoration of blood 
flow by thrombolytic therapy, bypass surgery or 
percutaneous coronary intervention (PCI) is cur-
rently the mainstay of treatment for AMI and is 
responsible for the significant reduction in AMI 
mortality [4]. The efficacy of reperfusion therapy 
has led to increasing survival of patients with 
severe AMI who would not otherwise survive. 
However, many (23%) of these survivors prog-
ress to fatal heart failure within 30 days [5]. This 
phenomenon of an increasing number of severe 
AMI survivors contributes to an ever growing 
epidemic of heart failures [6–8]. 
Heart failure is characterized by dilatation 
and hypertrophy with fibrosis within the myo-
cardium. The progression of an AMI survivor 
to heart failure is a multifactorial process that 
has been hypothesized to include the develop-
ment of myocardial stunning and hibernation, 
remodeling and chronic neuroendocrine activa-
tion [9], and is dependent on the extent of the 
AMI suffered by the patient [10–15]. The develop-
ment of reperfusion therapy and its subsequent 
improvements have significantly increased the 
salvage of ischemic myocardium from infarction 
and reduced infarct size, but further substantive 
improvement to reperfusion therapy is likely to 
require adjunctive therapies. 
Although it was recognized as early as 1960 
that reperfusion of severely ischemic tissue causes 
lethal injury [16], the concept that reperfusion 
causes de novo lethal injury became more widely 
accepted only when infarct size was shown to be 
reduced by interventions applied at the onset of 
reperfusion (reviewed in [10]). Such interventions, 
also known as postconditioning, involve ischemic 
conditioning or application of pharmacological 
agents before the onset of reperfusion, and have 
demonstrated some protection against reperfu-
sion injury in animals and in small clinical tri-
als. However, none of these agents have proven 
to be efficacious in large clinical trials and this 
has led to speculations that reducing reperfusion 
injury may not be tractable to pharmaceutical 
interventions [17].
With the emergence of stem cells as potential 
therapeutic agents, attempts to use stem cells to 
reduce infarct size and enhance cardiac function 
in animal models and patients have increased 
exponentially. To date, stem cell therapy for the 
heart accounts for a third of publications in the 
regenerative medicine field [18]. Mummery et al. 
have recently reviewed the use of both adult and 
embryonic stem cells, such as bone marrow-
derived stem cells, which include hematopoi-
etic stem cells (HSCs) and mesenchymal stem 
cells (MSCs), endogenous cardiac progenitor cells 
(CPCs), human embryonic stem cells (hESCs), 
Cardiovascular disease is a major target for many experimental stem cell-based therapies and mesenchymal 
stem cells (MSCs) are widely used in these therapies. Transplantation of MSCs to treat cardiac disease has 
always been predicated on the hypothesis that these cells would engraft, differentiate and replace 
damaged cardiac tissues. However, experimental or clinical observations so far have failed to demonstrate 
a therapeutically relevant level of transplanted MSC engraftment or differentiation. Instead, they indicate 
that transplanted MSCs secrete factors to reduce tissue injury and/or enhance tissue repair. Here we review 
the evidences supporting this hypothesis including the recent identification of exosome as a therapeutic 
agent in MSC secretion. In particular, we will discuss the potential and practicality of using this relatively 
novel entity as a therapeutic modality for the treatment of cardiac disease, particularly acute 
myocardial infarction.
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induced pluripotent stem cells, and hESC-
derived cardiomyocytes [18]. The use of bone 
marrow-derived stem cells such as HSCs and 
MSCs to repair cardiac tissues was predicated on 
the hypothesis that these cells could differentiate 
into cardiomyocytes and supporting cell types. 
However, careful rodent experimentation has 
demonstrated that few of the transplanted bone 
marrow cells engraft and survive, and fewer cells 
differentiate into cardiomyocytes or supporting 
cells [18]. In spite of this, transplantation of bone 
marrow stem cells improves some cardiac func-
tions in animal models and patients, and this 
has been attributed to a paracrine effect [18]. 
Although the presence of CPCs in fetal hearts is 
well established, the presence of CPCs in postna-
tal or adult heart remains controversial, and the 
possibility that the so-called CPCs from post-
natal hearts are bone marrow cells has remained 
unresolved. Transplanted cardiomyocytes iso-
lated from in vitro differentiation of hESCs and 
induced pluripotent stem cells could engraft in 
the heart to form a synctium with each other, 
but not with the recipient heart. This failure to 
couple with the recipient cardiomyocytes could 
cause arrhythmia, a potentially fatal condition. 
Despite our still evolving understanding of 
stem cell transplantation in treating cardiac 
disease, stem cell transplantation has already 
being tested in clinical trials. In a recent review 
of more than 20 clinical trials that primarily 
used adult stem cells, such as bone marrow stem 
cells, mobilized peripheral blood stem cells and 
skeletal myoblasts to treat heart disease [19], the 
trends favored such transplantations to treat car-
diac disease when measured using clinical end 
points of death, recurrence of AMI or hospitaliza-
tion for heart failure. The failure to elicit a more 
robust therapeutic response has been attributed 
to low engraftment of cells and poor survival 
of engrafted cells with an untested caveat that 
improved engraftment and survival will enhance 
the therapeutical efficacy. A general consensus 
from these clinical trials is that bone marrow- or 
blood-derived stem cells do not replenish lost car-
diomyocytes or vascular cells to any meaningful 
extent. Instead, circumstantial evidence suggests 
that these stem cells secrete factors that exert a 
paracrine effect on the heart tissues [19]. 
MSCs & the treatment of 
cardiovascular disease
Among the stem cells currently being tested in 
clinical trials for the heart, MSCs are the most 
widely used stem cells. Part of the reason for this is 
their easy availability in accessible tissues, such as 
bone marrow aspirate and fat tissue [20], and their 
large capacity for ex vivo expansion [21]. MSCs are 
also known to have immunosuppressive prop-
erties [22] and, therefore, could be used in allo-
geneic transplantation. They are also reported to 
have highly plastic differentiation potential that 
included not only adipogenesis, osteogenesis and 
chondrogenesis [23–28], but also endothelial, car-
diovascular [29], neurogenic [30–32] and neovascu-
lar differentiation [33–35]. MSCs transplantation 
in most animal models of AMI generally resulted 
in reduced infarct size, improved left ventricular 
ejection fraction, increased vascular density and 
myocardial perfusion [36–40]. In a recent Phase I, 
randomized, double-blind, placebo-controlled 
dose-escalation clinical trial, single infusion 
of allogeneic MSCs in patients with AMI was 
documented to be safe with some provisional 
indications that the MSC infusion improved 
outcomes with regard to cardiac arrhythmias, 
pulmonary function, left ventricular function 
and symptomatic global assessment [41]. 
Despite numerous studies on the transplanta-
tion of MSCs in patients and animal models, 
insight into the mechanistic issues underlying the 
effect of MSC transplantation remains vague. An 
often cited hypothesis is that transplanted MSCs 
differentiate into cardiomyocytes and support-
ing cell types to repair cardiac tissues. However, 
contrary to this differentiation hypothesis, most 
transplanted MSCs are entrapped in the lungs 
and the capillary beds of tissues other than the 
heart [42,43]. Furthermore, depending on the 
method of infusion, 6% or less of the trans-
planted MSCs persist in the heart 2 weeks after 
transplantation [44]. In addition, transplanted 
MSCs were observed to differentiate inefficiently 
into cardio myocytes [45] while ventricular func-
tion was rapidly restored less than 72 h after 
transplantation [46]. All these observations are 
physically and temporally incompatible with 
the differentiation hypothesis and have thus 
prompted an alternative hypothesis that the 
transplanted MSCs mediate their therapeutic 
effect through secretion of paracrine factors that 
promote survival and tissue repair [47].
Paracrine secretion of MSCs
Paracrine secretion of MSCs was reported more 
than 15 years ago when Haynesworth et al. [48] 
reported that MSCs synthesize and secrete a 
broad spectrum of growth factors and cytokines 
such as VEGF, FGF, MCP-1, HGF, IGF-I, SDF-1 
and thrombopoietin [49–53], which exert effects on 
cells in their vicinity. These factors have been pos-
tulated to promote arteriogenesis [51]; support the 
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stem cell crypt in the intestine [54]; protect against 
ischemic renal [49,50] and limb tissue injury [52]; 
support and maintain hematopoiesis [53]; and 
support the formation of megakaryocytes and 
proplatelets [55]. Many of these factors have also 
been demonstrated to exert beneficial effects 
on the heart, including neovascularization [56], 
attenuation of ventricular wall thinning [39] and 
increased angiogenesis [57,58]. 
In 2006, Gnecchi et al. demonstrated that 
intramyocardial injection of culture medium con-
ditioned by MSCs overexpressing the Akt gene 
(Akt-MSCs) or Akt-MSCs reduced infarct size in 
a rodent model of AMI to the same extent [46]. 
This provided the first direct evidence that cellu-
lar secretion could be cardioprotective [46,59]. The 
authors subsequently attributed the cardiopro-
tective effect of the conditioned medium to the 
culturing of the cells under hypoxia and the over-
expression of AKT, which induced secretion of 
Sfrp2. siRNA mediated-silencing of Sfrp2 expres-
sion in Akt-MSCs abrogated the cytoprotective 
effect of their secretion [60]. 
Our group recently demonstrated that culture 
medium conditioned by human ESC-derived 
MSCs (hESC-MSCs) significantly reduced 
infarct size by approximately 50% in a pig and 
mouse model of myocardial ischemia/reperfusion 
(MI/R) injury when administered intravenously 
in a single bolus just before reperfusion [61]. 
However, these MSCs were derived from hESCs 
instead of rat bone marrow and were not geneti-
cally modified to overexpress Akt. The condi-
tioned medium was prepared using a chemically 
defined medium without hypoxia treatment. 
We further demonstrated through size frac-
tionation studies that the active component was 
a large complex 50–200 nm in size. Using elec-
tron microscopy, ultracentrifugation studies, 
mass spectrometry and biochemical assays, we 
identified this complex as an exosome, a secreted 
bi-lipid membrane vesicle of endosomal origin 
(FIGURE 1). When purified by size exclusion using 
high-performance liquid chromatography, hESC-
MSC exosomes also reduced infarct size, but at a 
tenth of the protein dosage used for conditioned 
medium [62]. We subsequently showed that exo-
somes constitute about 10% of the conditioned 
medium in terms of protein amount [Lai RC, Lim SK, 
Unpublished Data]. Therefore, the therapeutic 
activity in the hESC-MSC conditioned medium 
could be attributed primarily to the exosome [62]. 
The secretion of cardioprotective exosomes was 
not unique to hESC-MSCs and was also found 
to be produced under non hypoxic culture con-
ditions by MSCs derived from aborted fetal 
tissues [63]. Therefore, these observations suggest 
that the secretion of protective exosomes is a char-
acteristic of MSCs and may be a reflection of the 
stromal support role of MSCs in maintaining a 
microenvironmental niche for other cells such as 
hematopoietic stem cells. The secretion of exo-
somes may also be a dominant function of MSCs. 
We recently observed that when GFP-labeled 
exosome-associated protein CD81 is expressed 
in hESC-MSCs (FIGURE 2A), they exhibit a punctate 
cytosolic distribution and these labeled proteins 
were secreted (FIGURE 2C). CD81 is a classical tet-
raspanin membrane protein usually found local-
ized to the plasma membrane (as typified by 
their distribution in HEK 293 cells) (FIGURE 2B). 
The cellular distribution of the labeled CD81 in 
hESC-MSCs and its cellular secretion suggest 
that MSCs are prolific producers of exosomes, 
and that exosome, whose main function is to 
mediate intercellular communication (as dis-
cussed later), is also MSCs’ vehicle of choice for 
intercellular communication.
What are exosomes?
Exosomes are one of several groups of secreted 
vesicles, which also include microvesicles, ecto-
somes, membrane particles, exosome-like vesicles 
or apoptotic bodies (reviewed in [64]). Exosomes 
were first found to be secreted by sheep reticu-
locytes approximately 50 years ago [65,66]. They 
have since been shown to be secreted by many cell 
types, including B cells [67], dendritic cells [68], 
mast cells [69], T cells [70], platelets [71], Schwann 
cells [72], tumor cells [73] and sperm [74]. They are 
also found in physiological fluids such as nor-
mal urine [75], plasma [76] and bronchial lavage 
fluid [77]. 
Compared with other secreted vesicles, exo-
somes have much better defined biophysical and 
biochemical properties(reviewed in [64]). They 
have a diameter of 40–100 nm, with a density in 
sucrose of 1.13–1.19 g/ml, and can be sedimented 
at 100,000 g. Their membranes are enriched in 
cholesterol, sphingomyelin and ceramide, and 
are known to contain lipid rafts. The presence of 
exposed phosphatidylserine was reported to be 
present on the membrane of some exosomes [78,79] 
and absent from others [80,81]. Exosomes contain 
both proteins and RNAs. Most exosomes have an 
evolutionarily conserved set of proteins, including 
tetraspanins (CD81, CD63 and CD9), Alix and 
Tsg101, but they also have unique tissue/cell type-
specific proteins that reflect their cellular source. 
Mathivanan and Simpson have set up ExoCarta, 
a freely accessible web-based compendium of 
proteins and RNAs found in exosomes [82,201]. 
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The functions of exosomes are not known, 
but they are believed to be important for inter-
cellular communications. Exosomes were first 
documented in 1996 to mediate immune com-
munication when it was observed that, when 
secreted by antigen-presenting cells (APCs), 
they bear functional peptide–MHC com-
plexes [67]. This also provides the implication 
that exosomes could be used therapeutically. 
The therapeutic potential of exosomes was 
subsequently illustrated by the use of exosomes 
secreted by tumor peptide-pulsed dendritic 
cells to suppress tumor growth [68]. Ironically, 
exosomes are also implicated in tumorigen-
esis, with the observation that microvesicles 
mediate intercellular transfer of the oncogenic 
receptor EGFRvIII [83]. Exosomes have also 
been reported to have the potential to protect 
against tissue injury such as MI/R injury [62] or 
acute tubular injury [84]. 
In recent years, exosomes have also been impli-
cated in neuronal communication or pathogen-
esis. For example, exosomes have been found to 
be released by neurons [85], astrocytes [86] and 
glial cells [87] to facilitate diverse functions that 
include removal of unwanted stress proteins [88] 
and amyloid fibril formation [89,90]. Exosomes 
containing D-synuclein have been demonstrated 
to cause cell death in neuronal cells, suggest-
ing that exosomes may amplify and propagate 
Parkinson’s disease-related pathology [91,92]. It 












Conventional view of paracrine secretion
– Soluble proteins
– Secreted through fusion of secretory granules 
   with membrane
– Local effect: affect cells in close proximity
– Communication via membrane receptors
Exosomes as mediators of paracrine effect
– Endosomal origin
– Secreted through fusion of multivesicular 
   bodies with cell membrane
– Bi-lipid membrane vesicles with proteins and mRNA
   – Secreted proteins and RNA are more stable
– Potential to exert local/remote effect
– Communication via membrane receptors or intracellular 
   uptake of exosome contents by endocytosis or 
   membrane fusion
 Figure 1. Paracrine effects of mesenchymal stem cells.
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E-amyloid is released in association with exo-
some [93]. More recently, oligodendrocytes were 
demonstrated to secrete exosomes to coordinate 
myelin membrane biogenesis [94]. Besides neu-
ronal communication, exosomes secreted by 





































Figure 2. Expression and detection of CD81–green fluorescent fusion protein in cell lines. 
(A & B) Expression of CD81–GFP in HuES9.E1 MSC and HEK293 cells. A CD81–GFP fusion gene was 
cloned into a pLVX-puro lentiviral expression vector to generate a CD81–GFP lentivirus. After infecting 
HuES9.E1 MSCs and HEK293 cells with the virus followed by drug selection, the cells were seeded 
onto a glass chamber slide and stained for DAPI. (C) Secretion of CD81–GFP fusion protein. Cell lysate 
and CM were prepared from HuES9.E1 MSCs and CD81–GFP-transfected HuES9.E1 MSCs. The cell 
lysate and CM were analyzed by western blot hybridization using antibodies against CD81 (top panel), 
GFP (middle panel) and ACTIN (bottom panel). 
CM: Conditioned media; GFP: Green fluorescent protein; MSC: Mesenchymal stem cell.
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to stimulate the migration of the endothelial 
cells [95], while those secreted by the egg facilitate 
the fusion of the sperm and egg [96]. 
Exosomes have also been implicated as a vehi-
cle for viral and bacterial infection (reviewed 
in [97]), including the assembly and release 
of HIV [98–100] and intercellular spreading of 
infectious prions in transmissible spongiform 
encephalopathies. The association of exosomes 
with disease or pathological conditions makes 
exosomes good sentinels for diseases. It was 
reported that the miRNA profile of circulating 
exosomes could be indicative or diagnostic of 
ovarian cancer [101]. Similarly, the proteins in 
the urinary exosome have been demonstrated 
to reflect acute kidney injury and are candi-
date diagnostic markers [102]. More recently, 
the function of exosomes as vehicles for inter-
cellular communication has been exploited for 
the delivery of therapeutic siRNAs to the brain 
and to provide for alternative drug delivery 
systems [103]. 
Exosome as an alternative 
therapeutic of MSCs?
The paracrine hypothesis introduces a radically 
different dimension to the therapeutic appli-
cations of MSCs in regenerative medicine. By 
replacing transplantation of MSCs with admin-
istration of their secreted exosomes, many of 
the safety concerns and limitations associated 
with the transplantation of viable replicating 
cells could be mitigated. For example, the use 
of viable replicating cells as therapeutic agents 
carries the risk that the biological potency of 
the agent may persist or be amplified over time 
when the need has been resolved, and cannot be 
attenuated after treatment is terminated. This 
could lead to dire consequences, especially if 
treatment was terminated as a recult of adverse 
outcomes. Although repeated direct endomyo-
cardial transplantation of MSCs has been dem-
onstrated to be relatively safe [104], intravascular 
administration could lead to occlusion in the 
distal microvasculature as a consequence of the 
relatively large cell size [105]. Transplantation 
of MSCs has been reported to induce proar-
rhythmic effects [106–108]. Their potential to dif-
ferentiate into osteocytes and chondrocytes has 
also raised long-term safety concerns regarding 
ossification and/or calcification in tissues as 
reported in some animal studies [109]. 
Besides mitigating the risks associated with 
cell transplantation, exosomes can also circum-
vent some of the challenges associated with the 
use of small soluble biological factors such as 
growth factors, chemokines, cytokines, tran-
scription factors, genes and RNAs [110]. The 
delivery of these factors to the right cell type 
and, in the case of those factors that work intra-
cellularly, the delivery into the right cellular 
compartments, while maintaining the stability, 
integrity and biological potency of these factors 
during manufacture, storage and subsequent 
administration remains a costly challenge. As 
a bi-lipid membrane vesicle, exosomes not only 
have the capacity to carry a large cargo load, 
but also protect the contents from degradative 
enzymes or chemicals. For example, protein and 
RNA in MSC exosomes were protected from 
degradation by trypsin and RNase as long as the 
lipid membrane was not compromised [62,111]. 
We also found that storage without potentially 
toxic cryopreservatives at -20°C for 6 months 
did not compromise the cardioprotective effects 
of MSC exosomes or their biochemical activities 
[Lai RC, Lim SK, Unpublished Data]. 
Exosomes are known to bear numerous 
membrane proteins that have binding affin-
ity to other ligands on cell membranes or the 
extracellular matrix, such as transferrin recep-
tor, tumor necrosis factor receptors, lactadherin, 
integrins and tetraspanin proteins (e.g., CD9, 
CD63 and CD81) [82]. These membrane bound 
molecules provide a potential mechanism for 
the homing of exosomes to a specific tissue or 
microenvironment. For example, integrins on 
exosomes could home exosomes to cardiomy-
ocytes that express ICAM1, a ligand of inte-
grins after MI/R injury [112], or to VCAM-1 
on endothelial cells [113]. Tetraspanin proteins, 
which function primarily to mediate cellular 
penetration, invasion and fusion events [114], 
could facilitate cellular uptake of exosomes by 
specific cell types. 
Exosomes may also facilitate the uptake of 
therapeutic proteins or RNAs into injured cells. 
Although cellular uptake of exosomes has been 
demonstrated to occur through endocytosis, 
phagocytosis and membrane fusion [115–117], the 
mechanism by which these processes are regu-
lated remains to be determined. It was observed 
that the efficiency of exosome uptake correlated 
directly with intracellular and microenviron-
mental acidity [117]. This may be a mechanism 
by which MSC exosomes exert their cardio-
protective effects on ischemic cardiomyoctyes 
that have a low intracellular pH [118]. 
Despite being smaller than a cell, exosomes 
are relatively complex biological entities that 
contain a range of biological molecules, includ-
ing proteins and RNA, making them an ideal 
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therapeutic candidate to treat complex injuries 
such as MI/R injury. It is well established that 
MI/R injury occurs paradoxically in response 
to a therapy that is highly effective in resolving 
the disease precipitating problem of no flow and 
ischemia. During MI/R injury, the restoration 
of blood and oxygen to ischemic myocardium 
paradoxically exacerbates the ischemia-induced 
cellular insults. This is because the biochemical 
cascades required for cell survival that are initi-
ated by cells during no flow and ischemia [119] 
are not compatible with the rapid restoration 
of flow and oxygen supply, and at the same 
time, cells cannot alter their biochemical 
activities expeditiously enough to adapt to this 
restoration. This latter phenomenon was best 
evidenced by the reduction of MI/R through 
postreperfusion conditioning or postcondi-
tioning where cells were exposed to repeated 
short nonlethal cycles of reperfusion/isch-
emia to facilitate biochemical adaptation to 
reperfusion [120–131]. 
We postulate that with their complex cargo, 
exosomes would have adequate potential to par-
ticipate in a wide spectrum of biochemical and 
cellular activities, and simultaneously target and 
correct the various ischemia-induced cascades, 
and prevent occurrence of the paradoxical reac-
tions induced by reperfusion. In addition, many 
of the proteins in the exosomes are enzymes. 
Since enzyme activities are catalytic rather than 
stoichiometric, and are dictated by their micro-
environment (e.g., substrate concentration or 
pH), the enzyme-based therapeutic activities 
of exosomes could be activated or attenuated 
according to the release of injury-associated 
substrates, which in turn, is proportional to the 
severity of disease-precipitating microenviron-
ment. Resolution of the disease-precipitating 
microenvironment would reduce the release of 
injury-associated substrates and also the activ-
ity of exosome enzymes. Consequently, the 
efficacy of exosome-based therapeutics could 
be highly responsive to, but also limited by, the 
disease-precipitating microenvironment. 
Together, the features discussed here ren-
der exosomes a highly efficacious therapeutic 
in neutralizing the complexity of MI/R and 
an effective adjuvant to complement current 
reperfusion therapy. 
Translating hESC-MSC exosomes  
into therapeutics
The translation of cardioprotective MSC exo-
somes into a therapeutic agent presents several 
unique challenges. The first major challenge 
would be to manufacture Good Manufacturing 
Practices (GMP) grade exosomes from non-
autologous cell sources. Although exosomes as 
therapeutics have already been tested as a form 
of cancer vaccine in the clinic [132–134], these 
tests were limited to exosomes produced dur-
ing short-term ex vivo culture of autologous 
dendritic cells. These exosomes, also known 
as dexosomes, were found to be safe in the 
small clinical trials [132]. Unfortunately, the 
manufacture of these exosomes cannot provide 
guidance for the large-scale GMP production 
of exosomes from nonautologous cell sources 
such as exosomes from hESC-MSCs. This 
manufacturing process faces many unique chal-
lenges, including ethical, legal, technical and 
regulatory/safety issues.
The use of hESCs for the derivation of MSCs 
presents both ethical and legal challenges. 
While ethical objections to the derivation and 
use of hESCs have initially hindered hESC 
research, they have abated. Instead, the use and 
applications of hESCs is now being hindered 
by complex and widespread patenting in some 
countries [135] and the ban on stem cell-related 
patents in other countries [136]. To encourage 
the development of hESC-based therapeutic 
applications, the need for freedom to use and 
share hESC resources and knowledge must be 
balanced with a need to incentivize commer-
cial development of stem cells by protecting the 
intellectual property generated from research 
and development efforts. Unfortunately, this 
balance has not yet been reached.
One of the major technical hurdles to the 
use of hESC-MSCs is their large but finite 
expansion capacity, resulting in the need for 
constant costly re-derivation from hESC and 
re-validation of each of the derived cell batch. 
Therefore, a robust scalable and highly renew-
able cell source will be central to the develop-
ment of a commercially viable manufacturing 
process for the production of MSC exosomes 
in sufficient quantity and quality to support 
clinical testing or applications. To address this 
issue, we demonstrated that immortalization of 
the ESC-MSC by Myc did not compromise the 
quality or yield of exosomes [137]. Therefore, this 
provides a potentially inexhaustible cell source 
for MSC exosome production. The translation 
of MSC exosomes into clinical applications is 
also complicated by the relative novelty of exo-
somes with few precedents in the regulatory and 
safety space of biopharmaceuticals. This will 
require the formulation of new standards for 
manufacture, safety and quality control.
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Future perspective
The discovery of stem cells and their potential in 
regenerative medicine has evoked much excite-
ment and hope in treating some of today’s most 
intractable diseases, including cardiac disease. 
However, much of the euphoria has dissipated as 
animal experimentation revealed and identified 
potential problems in translating the use of stem 
cells to treat cardiac disease. Although the repro-
ducible large-scale preparation of homogenous 
clinically compliant ‘normal’ healthy cells has 
been a major preoccupation in the development 
of stem cell-based therapies in general, this has 
proven not to be an impediment in the devel-
opment of such therapies for cardiac disease, as 
evidenced by the large number of stem cell-based 
clinical trials that are already being conducted. 
Instead, the problems facing stem cell-based 
therapies for cardiac disease are potentially more 
insidious. At present, most of the stem cells used 
in clinical trials are MSCs and bone marrow 
mononuclear cells that are generally considered 
to be safe. However, despite eliciting a sometimes 
positive therapeutic response, these cells often 
do not integrate or persist in the heart tissues. 
By contrast, the use of myogenic cells, such as 
Executive summary
Stem cells in the treatment of acute myocardial infarction
  Advances in reperfusion therapy have increased survival of patients with severe acute myocardial infarction and contributed to a 
growing epidemic of heart failure.
  As reperfusion therapy itself causes lethal injury and has been demonstrated to be intractable to pharmaceutical intervention, stem cells 
are being scrutinized as alternative therapeutic agents.
  Attempts using stem cells to treat heart disease have generated mixed outcomes.
  Transplantation of bone marrow stem cells generally improved cardiac functions with little evidence of engraftment and differentiation 
of the transplanted stem cells. 
  Effects of stem cell transplantation have been attributed to secretion of paracrine factors by the transplanted stem cells.
Mesenchymal stem cells & the treatment of cardiovascular disease
  Animal studies and early clinical trials demonstrated that mesenchymal stem cell (MSC) transplantation improved cardiac function after 
myocardial infarction.
  Inefficient MSC engraftment and differentiation, and their rapid cardioprotective effects suggested that MSCs act via a secretion-based 
paracrine effect rather than a cell replacement effect.
Paracrine secretion of MSCs
  MSCs synthesize a broad spectrum of growth factors and cytokines that exert paracrine effects.
  Gnecchi et al. produced the first evidence that cellular secretion alone improved cardiac function in an animal model of acute 
myocardial infarction.
  Culture medium conditioned under nonhypoxic conditions by untransformed MSCs derived from human embryonic stem cells or 
aborted fetal tissues reduce infarct size in animal models of myocardial ischemia/reperfusion.
  Exosome is the primary mediator of MSCs’ paracrine effect.
What are exosomes?
  Exosomes are bi-lipid membrane vesicles secreted by many cell types into culture medium and other bodily fluids such as blood and urine.
  They function as mediators of intercellular communication.
Exosome as an alternative therapeutic for MSC?
  Exosome-based therapy circumvents some of the concerns and limitations in using viable replicating cells and does not compromise 
some of the advantages associated with using complex therapeutic agents such as cells.
  Exosomes are ideal therapeutic agents because their complex cargo of proteins and genetic materials has the diversity and biochemical 
potential to participate in multiple biochemical and cellular processes, an important attribute in the treatment of complex disease.
  Exosomes home to specific tissue or microenvironment.
  Their bi-lipid membranes can protect their biologically active cargo allowing for easier storage of exosomes, which allows a longer shelf-
life and half-life in patients.
  Their biological activities are mainly enzyme-driven and, therefore, their effects are catalytic and not stoichiometric.
  Having enzyme-driven biological activities, they are dependent on the microenvironment (e.g., substrate concentration or pH) and could 
be activated or attenuated in proportion to the severity of disease-precipitating microenvironment.
  Exosome-based therapy cannot replace lost myocardium but can prevent or delay loss of myocardium.
Challenges for translating embryonic stem cell-MSC exosomes into therapeutics 
  Ethical issues exist, especially with the derivation and use of human embryonic stem cells for generating MSCs.
  Legal issues include excessive intellectual property protection in some countries, which hinder research and development. A ban on 
embryonic stem cell-related intellectual property in other countries de-incentivize research and development.
  Technical limitations include the need for a robust scalable and highly renewable cell source embryonic stem cell-MSCs to support large 
scale, commercially viable manufacturing process.
  Exosomes are relatively novel biological entities with few precedents to establish safety and manufacturing guidance.
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